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Abstract 
 
The BCL-2 family of proteins are important regulators of mitochondrial 
apoptosis, comprising both pro- and anti-apoptotic members that interact 
with one another at the mitochondrial outer membrane to determine cellular 
fate. Dysregulation of their activities in the cell is implicated in many forms of 
cancer; the development of molecules able to mimic and modulate their 
interactions is thus highly desirable and has been the subject of a great deal 
of research effort. The use of techniques including structure based design 
and peptidomimetic approaches has produced some notable successes in 
this area, but few have successfully transitioned from laboratory to clinic, 
and the search for more and better ways to develop such molecules 
continues. 
 
In this thesis, I present a novel approach to identifying binding partners for 
BCL-2 proteins, which uses phage display experiments and the production 
of non-antibody scaffold proteins called Affimers. Five BCL-2 family proteins 
were selected as targets for study, comprising a good cross section of pro- 
and anti-apoptotic members. In the following chapters, I first describe the 
work undertaken to purify and characterise these target proteins, then detail 
the work done to identify and purify Affimer binding partners for each of 
them. Finally, I report on structural studies carried out to explore the 
mechanism by which BAX, a pro-apoptotic family member, forms death 
inducing oligomers.  
 
Taken together, the results of this project lay the foundations for further 
structural studies of BAX oligomerisation, and demonstrate that the use of 
phage display to generate selectively binding non-antibody scaffold proteins 
can provide useful additions to the existing array of BCL2 family interacting 
molecules.  
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Chapter 1  - Introduction 
 
1.1 Apoptosis 
 
Apoptosis, or programmed cell death, carries out many essential functions in 
multicellular organisms [1]. It is characterised by distinct morphological and 
biochemical changes to the cell, including cell shrinkage; membrane 
blebbing; chromatin condensation; DNA degradation; nuclear fragmentation 
and exposure of phosphatidylserine on the outside of the plasma membrane. 
These changes lead to the formation of apoptotic bodies, which are removed 
in vivo by endogenous phagocytes, preventing the escape into tissues of 
potentially damaging cellular constituents [2]. During embryonic 
development, apoptosis is responsible for hollowing out ducts and removing 
superfluous cells, for example the interdigital cells lost during the formation 
of limbs. In the adult, it acts as a balance to mitosis in maintaining a steady 
level of healthy cells, especially in high turnover tissues such as the 
intestinal epithelium. Apoptosis also eliminates potentially dangerous 
immune cells with self recognizing antigen receptors that could cause auto-
immune disease [3], and limits pathogenic spread by forcing the suicide of 
infected cells [4]. 
	
Apoptosis is initiated by a variety of stimuli, leading to the downstream 
activation of caspases, a family of cysteine proteases that carry out 
nucleophilic attack on substrate proteins, cleaving peptide bonds on the 
carboxyl side of aspartic acid (Asp) residues [5]. Caspases are initially 
synthesized as inactive zymogens called pro-caspases, and become active 
through hetero-dimerisation, followed by cleavage into small and large 
subunits to form active hetero-tetramers (Figure 1-1) . Caspases involved in 
apoptosis consist of two sub-groups: the upstream initiators (caspases 2, 8, 
9 and 10) and the downstream ‘executioners’ (caspases 3, 6 and 7). 
Activated initiator caspases will cleave and activate the executioners, which 
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in turn act to degrade cellular components, resulting in the morphological 
changes associated with apoptosis, with each executioner caspase targeting 
many hundreds of components within the cell [6]. 
 
Apoptosis may be triggered extrinsically following ligation of Death 
Receptors (e.g. Fas, TNFα, TRAIL-R1), leading to formation of the Death 
Inducing Signaling Complex (DISC) and subsequent activation of initiator 
caspases [7, 8]. Less commonly, cytotoxic T cells and natural killer (NK) 
cells may release molecules onto the cell surface, including perforin and 
granzyme B, which respectively form pores in the membrane, and enter the 
newly formed pore to activate initiator caspases [9]. Alternatively, and of 
significance to this study, apoptosis can be triggered intrinsically (Figure 1-
1). This involves apoptotic stimuli that modulate interactions between 
endogenous proteins of the BCL-2 family, leading to the permeabilisation of 
the mitochondrial outer membrane (MOM) and escape of caspase activating 
factors, including cytochrome c, from the mitochondrial intermembrane 
space to the cytosol. The consequences of cytochrome c release are 
twofold: the disabling of energy production within mitochondria, and initiation 
of the caspase cascade that leads to apoptotic cell death [10]. 
 
Dysregulated apoptosis is linked to a variety of pathologies. Increased 
apoptosis is associated with atherosclerosis [11]; infertility; diabetes [12]; 
AIDS; renal failure; and neurodegenerative diseases including multiple 
sclerosis [13] and Parkinson’s, Huntington’s and Alzheimer’s diseases [14]. 
Excessive apoptosis also contributes to damage caused during chronic 
inflammation, myocardial infarction and stroke [15-17]. Conversely, impaired 
apoptosis is associated with many forms of cancer and autoimmune disease 
[18]. The ability to modulate and control apoptosis within the cell is therefore 
highly desirable. 
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Figure 1-1 – Alternative pathways to apoptosis. The extrinsic (death receptor 
mediated) pathway involves the binding of ligands to death receptors 
such as Fas. Alternatively, the intrinsic (mitochondrial) pathway is 
initiated by different forms of cellular stress, including DNA damage and 
hypoxia. Such stresses lead to an increase in pro-apoptotic members of 
the BCL-2 protein family, causing permeabilisation of the mitochondrial 
outer membrane (MOMP). The release of cytochrome c to the cytosol as 
a result of MOMP leads to a cascade of caspase activation, culminating 
in the break down of cellular components and apoptotic cell death. 
 
1.2 Mitochondrial Apoptosis and the BCL-2 family 
 
In mitochondrial, or intrinsic apoptosis, cell death is dependent on the 
apoptotic threshold, which is determined by interactions at the mitochondrial 
outer membrane between three distinct sub-groups of the BCL-2 family of 
proteins. Family members are classified as pro-apoptotic or anti-apoptotic 
(pro-survival) depending on whether they promote or inhibit mitochondrial 
outer membrane permeabilisation (MOMP), a process seen as the ‘point of 
no return’ of cellular fate in mitochondrial apoptosis. In simple terms, the 
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decision to induce apoptotic cell death depends on the balance of pro- and 
anti-apoptotic BCL-2 proteins present and functional in the cell.  
 
Members of the BCL-2 family are thus important regulators of intrinsic 
mitochondrial apoptosis. BCL-2, the prototype of this evolutionarily 
conserved family of proteins, was first identified from the break point of a 
chromosomal translocation frequently seen in follicular and large B-cell 
lymphomas [19], and the first evidence of its anti-apoptotic function came 
from its ability to prevent cell death in cytokine deprived haematopoietic cells 
[20]. Subsequently, over 25 sequence homology sharing family members 
have been identified in the genome of higher eukaryotes [21, 22]. Members 
of the BCL-2 family are present in all somatic cells, though with tissue 
specific patterns of expression. 
 
Three distinct sub-families exist (Figure 1-2). The pro-apoptotic effectors 
BAX and BAK are the mitochondrial pore forming members of the BCL-2 
family; on activation, they oligomerise and form pores in the MOM. This 
activity is inhibited by the anti-apoptotic / pro-survival family members (for 
the remainder of this thesis, the terms pro-survival and anti-apoptotic will be 
used interchangeably when referring to BCL-2 proteins), which sequester 
BAX and BAK in the MOM and, in the case of BAX, also in the cytoplasm 
[23]. Six anti-apoptotic family members have been identified: BCL-2, BCL-XL, 
MCL1, BFL1, BCL-W and BCL-B. Finally, BH3 only members act as sensors 
of cellular stress, relaying pro apoptotic signals to multi-domain members to 
modulate MOM permeability [24, 25]. They are further divided into ‘direct 
activators’ and ‘sensitisers’, based on the nature of their interactions with 
BAX and BAK, as described later in this section. 
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Figure 1-2 – The BCL-2 family. The family as a whole comprises members 
with pro-apoptotic and anti-apoptotic (pro-survival) functions. The pro-
apoptotic effectors, principally BAX and BAK (blue) form the 
mitochondrial pores responsible for MOMP. In order to do this, they 
need to oligomerise in the mitochondrial outer membrane (MOM) and 
are prevented from doing this when bound and sequestered by the anti-
apoptotic family members (shown in green). BH3 only family members 
(so named because they have only the third of the four identified family 
BH homology domains - see main body text for details) are either 
upregulated or become active as a result of cytotoxic stress. They bind 
and sequester the anti-apoptotic family members, freeing up BAX and 
BAK to oligomerise. A subset of BH3 only proteins (direct activators), 
also have a more active role in BAX and BAK activity. 
 
BCL-2 family members share sequence homology in a number of BCL-2 
homology (BH) domains, named BH1, 2, 3 and 4 (Figure 1-3). In addition to 
the BH domains, all BCL-2 family members have C terminal transmembrane 
domain, which is used to govern their cellular location at internal (mainly 
mitochondrial) membranes [21, 26]. Not all members share all BH domains: 
BH3 only members, such as BIM, BID and BAD, live up to their name by 
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sharing only the eponymous BH3 domain; anti-apoptotic family members 
have all four BH domains, and though it was initially thought that BAX and 
BAK shared only the first three of the four BH homology domains [27], later 
analyses clearly show they also share the BH4 domain [28].  BAX, BAK and 
the anti-apoptotic members are collectively referred to as the multi-domain 
members.  
 
 
 
Figure 1-3 – BCL-2 sub-families and BCL-2 homology (BH) domains. BH3 only 
family members share only one BH homology domain and are 
intrinsically disordered. BAX, BAK and the pro-survival members 
contain 4 BH domains and share a large degree of globular structural 
homology. BH domains are numbered according to the chronology of 
their discovery, rather than their sequential position in the protein. 
Helical segments on the multi-BH domain members are shown. TM – 
transmembrane domain, common to all BCL-2 family members. 
 
Multi-domain members are α-helix rich and, despite significant divergence in 
their primary amino acid sequence, share a large degree of structural 
homology, forming globular folds comprising  two central hydrophobic 
helices, surrounded by multiple amphipathic helices [29] [30], in a structure 
referred to as the BCL-2 core. (Figure 1-4). Though BAX and BAK are pro-
apoptotic and carry out opposing functions to the like of BCL-2 and BCL-XL, 
structural studies have revealed that their globular fold is remarkably similar 
to that found in their pro-survival counterparts [30-34]. In all of these 
structures, the BH1, 2 and 3 domains combine to form the top of a C-
terminal, solvent exposed, hydrophobic groove (the BC groove) that is 
crucial for interacting with the BH3 domain of pro-apoptotic BH3 only family 
members such as tBID and BIM (Figure 1-5a). 
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Figure 1-4 - The ‘BCL-2 core’. All multi-domain members of the BCL-2 family 
(anti-apoptotic members plus BAX and BAK) share a common globular 
fold, in which a pair of hydrophobic helices, α5 and α6 (shown in red 
and blue respectively), are surrounded by a further 6 amphipathic 
helices. The above figure shows the BCL-2 core of the anti-apoptotic 
family member BCL-XL (PDB 1BXL).  
 
Unlike the multi-domain members, BH3 only proteins are intrinsically 
disordered, though their BH3 domain adopts an α-helical conformation on 
interaction with a binding partner. There is one exception to this: BID is 
considered a member of the BH3 only subfamily, due to the fact that it 
shares only one region of BH homology with multi-domain family members, 
but it is unusual in that, rather than being intrinsically disordered, it forms a 
putative BCL-2 core and adopts a similar fold to the pro-survival family 
members, albeit with a shorter and flatter BC groove, which does not form a 
cleft into which the BH3 domain of other family members can bind [35, 36]. 
When cleaved by caspase 8, it forms the active truncation tBID in which its 
own BH3 domain is exposed, and is able to carry out its pro-apoptotic 
function. 
 
BH3 only proteins are upregulated in response to cytotoxic or genotoxic 
stress and exert their effects by two distinct mechanisms [37-39]: 
sequestration and neutralization of pro-survival BCL-2 family members [40-
42], and / or direct activation of BAX and BAK [25, 43-45]. 
 
180°	
α5	 α6	
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tBID, BIM and PUMA are able to directly bind BAX and BAK, inducing their 
oligomerisation [44-47]; they are collectively known as direct activator BH3 
only proteins (Figure 1-2). Though all three are able to activate both BAX and 
BAK, there is evidence for relative levels of selectivity, for instance tBID has 
been shown to preferentially activate BAK, while BIM preferentially activates 
BAX [48]. There have been claims that NOXA is able to directly activate BAK 
[46, 49], but this is disputed [50-52]. Studies using BAX-/- BAK-/- double 
negative mouse models have shown that direct activators act upstream of 
BAX and BAK, and are unable to initiate MOMP and apoptosis by 
themselves [53-55]. 
 
BH3 only proteins that are not direct activators are called ‘sensitizers’ or ‘de-
repressors’; they bind and inhibit pro-survival family members (Figure 1-2). 
Sensitizer BH3 only proteins exert no direct apoptotic activity: instead, 
indirect induction of MOMP occurs through the freeing up of sequestered 
BAX and BAK, and also the dissociation of direct activator BH3 only proteins 
from pro-survival heterodimers, allowing them to bind and activate quiescent 
BAX and BAK. Direct activators also partially act as sensitizers when bound 
to pro-survival partners. 
  
1.2.1 The Canonical Binding Interaction 
 
The canonical interaction between BCL-2 family proteins is for the BH3 
domain of a pro-apoptotic member (BAX, BAK, or a BH3 only) to bind the 
BC groove of a multi-domain member (Figure 1-5b). Most commonly, this BH3 
in BC groove interaction occurs between the BH3 domain of a BH3 only 
member and the BC groove of a pro-survival member, with each effectively 
cancelling out the pro- or anti-apoptotic effects of the other. However, 
conformational changes occurring during the activation of BAX and BAK 
result in the transient exposure of their respective BH3 domains. The 
exposed BH3 domains may then bind the BC groove of another activated 
molecule of BAX or BAK to form a pro-apoptotic homo-dimer, or be bound 
and sequestered by the BC groove of pro-survival members to form inactive 
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hetero-dimers, in which the pro-survival member acts as a dominant 
negative partner, preventing MOMP and inhibiting pro-apoptotic activity [22, 
23, 56, 57].  
 
	
	
Figure 1-5 - The BCL-2 family canonical binding interaction. This involves the 
binding of the BH3 domain from a pro-apoptotic family member (BAX, 
BAK or a BH3 only) to the BC groove of a multi-domain member (BAX, 
BAK, or an anti-apoptotic). This most often results in the formation of an 
anti-apoptotic heterodimer consisting of a pro-apoptotic member bound 
to an anti-apoptotic partner, but can also result in pro-apoptotic homo-
dimers of BAX or BAK. a) the C-terminal binding (BC) groove of multi 
domain members is formed by the conjunction of the BH1, 2 and 3 
domains (shown in blue, cyan and red respectively). Figure shown is of 
BCL-XL (PDB 1PQ1) in both surface and ribbon format; b) shows the 
structure from a) with the BH3 domain of BAD (magenta) bound. c) 
Basis for BH3 domain to BC groove binding: hydrophobic residues on 
one face of the BH3 domain helix bind to four hydrophobic pockets (P1 
– P4) in the BC groove. Figure adapted from [58]. 
c	
a	
b	
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BAX and BAK activation also involves a canonical binding event, with the 
BH3 domain of a direct activator binding the BC groove of BAX or BAK. 
However, while BH3 only proteins form stable heterodimers with pro-survival 
family members, the interactions of direct activators with BAX and BAK are 
thought to be of a transient ‘hit and run’ nature. This is likely due to direct 
activator binding causing the conformational changes in BAX and BAK 
described above, with exposure of the BAX / BAK BH3 domain causing 
dissociation of the activating BH3 only protein [59]. There is a wealth of 
structural and biochemical data to support direct activation of BAX and BAK 
[38, 47, 50, 52], but other factors are also likely to play a part [41, 57]. Post 
translational modifications of BAX and BAK [60-62] and changes to the intra-
cellular environment [63-66] have been implicated, and the MOM itself is 
likely to play a significant role; it has been shown, for instance, that BAX and 
tBID do not interact unless there is a membrane present [67-69]. 
 
In each of the above instances, the BH3 domain of the pro-apoptotic 
member acts as the endogenous ligand to the BC groove of the multi-
domain member. BH3 domains have a central, homologous segment with 
between three and four α-helical turns containing conserved Leu and Asp 
residues, and in all known structures of this BH3 in groove interaction, four 
conserved hydrophobic residues (including the aforementioned Leu residue) 
on a single face of the α-helical BH3 domain (H1-H4) interact with 4 
hydrophobic pockets (labelled P1-P4) in the BC groove [70-72] (Figure 1-5c). 
When BH3 only proteins bind multi-domain pro-survival members, this 
interaction is augmented by a salt bridge formed between the conserved 
aspartate residue on the BH3 domain of the pro-apoptotic family member 
and a conserved arginine residue on the BH1 domain of the pro-survival 
protein [70, 72, 73].  
 
The molecular basis by which the BC groove of a multi domain family 
member recognises the BH3 domain of pro-apoptotic members is 
remarkably similar for all BCL-2 family canonical interactions [50, 52, 74, 75]. 
Notwithstanding this, individual family members display preferences for 
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which of their pro-apoptotic counterparts they bind to [40, 76]. Such 
variances in binding affinity can be accounted for by differences in the 
primary amino acid sequence of different proteins, which change the 
electrostatic and hydrophobic contacts between individual binding pairs in 
the groove, and also alter the potential for steric clashes. This helps explain 
differences seen in specificity and selectivity, for example why BAD 
demonstrates strong affinity for BCL-XL and weak affinity for MCL1, while 
NOXA has strong affinity for MCL1, yet little or no affinity for BCL-XL [71, 77], 
and also why some BH3 onlys act as direct activators of BAX and BAK, 
while others act only as apoptotic sensitizers [50, 52, 78]. 
	
1.2.2 Downstream effects 
	
The anti-apoptotic family member BCL-XL was the first to have a high 
resolution structure published. Similarities between the structure of BCL-XL 
and the membrane insertion domains of the colicins and diphtheria toxin 
were observed [30], suggesting that BCL-2 family proteins may exert their 
apoptotic effects through pore formation in membranes. This has 
subsequently proved to be the case: MOMP involves the formation of pores, 
allowing the escape of pro-apoptotic molecules including cytochrome c from 
the intra-membrane space into the cytosol. As previously stated, this is 
considered to be the ‘point of no return’, the instant at which the cell 
becomes committed to undergoing apoptotic cell death. MOMP is the 
primary means of inducing cancer cell death in response to both 
radiotherapy and chemotherapy [79], as well as stresses incurred by the cell 
during tumour progression [80]. Downstream of MOMP, cytosolic 
cytochrome c binds the protein Apaf-1 (apoptotic protease activating factor 
1) [81], leading to Apaf-1 oligomerisation [82]. Procaspase 9 molecules then 
bind to each of the Apaf-1 monomers in the oligomeric structure to form a 
heptameric assembly known as the apoptosome, a high molecular weight 
complex that promotes caspase 9 activation [83] [84-86]. This causes a 
subsequent proteolytic cascade of executioner caspases, leading to 
cleavage of cellular components, apoptosis, and clearance of cellular debris 
[87, 88] (Figure 1-6).  
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Figure 1-6 – Apoptotic activity downstream of MOMP in mitochondrial 
apoptosis. Cytosolic cytochrome c molecules bind monomers of Apaf-1, 
which oligomerise to form a heptamer. Pro-caspase 9 molecules bind to 
each Apaf-1 monomer in the heptameric assembly, forming a high 
molecular weight assembly called the apoptosome, which promotes 
caspase 9 activation and initiates the caspase cascade. 
 
1.2.3 Non-canonical interactions 
 
It should be noted that the canonical BH3 in BC binding groove interaction is 
not the only binding event occurring between BCL-2 family members; other, 
non-canonical binding events occur, which act allosterically outside of the 
binding groove. They cause the activation or inhibition of BAX and BAK and 
induce their oligomerisation, regulate the affinity of BH3 only proteins for 
their pro-survival binding partners, and modulate binding activity with non 
BCL-2 family members[89]. 
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Pro-survival members also interact with downstream proteins in the 
apoptotic cascade, including some caspases. BCL-2 interactions hold pro-
caspase 8 in its inactive form, preventing it from cleaving BID to its active, 
truncated tBID variant and stalling the caspase cascade of extrinsic 
apoptosis in some cases of neuroblastoma. Also, BCL-XL has been shown to 
interact with both Apaf-1 and caspase 9, preventing the formation of the 
apoptosome downstream of MOMP in mammalian cell systems [90, 91]. 
 
Proteins from outside the BCL-2 family bind and regulate the activity of 
family members. They may do this through increasing [92], or decreasing 
[93, 94] the interactions of pro-survival family members with the MOM, doing 
so by way of direct protein to protein interactions, or through post translation 
modifications [95-97]. Other proteins interact with pro-survival members to 
regulate their stability in the cell [98, 99]. 
 
1.3 BCL-2 family dysregulation 
 
From the first use of the term apoptosis almost 50 years ago, predictions 
were made that its dysregulation was likely to underlie a number of diseased 
states [100]. This is true for many types of cancer; indeed, the ability to 
evade apoptosis is one of the hallmarks of cancer identified by Hanahan and 
Weinberg in their landmark Cell paper [17] (Figure 1-7). 
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Figure 1-7 – Evading apoptosis as a hallmark of cancer. Figure adapted from 
[17] 
 
It is thought that the mutations to cancer cells that result in dysregulation of 
apoptosis occur early in tumour progression: this allows the cells to survive 
and accumulate other oncogenic mutations that drive further tumour 
development. Cancer cells hijack the same BCL-2 intra-family interactions 
that occur in healthy cells under normal physiological conditions, but alter 
the balance between pro- and anti-apoptotic members to increase the 
apoptotic threshold (Figure 1-8). This means that in many cancers, despite 
high levels of cellular stress, the balance is pushed towards cell survival, 
often due to increases in the levels of functional pro-survival members. 
Genomic changes leading to the over expression of anti-apoptotic members 
have been detected in many cancers [19, 101], likewise genetic deletions or 
mutations to pro-apoptotic members are also seen [102, 103]. Increased 
expression of pro-survival members such as BCL-2, BCL-XL or MCL1 
provides competitive and selective advantage to cancer cells; such cells are 
described as being ‘addicted’ to these anti-apoptotic members, as without 
them, they cannot survive in the face of the death inducing signals that 
persist during tumour progression. 
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Figure 1-8 – ‘BCL-2 family addiction’ in cancer.  Healthy cells in the Basal 
State have an excess of anti-apoptotic BCL-2 family proteins, and the 
apoptotic threshold is balanced in favour of cell survival. When cells are 
subjected to cytotoxic stress, they upregulate levels of BH3 only 
proteins, and the balance moves in favour of apoptosis. However, 
cancer cells often circumvent this process by upregulating pro-survival 
BCL-2 family members, setting the balance back in favour of cell 
survival. Such cancer clones are said to be ‘addicted’ to the BCL-2 
family protein they over express.  
 
Some of these death signals are induced by the very oncogenes that 
promote tumour growth: during tumour progression, c-MYC activity promotes 
both cellular proliferation and apoptosis [80, 104], and is thereby self limiting 
in its ability to transform cells (Figure 1-9); to overcome this, BCL-2 or BCL-XL 
may be overexpressed as a compensatory measure to promote cell survival 
[20, 105, 106].  
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Figure 1-9 – The oncogene c-MYC also promotes apoptosis. Illustrative of the 
complex network of protein to protein interactions that underpin tumour 
progression. c-MYC directly regulates the transcription of BIM and 
NOXA, and activates the p53 pathway of tumour suppression, which 
involves transcription of NOXA and PUMA, and activation of BAX. 
Upregulation of pro-survival proteins often occurs as a compensatory 
measure, leading to BCL-2 or BCL-XL addiction. 
 
Defects in the mitochondrial apoptotic pathway are also common features of 
chemo-resistant cancers [104, 107]. This is usually due to deficiencies in the 
expression of, or failure to up-regulate, specific BH3 only proteins. Take BIM 
as an example: this BH3 only member is required for the action of 
therapeutics including paclitaxel [108], glucocorticoids [109], and kinase 
inhibitors including imatinib, erlotinib and gefitinib [110-113]. 
 
1.4 BCL-2 family proteins and cancer 
 
1.4.1 BCL-2 
 
More than thirty years ago, a number of groups began to report a novel 
t(14;18) translocation between chromosomes 14 and 18, resulting in the 
fusion of the immunoglobin heavy chain and BCL2 (B cell leukaemia locus 
2), in acute B cell leukaemia and follicular lymphoma cells. This caused 
overexpression of the BCL-2 protein [114-118], a phenomenon that was 
subsequently shown to enhance the survival of cells under apoptotic stress 
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[20, 119-121]. BCL-2 was therefore identified as an anti-apoptotic protein 
and became the ‘founding member’ of the BCL-2 family.  
 
Elevated levels of BCL-2 are seen in numerous solid and blood borne 
tumours. In addition to the t(14;18) related increase seen in follicular and 
large B cell lymphomas, BCL-2 is also overexpressed in melanoma, 
neuroblastoma, and in breast, prostate, colorectal and small cell lung 
cancers [122-128]. The causes of overexpression are varied. In lymphomas, 
the aforementioned t(14:18) translocation places the Bcl-2 gene adjacent to 
immunoglobulin heavy chain enhancer elements, leading to increased levels 
of BCL-2 transcription [19, 114, 116]. The half life of BCL-2 in the cell is 
regulated by the ubiquitin-proteosomal system [129-131], and mutations in 
proteins involved in this process such as INrf2 reduce the level of ubiquitin 
tagging of BCL-2, reduce turnover rates, and stabilise levels of BCL-2 under 
conditions of apoptotic stress [131]. BCL-2 levels are also indirectly 
increased due to genetic mutations resulting in the loss of miR-15a and miR-
16, which would normally target BCL-2 mRNA: such mutations are seen in 
over 50% of CLL patients [132]. 
 
BCL-2 is also able to promote tumour progression by means outside its 
canonical role as an apoptotic inhibitor.  It is implicated in promoting the 
epithelial-mesenchymal transition, and in elevating levels of invasiveness 
and enhanced metastatic potential in multiple cancer cell lines, including 
breast carcinoma, glioma, squamous carcinoma and neuroblastoma cells 
[133-137]. It is also implicated in angiogenesis in multiple tumour types [138-
141]: its overexpression is often seen in tandem with hypoxia in cancer cells, 
where it promotes the release of VEGF, a potent pro-angiogenic factor [142-
144]. 
 
1.4.2 BCL-XL 
 
BCL-2 overexpression is seen in many blood borne malignancies, but BCL-
XL is thought to have a more important pro-survival role than BCL-2 in many 
solid tumours. Evidence also points to BCL-XL being more potent in its anti-
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apoptotic activity, due to the broad range of pro-apoptotic partners it 
interacts with. Its overexpression also leads to chemo-resistance in multiple 
cancer cell lines [145].  
 
BCL-XL has been found to be over-expressed in prostate and breast cancer 
patients [146, 147]. Increased copy number of the BCL-XL gene has also 
been found in multiple solid tumours [148]. Levels of BCL-XL activity may 
also be elevated in cancer cells in which certain miRNAs are deficient: for 
example, reductions in levels of miR-let7c have been seen in lung cancers, 
hepatocellular carcinomas and AML [149-151], and reduced levels of miR-
491-5P in ovarian, colorectal and pancreatic cancers [152, 153]. 
 
BCL-XL exerts other tumour promoting effects outside of its canonical role in 
mitochondrial apoptosis. Studies have reported its ability to induce EMT, a 
pre-requisite for metastatic activity, in lung, breast and pancreatic cell lines 
[154, 155], and to promote invasive behavior in breast carcinoma, glioma, 
and colon cancer cells [154, 156-158]. It has been shown to directly interact 
with the RAS oncogene in a BH4 dependent manner, modulating RAS’s 
downstream activity to induce production of the proteins HMGA2 and 
FOSL1, which promote a non-differentiated, stem like phenotype in cancer 
cells [159]. 
 
Worthy of specific comment in the context of apoptotic dysregulation are the 
interactions between BCL-XL and the pro-apoptotic effector BAX. BCL-XL is 
recruited to the MOM bound to tBID. Once at the membrane, it behaves in 
the same way as other pro-survival family members, binding BAX, 
preventing its oligomerisation and MOMP, thus aiding cell survival, even in 
the presence of BAX activating stimuli [67]. But BCL-XL has also been 
shown to retrotranslocate BAX away from the MOM and back to the cytosol, 
abrogating BAX insertion in the membrane and preventing its subsequent 
activation by pro-apoptotic factors [160, 161]. As only around 100 molecules 
of BAX are required per mitochondria to induce MOMP [162], retro-
translocation by BCL-XL may prove to be an extremely important protective 
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function. Over expression of BCL-XL therefore benefits tumour progression 
by a variety of mechanisms. 
 
1.4.3 MCL1 
 
While MCL1 shares many features with other pro-survival family members, it 
also has  a number of unique differences. Compared to BCL-2 and BCL-XL, 
its transcription, translation and proteosomal degradation in the cell are very 
tightly controlled [163], hence it has a much shorter cellular half life, of up to 
4 hours, but often much less, depending on cell type and intra-cellular 
conditions [164]. MCL1 also has an extended N-terminus, which is thought 
to be involved in regulating MCL1 turnover rates and localisation in the cell.  
 
MCL1 is considered an important target in cancer therapy, as its over-
expression is one of the most common genetic abnormalities seen in 
multiple tumour types [101, 145]. MCL1 has been found over-expressed in 
CLL and multiple myeloma samples [165-168], also in solid tumours 
including breast, ovarian, gastric and hepatocellular carcinomas, and in liver 
metastases from colorectal cancer patients [169-173]. Additionally, MCL1 
over-expression is a major resistance factor in many chemo-resistant cell 
lines [174-176]. It also confers resistance to tumours treated with drugs that 
are selective for other pro-survival members, including BCL-2 and BCL-XL.  
 
To date, the development of binders / inhibitors for MCL1 has proven difficult 
in comparison to other pro-survival members, possibly due to the fact that 
the hydrophobic BC binding groove of MCL1 is more rigid than that on either 
BCL-2 or BCL-XL  [73].  
 
1.4.4 BAX and BAK 
 
Much of the research carried out on the role of BAX in tumour progression 
has been done using cellular systems [177, 178] or mouse models [179-
182]. Inactivating BAX mutations in tumour samples are relatively 
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uncommon, compared to mutations that cause upregulation of pro-survival 
family members. However, frameshift mutations of BAX have been detected 
in colon cancers of patients suffering from defects in DNA mismatch repair, 
known as the microsatellite mutator phenotype [102, 183]. BAX mutations 
were also found in 21% of human haematopoietic malignancies sampled, 
especially in samples of acute lymphoblastic leukaemias [184]. These 
mutations led to alterations in BAX dimerization and inhibition of its pro-
apoptotic function.  Epigenetic silencing of BAX, through hyper-methylation 
of the 5’UTR near the TATA box of the Bax gene, has also been found in 
glioblastoma patients [185]. 
 
Inactivating BAK mutations are encountered even less frequently, but have 
been seen in gastric and colorectal cancers [186].  
 
1.5 BAX / BAK Oligomerisation 
 
BAX and BAK are the pro-apoptotic effector members of the BCL-2 family, 
oligomerising at the mitochondrial outer membrane to cause MOMP, which 
effectively commits the cell to undergo apoptotic cell death. As such, BAX 
and BAK are essential to the apoptotic process, but their activity must be 
tightly regulated to prevent damage to healthy cells. 
 
Monomeric BAX and BAK molecules are dormant, and must be activated 
before they are able to oligomerise, form pores at the MOM, and trigger their 
apoptotic effects. In their inactive, monomeric states, BAX and BAK reside in 
different parts of the cell. Unique among the multi domain family members, 
BAX sequesters its own C terminal transmembrane TM domain (α9) in its 
own BC binding groove (Figure 1-10b). This not only covers the hydrophobic 
residues of the BC groove, but also conceals the hydrophobic residues of 
the α9 helix, hence BAX is predominantly cytosolic rather than membrane 
bound in healthy cells. The α9 TM domain of BAK contains more 
hydrophobic residues than that on BAX; it appears to prefer the overtly 
hydrophobic membrane environment to the more amphipathic environment 
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of its own BC groove, and is therefore found constitutively membrane bound 
in the MOM (Figure 1-10a). 
 
 
 
Figure 1-10 - BAX and BAK localisation at the Mitochondrial Outer Membrane. 
a) BAX and BAK transmembrane domain sequences. Hydrophobic 
residues are shown in red. The higher proportion of hydrophobic 
residues in the BAK TM may explain why BAK is constitutively located 
at the MOM, while cytosolic BAX sequesters its own TM domain in its 
amphipathic BC groove. b) Structure showing the C terminal TM domain 
of BAX (red) bound in the BC groove (PDB 1F16). c) BAX requires a pre-
activation step before it translocates to the mitochondrial membrane. 
This is thought to be triggered by the transient binding of a BH3 family 
member to a rear pocket at the conjunction of the α1 and α6 helices, 
which is on the opposite side of BAX to the BC groove. Figure shows 
the BH3 domain of BIM (red) bound to the rear pocket. α1 helix shown in 
blue, α6 helix in magenta (PDB 2K7W). 
 
BAX requires a pre-activation step before translocating to the mitochondrial 
outer membrane. This pre-activation step is thought to involve a transient 
interaction with an activator BH3 only protein at a non-canonical, N-terminal 
binding site on BAX, which acts allosterically to cause a conformational 
change that displaces the TM domain from the BC groove [45, 187, 188]. 
The binding site is located on the rear side of BAX (opposite the BC groove), 
is partially masked by the unstructured loop region between α1 and α2, and 
has a similar distribution of charged and hydrophobic residues to the 
canonical BC groove [45, 189] (Figure 1-10c). Displacement of the TM 
BAX	TM	-						WQTVTIFVAGVLTASLTIWKKMG 
	
BAK	TM	-						LNVLVVLGVVLLGQFVVRRFFKS 
a	
b	 c	
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domain facilitates the translocation of BAX from the cytosol to the MOM. 
Interestingly, BAX may be subject to an additional level of regulation: work 
carried out by the same group that initially discovered the BAX N terminal 
binding site also identified the presence of an autoinhibited dimeric form of 
BAX in the cytosol, in which the N-terminal activation site of one protomer 
binds the C terminal, TM domain containing surface of another [190]. 
Interactions with BH3 only proteins disrupt these dimers, causing them to 
dissociate to monomers, which can then translocate to the mitochondria and 
become active.  
 
Activation of BAX and BAK is required at the MOM as a pre-requisite to the 
formation of higher order oligomers. Complexes of the BCL-2 core of BAK 
bound to the BH3 domain of BID studied using solution NMR [50], and 
crystal structures of BAX bound to BID BH3 [52] indicate that the activation 
step involves low affinity binding of a BH3 only direct activator at the BC 
groove of BAX or BAK, with subsequent conformational changes in the BCL-
2 core that exposes their respective BH3 domains.  
 
Exposure of the BH3 domain uncovers hydrophobic regions on BAX and 
BAK that need embedding into membranes, or alternative hydrophobic 
protein interfaces; this leads to oligomerisation. The nature and method of 
formation of these oligomers remains to be elucidated. It is also unknown 
whether BAX and BAK oligomers form proteinaceous or lipidic pores, and 
whether the pores are closed, linear assemblies, or unstructured aggregates 
[191, 192]. A number of models exist, competing to explain the means of 
activation, and subsequent oligomerisation and pore formation. Each model 
has biochemical evidence backing its claims, but a relative dearth of 
supporting structural data.  
 
Initially, a single interface ‘daisy chain’ model of oligomerisation was 
proposed for BAX, with the BH3 domain of one BAX monomer engaging a 
groove formed by the intersection of α1 and α6 helices on another [193]. A 
similar model was also proposed for BAK [194]. However, there is now a 
body of evidence to support the formation of symmetric BH3 in groove 
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homodimers as the basic oligomeric unit for both BAX and BAK [52, 195-
199]. Various methods have been used to confirm this mechanism in vitro, 
including stabilization of complexes with antibodies recognizing BH3 
domains and N-terminal sequences, limited proteolysis assays to identify 
stable and exposed fragments during conformational changes, and 
supporting mutagenesis studies [39, 195, 200, 201]. High resolution 
structural data for these complexes in the mitochondrial outer membrane 
have yet to be obtained. How and whether these dimers go on to form higher 
order oligomers is a subject of ongoing debate and study. Biochemical 
studies suggest that the α6 helix, on the opposite side of BAX and BAK to 
the BC groove, may mediate a non-canonical binding interaction, but no 
structural data exist to support this claim [202, 203]. Structural studies of the 
BAX BH3 in groove dimer have raised another possible mechanism for the 
induction of MOMP, which abrogates the requirement for formation of a 
structured pore in the MOM: dimer formation results in exposure of a high 
concentration of lipophilic residues, which may penetrate the mitochondrial 
membrane, displacing phospholipid headgroups and inducing membrane 
curvature that would eventually cause the membrane to tear. Should this 
prove to be the case under physiological conditions, oligomerisation of BAX 
dimers into unstructured aggregates could cause MOMP, without the need 
for a structured proteinaceous or lipidic pore. This would be analogous to the 
‘carpet’ model of membrane permeabilisation employed by anti-bacterial 
toxins such as the melittins [204, 205].  
 
The structural mechanics of how BAK and BAX insert into the MOM to cause 
MOMP is also an open question. The core α5-α6 helices of both effector 
proteins are able to insert as hairpins into the MOM, where they bear striking 
similarity to the pore forming domains of bacterial toxins such as colicin A 
and diphtheria toxin [30, 206] (Figure 1-11). Synthetic peptides based on this 
α5-α6 combination also have pore forming abilities [207-209]. However, 
structural studies on BAX carried out by Czabotar and co-workers provide 
compelling evidence that the α5 and α6 helices dissociate on membrane 
binding [52], separating BAX into α1-α5 ‘core’ and α6-α8 ‘latch’ domains, 
and that this is an essential step in the ability of BAX to form domain 
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swapped dimers. Recent work by the same group has uncovered a similar 
mechanism for BAK [51]. 
 
 
Figure 1-11 – Comparison of the pore forming domains of Colicin A in red 
(PDB 1COL, left) and BAX in blue (PDB F16, right). Both comprise a pair 
of alpha helices, able to insert as hairpins in cellular membranes. 
 
1.6 BCL-2 family therapeutics 
 
As the dysregulation of BCL-2 family proteins is implicated in human 
disease, the family is considered a worthwhile target for the development of 
novel therapies [210, 211], particularly those targeting cancer. A strange 
paradox exists for cancer cells: although they are able to circumvent 
apoptosis, most of them are closer to their apoptotic threshold, and therefore 
more ‘primed to die’, than their normal, cellular counterparts. Evidence 
points to this being due to elevated levels of BH3 only proteins [43, 212, 
213]. Tumour cells should therefore be more responsive than normal, 
healthy cells to therapeutics targeting the mitochondrial apoptotic pathway, 
specifically those able to tip the balance of BCL-2 family activity back in 
favour of apoptosis. Such therapies would include molecules that mimic the 
pro-apoptotic function of the BH3 domain, so called BH3 mimetics.  
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1.6.1 BH3 mimetics 
 
Much research effort has gone into the development of BH3 mimetics, 
molecules able to mimic the canonical BH3 in BC binding groove interaction 
described earlier in this chapter. Targeting this interaction with novel 
inhibitors is difficult, because the BC groove is shallow.  
 
For a small molecule, peptide, or other binder to truly be considered a BH3 
mimetic, it must meet certain criteria: it must have high affinity for at least 
one anti-apoptotic BCL-2 family member, and its cytotoxic effects must be 
BAX and  / or BAK dependent [214]. Many molecules first thought to act as 
BH3 mimetics had only moderate affinity for their targets and have since 
been found to act through off target effects, independent of BAX or BAK 
[214-216]. 
 
It is also important to consider the size of the therapeutic window available 
for such molecules, given the important physiological roles carried out by 
many pro-survival proteins outside of their canonical roles in mitochondrial 
apoptosis. Gene deletion experiments have demonstrated the 
consequences of losing individual pro-survival members: BCL-2 ablation 
causes the death of renal epithelial progenitor cells, leading to polycystic 
kidney disease [217], while loss of BCL-XL is linked to reduced platelet 
counts and cirrhosis of the liver [218, 219]. Loss of MCL1 causes the 
greatest level of physiological damage, as it is crucial for the ongoing 
survival of several cell types, including lymphocytes, haematopoietic stem 
and progenitor cells, and cardiomyocytes [220-225]. Unless they can be 
selectively targeted to cancer cells, very strong binders that may 
permanently sequester their targets could have negative consequences in 
healthy cells.  
 
Notwithstanding the difficulties outlined above, efforts to develop small 
molecule inhibitors of pro-survival members have been underway since the 
turn of the millennium. Early breakthroughs were made using computer 
based screening and docking strategies, yielding binders to BCL-2 with low 
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micromolar affinities [226, 227]. Soon after, high throughput screens were 
used to identify low micromolar affinity binders of BCL-XL [228, 229]. These 
molecules were shown to be effective in anti-proliferation assays, and were 
able to induce apoptosis in cellular systems. 
 
1.6.2 BH3 peptidomimetics 
 
A strategy that has proved successful is the use of peptidomimetics, small, 
protein like chains that mimic peptides, and usually arise from the 
modification of an existing peptide. An early development in this field was 
the design of terphenyl derivatives mimicking the amphipathic BH3 helix of 
BAK, which bound to the BC groove of BCL-XL with sub-micromolar affinity 
[230, 231]. 
 
In general, unmodified peptides are not good drug candidates, as they suffer 
a number of pharmacological drawbacks, including limited membrane 
penetration and a lack of proteolytic stability once inside the cell. Organic 
chemists have been creative in devising strategies to overcome these 
issues. The incorporation of β-amino acids into peptides to create α/β 
foldamers has been shown to increase proteolytic stability, while maintaining 
the essential α-helical nature of the peptide [232]. This approach has been 
used in the design and synthesis of BIM and PUMA BH3 α/β peptides, which 
have been tested successfully in cellular assays using mouse embryonic 
fibroblast (MEF) cells [232-234]. 
 
Constrained peptides (also known as stapled peptides or SAHBs) have been 
shown to demonstrate improved cell penetration and stability [235, 236]. 
These modified peptides incorporate a constraint between two amino acids 
on the opposite side of the peptide α-helix to the H1-H4 binding residues, 
which stabilises the peptide in a helical conformation. The constraint is 
usually achieved through use of a ring closing olefin cross-metathesis 
reaction, as shown in Figure 1-12, but can also be achieved using amide or 
‘click’ triazole linkages [237-240]. The peptide staple / constraint itself has 
proved to be a far from passive molecular addition: it has been found to 
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impact binding affinity in both positive and negative ways, and must 
therefore be considered when designing and testing such molecules [241-
243]. 
 
 
 
Figure 1-12 – BH3 mimetics - constrained peptides. Comparison of sequences 
of peptides for the BH3 domain of wild type BIM (BIM WT) and a mono-
metathasised variant (BIM MM,) synthesised at the University of Leeds, 
in which monosubstituted α-alkenyl amino acids are substituted at i and 
i+4 positions, then metathesized to create a covalent cross-link on one 
side of the peptide. The cross-link ‘constrains’ the peptide in a helical 
structure, affording improved helicity and proteolytic stability. The 
structure on the right of the figure shows the BIM MM peptide bound to 
BCL-XL (PDB 5C3G). BIM MM was shown to inhibit interactions between 
BCL-XL and BAK BH3 with much greater potency than BIM WT (IC50 11.9 
±	3.8μM for BIM MM, compared to IC50 320 ± 70μM for BIM WT) [244]. 
 
 
1.6.3 Small molecule inhibitors 
 
The use of small molecule inhibitors of pro-survival BCL-2s, typified by the 
acyl-sulfonamides pioneered by Abbott laboratories, has been a notable 
success story in the field of BH3 mimetics. ABT-737 (Figure 1-13a) was the 
first such molecule developed, demonstrating high affinity (Kd <1nM) for 
BCL-2, BCL-XL and BCL-W [245], and able to kill cells in a BAX / BAK 
dependent manner [215, 246]. The fact that ABT-737 exhibits poor aqueous 
solubility and oral bioavailability precluded its clinical development, but it is 
still widely used as a molecular probe. ABT-263 (navitoclax) was 
subsequently developed as an orally available analogue of ABT-737 (Figure 
1-13a).   
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Figure 1-13 – BH3 mimetic small molecules - acyl sulphonamides. a) ABT-737 
and its orally available analogue ABT-263 (navitoclax). b) ABT-737 and 
ABT-263 share a similar mechanism of action, binding strongly to the P2 
and P4 pockets in the BC groove of their target proteins. Shown here is 
ABT-737 bound to BCL-XL. Figure adapted from [247]. 
 
ABT -737 and navitoclax share a similar mechanism of action: both are seen 
to bind the P2 and P4 pockets in the BC groove of their target proteins, with 
evidence of substantial remodelling of the P2 pocket on binding [248, 249] 
(Figure 1-13b). Navitoclax has undergone clinical trials for treatment of 
haematological tumours, both as a single agent and in combination, and 
demonstrated early promise in patients suffering from CLL [212, 250-254]. 
Unfortunately, navitoclax also induced acute thrombocytopaenia (a sudden 
drop in platelet levels) in these patients, highlighting the important role 
carried out by BCL-XL in platelet survival [251, 255], and resulting in a limited 
therapeutic window for the treatment of lymphoid malignancies.  
 
The limited therapeutic window of multi-target small molecules such as ABT-
263 has driven the search for single target inhibitors. Abbott laboratories 
designed ABT-199 (venetoclax), a selective inhibitor of BCL-2, specifically to 
a	
a	
b	
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avoid the thrombocytopaenia caused by BCL-XL inhibition [249] (Figure 1-14). 
To date, venetoclax is the only BH3 mimetic to attain FDA approval, for use 
in the treatment of CLL patients with an identified chromosomal 17p deletion, 
where it has been shown to act without inducing thrombocytopaenia. 
	
	
	
	
	
	
Figure 1-14 - Single target inhibitors. ABT-199 selectively targets BCL-2. 
WEHI-539 is a selective inhibitor of BCL-XL. 
 
Many solid tumours are addicted to BCL-XL, hence selective inhibitors of this 
protein are an attractive proposition. Researchers at WEHI, in collaboration 
with a team from Genentech, used high throughput screening, combined 
with structure guided design and classical medicinal chemistry techniques, 
to develop WEHI-539, which binds BCL-XL with sub nanomolar affinity, and 
high selectivity over other pro-survival members (more than 400 fold 
compared to BCL-2) [256, 257] (Figure 1-14). WEHI-539 does appear to be a 
genuine and selective BH3 mimetic acting against BCL-XL, as do its recently 
synthesised analogues A-1155463 and A-1331852 [257-259]. WEHI-539 
has shown synergistic anti-tumour activity in combination with doxorubicin in 
osteosarcoma samples, and when combined with carboplatin against 
ovarian cancer cells [260, 261], and A-1155463 inhibits SCLC xenograft 
growth in mouse models [259]. However, due to the role of BCL-XL in 
platelet survival, the ongoing issue of thromobcytopaenia means that the 
clinical application of any BCL-XL inhibitor remains an issue. 
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Some BH3 mimetics have reached the clinical trials stage, but almost all 
have failed to be approved for use in the clinic due to their lack of efficacy as 
single agents, or the rapid appearance of resistant clones [262]. Therapeutic 
resistance to mimetics such as navitoclax and venetoclax is most commonly 
caused by increased levels of cellular MCL1 [175, 215, 263-266].  The 
search for MCL1 inhibitors has therefore been an active area of research, 
though many of the putative BH3 mimetics discovered that apparently target 
MCL1 appear to exert their effects indirectly through NOXA upregulation. An 
exception to this is A-1210477, a recently discovered indole-2-carboxylic 
acid molecule, which disrupts MCL1:BIM complexes in the cell, has been 
shown to induce apoptosis in MCL1 dependent cells as a single agent, and 
enhances ABT-263 activity in other cells lines [265]. Strangely, the effect of 
treatment with A-1210477 is an accumulation of MCL1 in cells prior to 
apoptosis: this is thought to be due to MCL1 being sequestered and held 
inactive, and therefore being unavailable to bind to HUWE1 (MULE), an E3 
ligase that ubiquitylates MCL1, tagging it for degradation at the proteasome.  
 
For the apoptotic effectors, there is interest in developing direct activators of 
BAX and BAK as potential cancer treatments [267], and conversely for 
inhibitors of BAX and BAK to be used in diseases such as amyotrophic 
lateral sclerosis, or for patients suffering ischaemic reperfusion injury, where 
excessive acute levels of apoptosis occur [268-270]. In principle, molecules 
could be developed to directly activate BAX and BAK, by mimicking the 
actions of direct activator BH3s, in instances where, for instance, direct 
activators have been downregulated by tumours [101, 271]. The ability to 
directly target BAX and BAK in this manner would also provide a means of 
avoiding the cytotoxic side effects of targeting anti-apoptotic family 
members. Conversely, the ability to dampen the activity of effector proteins 
could also be put to good use in limiting the levels of ischaemic cell death in 
patients suffering heart attack or stroke [272]. 
	
The ability to develop molecules that target individual BCL-2 family members 
not only provides the basis for the development of therapeutics, but also 
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allows for the development of molecular tools to uncover the physiological 
activities of their target proteins, in both normal and pathological states, and 
to help unravel the interactions of BCL-2 protein family members, both within 
and without the family. The search for more and better ways to identify and 
synthesize such molecules continues.  
 
1.7 Use of Phage Display and Affimers to identify novel 
binders for target proteins 
 
Phage display has proven to be a useful tool in drug discovery, providing a 
relatively fast and cost effective means of identifying ligands for targeted 
proteins. It is dependent on the ability of bacteriophages to display protein 
fragments, peptides and other structures on their coat proteins, achieved by 
insertion of the nucleotides encoding the sequence of interest into the coat 
protein gene [273]. Based on this ability, simple molecular biology methods 
can be used to develop large libraries of clones, which are screened against 
target proteins to identify novel binding partners [274]. 
 
A typical phage display experiment begins with immobilisation of the target 
protein, followed by a series of ‘panning rounds’, in which the target is 
incubated with the phage library, non-bound phage is washed off, then 
bound phage is eluted and amplified by transfecting a phage display 
competent strain of bacterial cell. The use of multiple panning rounds results 
in the selection of high affinity binders for the target protein [274], which can 
then be sequenced to establish the genotype and phenotype of the binding 
residues (Figure 1-15). 
 
- 32 - 
	
	
	
 
Figure 1-15 - Typical phage display experiment. A phage library (> 1010 
clones) is generated. This library is incubated with an immobilised 
target protein in the first of a series of ‘panning rounds’. Unbound phage 
is washed off, then bound phage is eluted and amplified by transfecting 
a phage competent strain of E.coli. Amplified phage is used in future 
panning rounds and the process is repeated, leading to the selection of 
high affinity binders, which can be sequenced to establish genotype, 
and subcloned into appropriate vectors for recombinant protein 
expression. Adapted from [275] 
 
High affinity binding sequences can be sub-cloned into suitable vectors and  
recombinantly expressed as binding proteins, for further structural and 
biophysical analysis.  Such proteins may mimic natural ligands for the target 
proteins, or they may display completely novel epitopes, which none the less 
still bind potently, and may affect endogenous interactions or induce 
conformational changes by allosteric mechnisms. Such epitopes may be 
transferable to small molecule scaffolds, which can be used to develop new 
drug targets. 
 
Historically, antibodies have been the most commonly used binding proteins 
[276], but they are not without limitations. Being reliant on animals and 
mammalian cell culture systems for their production, they are both costly and 
time consuming to produce. They cannot be recombinantly expressed in 
bacterial systems, and are not always thermally stable. Protein engineering 
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methods have therefore been used to develop alternative non-antibody 
binding proteins, which mimic the positive molecular recognition properties 
of antibodies, but overcome their drawbacks. These include reagents such 
as DARPins [277], Monobodies [278] and Affibodies [279]. 
 
Affimers (adhirons) are another such class of novel non-antibody scaffold 
proteins, developed at the University of Leeds [280]. They are based on a 
phytocystatin consensus sequence, derived by identifying the most common 
amino acid residues at each position in an alignment of 57 individual 
phytocystatin sequences. Phytocystatins are small, plant derived cysteine 
protease inhibitors [281]. An Affimer comprises four β-strands, one α-helix, 
and two loops connecting each pair of β-strands and displays all the 
desirable properties of an ideal non-antibody binding protein: small, 
monomeric, high solubility, thermal stability, with a lack of disulphide bonds 
and glycosylation sites, and is therefore ideal for peptide presentation. The 
Affimer scaffold has been used to construct a phage display library 
containing over ten billion clones in which the inhibitory sequences on the 
phytocystatin scaffold have been replaced with a pair of nine residue 
variable peptide loops, which can be used to ‘pan’ against target proteins to 
identify novel binders for those proteins (Figure 1-16). 
 
Affimers have proved useful in a variety of ways. They have been raised 
against a large number of individual proteins, and are able to distinguish 
different isoforms [280, 282]. In the last couple of years, Affimers have been 
developed for use in the production of biosensors [283], with practical 
applications targeting molecules such as interleukin 8 (IL-8), which is 
associated with chronic inflammatory diseases. Such biosensors can be 
used to track disease progression [284]. Affimers have also been tagged 
with gandolinium(III) complexes for potential use as contrast agents in MRI 
[285], and have been used to probe the surface of molecules such as p300, 
to help inform future inhibitor design to antagonise the HIF-1α : p300 
interaction [286], which is thought to be involved in tumour growth, 
vascularization and metastatic potential [287, 288]. Most recently, they have 
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been shown to inhibit protein to protein interactions, both by direct binding, 
and by allosteric actions [289]. 
 
 
	
	
	
 
Figure 1-16 – Affimers are non-antibody scaffold proteins based on a highly 
stable phytocystatin concensus sequence. The scaffold structure 
comprises four β-strands, one α-helix, and two loops connecting each 
pair of β-strands. The Affimer scaffold has been used to construct a 
phage display library containing over ten billion clones in which each of 
the connecting loops (circled in red) contain nine randomly assigned 
residues, which can be used to ‘pan’ against target proteins to identify 
novel binders for those proteins (PDB 4N6T). 
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1.8 Project Aims 
 
In recent years, great progress has been made in elucidating the interactions 
between different BCL-2 family members, and in the design and synthesis of 
molecules to mimic or antagonise those interactions. Much effort in this field 
has been directed towards the development of inhibitors of the pro-survival 
BCL-2 family members, with a view to directing the design of drug 
candidates to negate any survival advantage gained by cancer cells that 
avoid apoptosis through overexpressing these proteins. Though success in 
the clinic has so far been limited, molecules that selectively engage different 
BCL-2 family members have proved to have other benefits, such as helping 
to elucidate the activities of individual family members using in vitro and in 
cellulo assays. Efforts to develop mimetics targeting the pro-apoptotic 
effectors BAX and BAK have proved more difficult, though recent 
breakthroughs providing structural details of these proteins and their likely 
mode of activation have provided renewed impetus in this area. There has 
also been a growth in interest in non-canonical interactions occurring outside 
the BC groove, which may regulate apoptotic activity through allosteric 
mechanisms.  
 
In its original form, this research project was focussed entirely on BAX, with 
the aim of using cellular systems and proteomic methods to characterise the 
BAX interactome at different stages of apoptotic induction. The hypothesis 
behind this work was that as yet undiscovered endogenous binding partners 
exist for BAX, and that discovering them and studying the nature of their 
interactions would help elucidate the mechanism of BAX activation in the 
cell.  
 
Initial experiments aimed to capture BAX at various time-points between the 
application of an apoptotic stimulus and the appearance of apoptotic 
features in a panel of Mouse Embryonic Fibroblast (MEF) knock out cell 
lines, but issues were encountered in setting up a credible, working cellular 
system: the BAX -/- BAK -/- double knock out cell line responded to apoptotic 
stimuli in the same manner as the BAX -/- and BAK -/- single knock out lines. 
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This, combined with difficulties in obtaining anti-BAX antibodies sensitive 
enough to detect small amounts of BAX in extracts from sub-cellular 
cytosolic and mitochondrial fractions, led to a change in direction for the 
project at the transfer stage. 
 
The revised project continued to involve study of protein-protein interactions 
of BAX, but also expanded its remit to include other members of the BCL-2 
family. The primary aim of this project was to expand the toolbox of 
molecules able to bind (and hopefully regulate the activity of) BCL-2 family 
members, using the Affimer scaffold developed at the university of Leeds. It 
was hypothesised that the use of phage display experiments to probe the 
entire surface of target BCL-2 proteins would identify Affimers with the ability 
to bind the BC groove using novel binding motifs, and also identify binding 
sequences targeting novel sites on the protein surface that may moderate 
interactions through allosteric mechanisms. The use of multiple panning 
rounds would also allow for ‘cross-panning’ against multiple BCL-2 family 
members, with the view of identifying cross-reacting binding sequences that 
are able to target more than one family member at once. Within this context, 
the project aimed to raise Affimers as detailed below, and to characterise, as 
far as possible, their interactions with target proteins: - 
 
• Raise Affimers selectively against the pro-apoptotic effectors BAX 
and BAK. 
• Raise Affimers selectively against the pro-survival proteins BCL-2, 
BCL-XL and MCL1. 
• Cross pan to raise Affimers able to act against multiple pro-survival 
proteins. 
 
The lack of structural evidence relating to higher order oligomers of BAX and 
BAK remains an issue in resolving outstanding questions relating to the 
apoptotic activity of these proteins. From in vitro studies, it has long been 
known that detergents are able to induce complex formation in BAX [290]. 
Titration of BAX with BOG is seen to trigger oligomerisation, and the same is 
true of other non-ionic detergents, though the nature of such oligomers has 
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not previously been characterised. A secondary aim of this project was to 
use structural techniques, specifically negative stain electron microscopy, to 
investigate the nature of the oligomers formed when BAX and BAK were 
treated with Tween 20. Though not replicating physiological membrane 
conditions, it was hypothesised that any data obtained could inform future 
research into higher order oligomerisation of these proteins, and help 
determine whether a structured pore is required to induce MOMP. 
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Chapter 2  
 Materials and Methods 
2.1 Materials 
2.1.1 DNA Constructs Used 
 
BCL-XL ML (1-26, 83-209 ‘Missing-Loop’) 
MCL1172-327 
BCL-2 1-205   
BAK 16-185 C-S (C166S) 
BAX 1-171 C-S (C62S C126S) 
 
2.1.2 Bacterial Strains Used 
 
Competent DH5α E. coli cells (Invitrogen, genotype F- endAI hsdRJ7 (r-k, 
Mk+) supE44 thi-I λ- recAl gyrA96 relAI deoR Δ(lacZYA-argF)-U169 
Φ80dlacZΔM15) were used to amplify plasmid vectors containing insert 
DNA. 
 
E. coli expression strain BL21 (DE3) Rosetta 2 (Novagen, genotype F- ompT 
hsdSB(rB- mB-) gal dcm pRARE2 (CamR)) encoding T7 RNA polymerase 
and chloramphenicol resistance was used for over expression of protein 
from plasmid DNA in all cases except those noted immediately below. 
 
Chemically competent C41 (DE3) E. coli cells (Lucigen, genotype F – ompT 
hsdSB (rB- mB-) gal dcm (DE3)) were used to express protein from plasmid 
DNA encoding BAX 1-171 C-S and BAK 16-185 C-S constructs. 
 
E. coli ER2738 cells (NEB, genotype F ´proA+B+ lacIq Δ(lacZ)M15 
zzf::Tn10(TetR)/ fhuA2 glnV Δ(lac-proAB) thi-1 Δ(hsdS-mcrB)5) were used 
for the amplification of phage during affimer panning. 
 
All strains were stored at -80°C, with the addition of 20% glycerol. 
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2.1.3 Plasmid Vectors Used 
 
pET-28a (Novagen), with kanamycin resistance and the addition of a SUMO 
fusion tag (pET-28a-SUMO), was used to clone DNA for all constructs 
except those noted immediately below. 
 
pGEX-6p-1 (GE Healthcare), with ampicillin resistance, was used to clone 
DNA for the BCL-2 1-205  construct. 
 
pTXB1 (NEB), with ampicillin resistance, was used to clone DNA for BAX 1-
171 C-S and BAK 16-185 C-S constructs. 
 
pET-11a (Novagen), with ampicillin resistance, was used to clone DNA for 
all affimers. 
 
2.1.4 Media 
 
Cultures were grown in either LB or 2xYT media, autoclaved and 
supplemented with the appropriate antibiotic.  
 
LB media was made with 10g tryptone soya broth, 5g yeast extract and 10g 
sodium chloride per 1L ddH2O. 
 
2xYT media was made with 16g tryptone soya broth, 10g yeast extract and 
10g sodium chloride per 1L dd H2O.  
 
Agar plates were made with 10g Tryptone, 5g Yeast Extract, 10g NaCl, 20g 
Agar per 1L dd H2O. 
 
Stock solutions of antibiotics were stored at -20°C, and added to media at a 
ratio of 1:1000. Stock concentration of Kanamycin was 50mg/mL, stock 
concentration of Ampicillin 100mg/mL, giving working concentrations of 
50µg/mL and 100µg/mL respectively. 
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2.1.5 Buffers 
	
Buffers used throughout this study are summarized in Table 2-1below. 
 
Table 2-1 – Buffers used in this study 
Procedure / Assay Buffer 
BAX / BAK column buffer 20mM HEPES pH 7.0 
100mM NaCl 
1mM EDTA 
BAX / BAK size exclusion buffer 50mM Sodium Phosphate pH 7.0 
BCL-2 lysis buffer 50mM Tris pH 8.0 
200mM NaCl 
5mM DTT 
1mM EDTA 
0.1% Triton X-100 
BCL-2 high salt wash buffer 50mM Tris pH 8.0 
500mM NaCl 
1mM DTT 
1mM EDTA 
10% glycerol 
0.01% Triton X-100 
BCL-2 low salt wash buffer 50mM Tris pH 8.0 
200mM NaCl 
1mM DTT 
1mM EDTA 
10% glycerol 
0.01% Triton X-100 
BCL-2 size exclusion buffer 20mM Tris pH 8.0 
200mM NaCl 
0.5mM DTT 
5% glycerol 
BclXL / MCL1 column buffer 50mM Tris pH 8.0 
500mM NaCl 
15mM imidazole (wash / elute with 
increased concentration of imidazole: 
50mM, 100mM, 300mM) 
BclXL / MCL1 dialysis buffer 50mM Tris pH 8.0 
250mM NaCl 
BclXL / MCL1 size exclusion buffer 50mM Tris pH 8.0 
250mM NaCl 
0.5mM DTT 
2.5% glycerol 
Affimer lysis buffer 50mM Tris pH 8.0 
500mM NaCl 
15mM imidazole 
FA binding buffer (MCL1, BclXL, BCL-
2) 
20mM Tris pH8.0 
150mM NaCl 
0.01% Triton x100 
FA binding buffer (BAX, BAK) 50mM Sodium Phosphate pH 7.0 
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0.02% v/v BSA 
SDS running buffer 25mM Tris pH6.8 
190mM Glycine 
0.1% w/v SDS 
WB transfer buffer 25mM Tris pH6.8 
190mM Glycine 
20% MeOH 
CD Buffer 50mM Sodium Phosphate pH 7.0 
 
2.1.6 Reagents 
	
All reagents were supplied by Sigma Aldrich, unless otherwise specified. 
2.2 Methods 
2.2.1 Recombinant DNA methods 
2.2.1.1 PCR 
	
Affimer PCR subcloning experiments were conducted in 0.2 mL thin-walled 
dome capped tubes (Alpha Laboratories). The total reaction mixture was 25 
µL containing 5µL 5x Phusion polymerase buffer (New England Biolabs), 
0.75 µL DMSO, 1µL dNTP stock solution (2.5 mM of each dNTP, Invitrogen), 
2 µL each of 10 µM forward and reverse primers, 1 µL PCR DNA template, 
0.25 µL Phusion DNA polymerase (New England Biolabs) and 13 µL water. 
PCR was conducted in a Prime thermocycler (Techne). The PCR protocol is 
detailed in Table 2-2 below. 
Table 2-2 – Affimer PCR subcloning protocol 
Step	 Temp	(°C)	 Time	 ♯of	cycles	
1	 98	 30	sec	 1	
2	 98	
54	
72	
20	sec	
20	sec	
20	sec	
30	
3	 72	 10	min	 1	
4	 4	 	 	
 
PCR amplified samples were digested with 0.5 µL Dpn1 for 1 hour at 37°C, 
analysed by agarose gel electrophoresis and purified using the QIAquick gel 
extraction kit (QIAGEN), following the manufacturer’s recommended 
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protocol. 
 
All other PCR experiments were conducted in 0.2 mL thin-walled dome 
capped tubes (Alpha Laboratories). The total reaction mixture was 50 µL 
containing 10µL 5x Phusion polymerase buffer (New England Biolabs), 1µL 
dNTP stock solution (2.5 mM of each dNTP, Invitrogen), 1 µL each of 10 µM 
forward and reverse primers, 1 µL PCR DNA template, 0.5 µL Phusion DNA 
polymerase (New England Biolabs) and 35.5 µL water. PCR was conducted 
in a Prime thermocycler (Techne). The PCR protocol is detailed in Table 2-3 
below. 
Table 2-3 – General PCR protocol 
Step	 Temp	(°C)	 Time	 ♯of	cycles	
1	 98	 30	sec	 1	
2	 98	
68	
72	
30	sec	
30	sec	
30	sec	
30	
3	 72	 5	min	 1	
4	 4	 	 	
 
PCR samples were analysed by agarose gel electrophoresis and purified 
using the QIAquick gel extraction kit (QIAGEN), following the manufacturer’s 
recommended protocol. 
	
2.2.1.2 Vector Digests and Ligations 
	
Destination vectors used in sub-cloning experiments were cut using 
restriction endonucleases. 1 µg of vector DNA was mixed with 1 µL of each 
restriction endonuclease, 10 µL of appropriate RE buffer (e.g. Cutsmart® 
(New England Biolabs)), and the addition of ddH2O to a total reaction volume 
of 50 µL. Reactions were incubated at 37°C for 3 hours, or at 25°C 
overnight. Cut vector DNA was analysed by agarose gel electrophoresis, 
then extracted and purified using the QIAquick gel extraction kit (QIAGEN), 
following the manufacturer’s recommended protocol. 
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Ligation reactions were set up using 3 molar equivalents DNA insert to 1 
molar equivalent cut vector, 1uL 10x ligation buffer and 1uL T4 ligase (New 
England Biolabs) and the addition of ddH2O to a total reaction volume of 10 
µL. Reactions were incubated at 25°C for 30 minutes., after which ligated 
product was stored at -20°C, ready to be used in transformation 
experiments. 
	
2.2.1.3 Agarose gel electrophoresis 
	
Agarose gels were prepared using 0.5x TBE buffer containing 10,000 x 
SYBR Safe DNA gel stain (Invitrogen). Samples were mixed with 6x DNA 
loading dye (New England Biolabs) prior to loading onto gels. Gels were run 
at 100 V in 0.5x TBE buffer until bands were sufficiently separated. Band 
size was measured by inclusion of a DNA ladder (100 bp or 1kbp)(New 
England Biolabs) alongside the samples. 
 
2.2.1.4 Gibson Assembly 
	
PCR amplified DNA samples were inserted into cut vectors using Gibson 
Assembly® (New England Biolabs) following the manufacturer’s 
recommended protocol. On ice, 50 – 100ng of cut vector was mixed with a 
2-3 x molar excess of DNA insert, made up to 10 µL with dd H2O, and added 
to 10 µL 2x Gibson Assembly® or HiFi® master mix (New England Biolabs) 
for a total reaction volume of 20 µL. Reactions were incubated at 50°C for 20 
minutes on a Prime thermocycler (Techne). 
	
2.2.1.5 Competent cell transformation 
	
50 µL competent E.coli DH5α, BL21 (DE3) or C41 (DE3) cells were 
transformed by addition of 1 µL assembled DNA vector product in ice chilled 
1.5ml Eppendorf tubes, with gentle mixing. Cells were then incubated for 30 
minutes on ice, heat shocked at 42°C for 45 seconds and returned to ice for 
2 minutes. 450 µL of LB was added and the transformation mixture was then 
incubated at 37°C for 1 hour with shaking at 180rpm. 100 µL of transformed 
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cells were spread onto agar plates inoculated with the appropriate antibiotic.  
	
2.2.1.6 Plasmid extraction 
	
Plasmid DNA was extracted from 5 mL of overnight culture using QIAprep 
spin miniprep kit (QIAGEN) as per the manufacturers handbook. The 
extracted DNA samples were stored at -20 °C. Each new plasmid obtained 
from positive colonies was transformed into both DH5α and BL21(DE3) or 
C41(DE3) E. coli strains and glycerol stocks of the resulting cells were 
produced by the addition of 0.6 mL sterile 50 % glycerol to 0.9 mL of 
overnight culture prior to storage at -80. 
 
2.2.1.7 Sanger sequencing 
	
15 µL of each purified recombinant plasmid was sent to Cogenics (Essex) to 
be sequenced prior to expression trials, to test for any mutations introduced 
during PCR. 
	
	
2.2.2 Protein preparation and purification 
 
2.2.2.1 Protein expression – general and small scale 
2.2.2.1.1 OD600 Measurement 
	
The Optical Density (OD) of cell cultures was read with a spectrophotometer 
(Helious β) set to 600 nm by using 1 mL of culture in a plastic cuvette 
(brand) after the spectrophotometer was blanked against a 1mL sample of 
un-inoculated media. 
2.2.2.1.2 Size Exclusion Chromatography 
	
Size exclusion chromatography was performed on a Superdex 75 (26/600) 
column (GE healthcare) attached to an Akta prime system at 4 °C. The 
column, stored in 20% ethanol, was washed with water and equilibrated with 
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appropriate SEC buffer. 5 mL of filtered protein sample (after affinity 
chromatography) was loaded onto the column using a 5 mL injection loop. 
The absorbance of the sample was monitored at 280 nm throughout. Upon 
completion of the method, the column was washed with water and stored in 
20% ethanol. Fractions from within the peak of the UV trace were analysed 
by SDS-PAGE. 
2.2.2.1.3 Protein Concentration Measurement 
	
Approximate protein concentration was determined using a protein assay 
reagent dye (Bio-Rad). 200 µL of dye was added to 800 µL of water and 20 
µL of protein. The sample was placed in a plastic cuvette (Brand) and 
absorbance measured at 595 nm in a UV/visible spectrophotometer 
(Spectronic). The spectrophotometer was first blanked against a sample in 
which 20 µL of appropriate buffer was substituted for protein. In the assay an 
absorbance of 1 signifies a concentration of 1 mg/mL for readings between 
0.2-0.8; if outside this range the volume of protein sample added is adjusted. 
 
Accurate protein concentration was determined by measuring absorbance at 
280nm. The sample was placed in a high precision quartz cuvette (Hellma 
Analytics), with a 10mm light path, and absorbance measured at 280 nm in a 
UV/visible spectrophotometer (Spectronic). The spectrophotometer was first 
blanked against appropriate buffer.  
	
2.2.2.2 Chitin Affinity Chromatography 
	
Mxe intein / chitin binding domain (CBD) tagged fusion protein constructs 
were over-expressed in E.coli C41 (DE3) cells, and purified using a protocol 
adapted from ref[291]. 2 ml of overnight starter culture was used to inoculate 
1 L LB containing 100 µg/ml Ampicillin. Cultures were grown at 37°C plus 
shaking at 180rpm until OD600 reached 0.6 – 0.8. For BAX 1-171 C-S protein 
expression was induced by adding 0.1mM IPTG. Induced cultures were 
grown at 28°C plus shaking at 180rpm overnight. For BAK 16-185 C-S protein 
expression was induced by adding 1mM IPTG, and induced cultures were 
grown at 37°C plus shaking at 180rpm for 4 hours. Cells were harvested by 
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centrifugation (Beckmann JLS 8.1, 5000rpm, 15minutes, 8°C). Cell pellets 
were resuspended in lysis buffer (20mM HEPES pH7.0, 100mM NaCl, 1mM 
EDTA)) and lysed by sonication. Cell lysate was clarified (Sorvall SS34 rotor, 
18,000 rpm, 45 min, 8°C), the supernatant was filtered (0.22 µM Minisart, 
Sartorius). Clarified cell lysate was added to approximately 20 mL Chitin 
Resin (New England Biolabs) packed in a free-flow gravity column, 
equilibriated with 20 column volumes of lysis buffer. The lysate was then 
added to the column and eluted from the column at a flow rate of 1mL/min, 
then the resin was washed with 10 column volumes of lysis buffer. The 
column was quickly equilibriated with 3 column volumes of lysis buffer 
supplemented with 50mM DTT.  The resin was then resuspended in 1 
column volume of lysis buffer supplemented with 50mM DTT. Following 
overnight incubation on an analogue roller mixer (SKS science) at 25°C, 
cleaved protein was obtained by collecting the flow through from the column. 
To collect all cleaved protein, the resin was washed with 50ml of lysis buffer, 
then a further 100ml of lysis buffer. All wash fractions were collected and 
analysed by SDS-PAGE. Columns were stored in 20% ethanol. 
	
Cleaved protein was concentrated (Amicon, MWCO 10,000) to 10 ml, filtered 
(0.22 µM Minisart, Sartorius) and further purified by Size Exclusion 
Chromatography. Purified protein was stored at 4°C, for a maximum of 42 
days, without further concentration.  
	
2.2.2.3 Nickel Affinity Chromatography  
	
His-SUMO tagged MCL1172-327 and BCL-XL ML  fusion protein constructs were 
over-expressed in E.coli BL21 (DE3) Rosetta 2, and purified using a protocol 
adapted from ref[292]. 10 ml of overnight starter culture was used to 
inoculate 1 L 2 xYT containing 50 µg/ml Kanamycin. Cultures were grown at 
37 °C plus shaking at 180rpm until OD600 reached 0.6 – 0.8. The 
temperature was reduced to 18 °C and protein expression induced by 
adding 0.5mM IPTG. Induced cultures were grown at 18°C plus shaking at 
180rpm overnight before harvesting by centrifugation (Beckmann JLS 8.1, 
5000rpm, 15minutes, 4°C). Cell pellets were resuspended in column buffer 
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(50 mM TRIS pH 8.0, 500 mM NaCl, 15 mM imidazole) and lysed by 
sonication in the presence of 10 µL of 1 U/ml-1 DNase I per litre of over-
expression culture. Cell lysate was clarified (Sorvall SS34 rotor, 18,000 rpm, 
45 min, 4°C), the supernatant was filtered (0.45 µM Minisart, Sartorius). 
Clarified cell lysate was applied to a 5 mL Ni2+ sepharose HisTrap HP 
column (GE Healthcare) charged with 0.1 M NiSO4 and equilibrated with 
column buffer, using a peristaltic pump to maintain a flow rate of 1mL/min. 
The HisTrap was then washed with 10 volumes of column buffer, followed by 
10 volumes of column buffer supplemented with 50 mM imidazole, and 10 
volumes of column buffer supplemented with 100 mM imidazole. Fusion 
proteins were then eluted from the HisTrap with column buffer supplemented 
with 300 mM imidazole. The His-SUMO tag was cleaved from fusion protein 
in dialysis buffer (50 mM TRIS pH 8.0, 250 mM NaCl in the presence of 
Smt3 protease, Ulp1), overnight at 4°C. The dialysed sample was reapplied 
to a 5mL HisTrap and the flow through containing cleaved protein collected.  
 
Cleaved protein was concentrated (Amicon, MWCO 10,000) to 5 ml, filtered 
(0.22 µM Minisart, Sartorius) and further purified by Size Exclusion 
Chromatography. Purified protein was concentrated and stored at -80°C, 
with the addition of 5% glycerol to aid long term stability.  
	
2.2.2.4 Glutathione affinity chromatography  
	
Glutathione S-transferase (GST) tagged BCL-2 1-205 fusion protein constructs 
were over-expressed in E.coli BL21 (DE3) Rosetta 2, and purified using a 
protocol adapted from ref[293]. 10 ml of overnight starter culture was used to 
inoculate 1 L 2 xYT containing 100 µg/ml Ampicillin. Cultures were grown at 
37 °C plus shaking at 180rpm until OD600 reached 0.6 – 0.8. The 
temperature was reduced to 18 °C and protein expression induced by 
adding 0.3mM IPTG. Induced cultures were grown at 18°C plus shaking at 
180rpm overnight before harvesting by centrifugation (Beckmann JLS 8.1, 
5000rpm, 15minutes, 4°C). Cell pellets were resuspended in lysis buffer 
(50mM TRIS pH 8.0, 200mM NaCl, 5mM DTT, 1mM EDTA) and lysed by 
sonication in the presence of 10 µL of 1 U.ml-1 DNase I per litre of over-
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expression culture. Cell lysate was clarified (Sorvall SS34 rotor, 18,000 rpm, 
45 min, 4°C), the supernatant was filtered (0.45 µM Minisart, Sartorius). 
Clarified cell lysate was added to approximately 10 mL Glutathione 
Superflow Resin (Generon) packed in a free-flow gravity column. The 
column was washed with 5 column volumes of water and equilibrated with 5 
column volumes of lysis buffer. The lysate was then added to the column 
and and placed on an analogue roller mixer (SKS science) at 4°C for 1-3 
hours. Lysate was then eluted from the column under gravity, and the resin 
was washed first with 100ml high salt wash buffer (50mM Tris pH8, 1mM 
DTT, 1mM EDTA, 500mM NaCl, 10% glycerol, 0.01% Triton), then 100mL 
low salt wash buffer (50mM Tris pH8, 1mM DTT, 1mM EDTA, 200mM NaCl, 
10% glycerol, 0.01% Triton). The resin was re-suspended in 20mL of low 
salt wash buffer, supplemented with 400µL Prescission protease to cleave 
the GST tag from the fusion protein. Following overnight incubation on an 
analogue roller mixer (SKS science) at 4°C, cleaved protein was obtained by 
collecting the flow through from the column. To collect all cleaved protein, 
the resin was washed with 50ml of low salt wash buffer, and the flow through 
collected. All wash fractions were collected and analysed by SDS-PAGE. 
Columns were stored in 20% ethanol. 
	
Cleaved protein was concentrated (Amicon, MWCO 10,000) to 5 ml, filtered 
(0.22 µM Minisart, Sartorius) and further purified by Size Exclusion 
Chromatography. Purified protein was concentrated and stored at -80°C, 
with the addition of 5% glycerol to aid long term stability.  
	
2.2.3 Protein characterisation 
	
2.2.3.1 SDS PAGE 
	
Sodium dodecyl sulphate polyacrylamide (SDS-PAGE) gel electrophoresis 
was performed based on the method described by Laemmli [294]. 12%, 15 
% and 17% gels were prepared. Protein samples were mixed with 4x loading 
buffer in a 3:1 ratio, heated at 95°C for 6 minutes, and electrophoresed 
through SDS PAGE gels in SDS running buffer at 120V-150V. Proteins were 
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visualized using coomassie blue stain (45% (v/v) methanol, 10% (v/v) acetic 
acid, 0.25% (w/v) coomassie brilliant blue R-250), then destained in 30% 
(v/v) methanol, 10% (v/v) acetic acid. A broad range molecular marker was 
included in the first lane of each gel to ascertain the Mr of proteins. 
	
2.2.3.2 Western Blot 
 
Samples from different stages of protein purification were separated by 
SDS-PAGE and immunoblotted. Samples were boiled for 6 minutes in 2 x 
SDS sample buffer (100mM Tris pH6.8, 4% SDS, 20% glycerol, 0.2% 
bromophenol blue, 200mM DTT), submitted to polyacrylamide gel 
electrophoresis in 1% SDS running buffer and immunoblotted with anti-BAX 
(Abcam ab 7977).  
	
2.2.3.3 Mass Spectrometry  
	
High Resolution Mass Spectrometry (HRMS) was used to confirm the 
correct Mw of proteins and affimers. Samples at 1mg / mL were analysed 
using a Bruker Maxis impact mass spectrometer, using Electro-spray 
Ionisation (ESI), with values reported as a ratio of mass to charge. 
 
2.2.3.4 Circular Dichroism (CD) 
	
CD was performed using Applied Photophysics ChiraScan apparatus and 
software. Secondary structure was determined using standard CD scans in 
the ultraviolet range. For each CD scan, the following parameters were 
used: 190-260 nm range; time per point 1.0 s; step = 1 nm; bandwidth = 2.5 
nm; path length = 10 mm. Scans were carried out in duplicate and averaged. 
Samples were prepared in the appropriate buffer (described in results for 
individual experiments). The raw circular dichroism data obtained for the 
peptides was processed by the subtraction of the solvent signal and 
converted into a mean residue ellipticity. 
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 [θ] = θ / (10 x c x l) 
 
Equation 1 
 [θ]MRE = [θ] / (R – 1) 
 
Equation 2 
Where θ = raw circular dichroism, c = protein molar concentration, l = 
pathlength (in cm), R = number of residues in protein construct. 
	
2.2.3.5 Analytical SEC 
	
Analytical SEC was performed on a Superdex 200 (5/150) column (GE 
healthcare) attached to an Akta pure system at 25°C. The column, stored in 
20% ethanol, was washed with water and equilibrated with appropriate SEC 
buffer. 100 µL of filtered protein sample was loaded onto the column using a 
100 µL injection loop. The absorbance of the sample was monitored at 280 
nm throughout. 
	
2.2.3.6 Direct Binding Fluorescence Anisotropy (FA) 
	
Protein binding assays were performed in 384 well plates. Experiments were 
carried out in triplicate. 20 µL binding buffer was added to all experimental 
and control wells. 40 µL of protein was added to the first column well of each 
row, then serially diluted across the plate. 20 µL FITC labelled tracer peptide 
diluted to 20nM in binding buffer was added to all experimental wells (giving 
a final concentration of 10nM), and 20 µL binding buffer added to control 
wells. The plate was incubated under foil for 1 hour, then read on a Tecan 
Spark 10M plate reader at 25.0°C with excitation at 485 (20) nm and 
emission at 535 (25) nm. The intensity was calculated for each point using 
Equation 3 and used to calculated anisotropy using Equation 4. The data 
were then fitted using Equation 5 in OriginPro 9 to determine the dissociation 
constant, Kd. 
 
 I = (2PG) + S 
 
Equation 3 
 R = (S - PG) / I Equation 4 
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 y = ((Kd +x+[FL])-√((Kd +x+[FL])2 -4x[FL]))/2 
 
Equation 5 
Where R= anisotropy, I= total intensity, P=perpendicular intensity, S= 
parallel intensity, G = an instrument factor set to 1, [FL] = concentration of 
fluorescent peptide, Kd = dissociation constant,  x = protein concentration 
	
2.2.3.7 SPR 
 
0.5 nM affimer was isolated on to one flow cell of a CM5 chip (GE 
Healthcare), at a flow rate of 5 uL/min, while the other flow cell was left 
unfunctionalised. A series of concentrations of target protein were tested. 
Each concentration was flowed over both the functionalised and the 
unfunctionalised flow cells at 40 µL/min and the on- and off-rates were 
calculated using the Biacore software. The on- and off-rates were used to 
calculate the Kd.  
 
2.2.3.8 Crystallography 
 
Factorial screens were set up using 384 unique buffer conditions, and 
carried out using a Douglas Instruments Oryx 6 plate loader with NT8 
robotics software. Drops of 0.2 µL of protein in a 1:1 drop ratio with mother 
liquor were used in 96 well MRC 3-drop sitting drop plates (Molecular 
Dimensions). Wells were filled with 25 µL mother liquor, sealed with 
pressure adhesive clear seals (Viewseal) and incubated at 4°C. Initial hits 
from the factorial screens were optimised in 24 well hanging drop plates, 
with 1 µL protein added to 1 µL mother liquor. Optimisations centred on the 
variation of precipitant and pH. Crystals were picked using a nylon loop 
mounded on a cryo pin (Hampton Research) and submerged in to 1 µL of 
mother liquor + appropriate cryo protectant. Crystals were then immediately 
immersed in liquid nitrogen for storage and transport. All data was collected 
at Diamond light source, using various beamlines. 
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2.2.3.9 Negative Stain Electron Microscopy (EM)  
	
Samples were added to glow-discharged carbon-coated EM copper grids, 
stained with 1% uranyl acetate, and then imaged on a FEI Tecnai-F20 
microscope using low-dose protocols and a dose of ∼40 e-/Å2. Micrographs 
were recorded with a Gatan US4000 CCD camera at a calibrated 
magnification of ×25,500, giving a final object sampling of 3.51 Å/pixel. Class 
averages were collected and analysed using RELION software (MRC-LMB). 
	
2.2.3.10 Detergent Treatment 
	
All detergents were dissolved at 10x desired final concentration in 50mM 
Sodium Phosphate pH 7.0. 50µL of 10x detergent solution was then added 
to 450µL of protein.  
 
 
2.2.4 Affimer Identification, Expression and Purification 
 
2.2.4.1 Affimer Phage display 
	
Target BCL-2 family proteins were biotinylated using EZ-link NHS-SS-biotin 
(Pierce), then desalted to remove any remaining biotin using Zeba Spin 
Desalting Columns, 7K MWCO (Thermo Scientific) according to the 
manufacturer’s instructions. Biotinylation was confirmed using streptavidin 
conjugated to horseradish peroxidase (HRP). Biotinylated target protein was 
bound to streptavidin-coated wells (Pierce) for 1-2 hours, then 1012  cfu pre-
panned phage were added for 2 hours with shaking. Panning wells were 
washed 27 times with PBST and bound phage eluted with 50 mM glycine–
HCl (pH 2.2) for 10 min, neutralised with 1 M Tris–HCL (pH 9.1), further 
eluted with triethylamine 100 mM for 6 min, and neutralized with 1M Tris–
HCl (pH 7). Eluted phage were used to infect ER2738 cells for 1 hour at 37° 
C and 90 rpm then plated onto LB agar plates with 100 mg/ml carbenicillin 
and grown overnight. Colonies were scraped into 5 ml of 2TY medium, 
inoculated in 25 ml of 2TY medium with carbenicillin (100 m g/ml) and 
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infected with ca. 1 x 109  M13K07 helper phage. After 1 hour at 90 rpm, 
kanamycin was added to 25 mg/ml for overnight incubation at 25° C and 170 
rpm. Phage were precipitated with 4% polyethylene glycol 8000, 0.3 M NaCl 
and resuspended in 1 ml of 10 mM Tris, pH 8.0, 1 mM EDTA (TE buffer). A 2 
ml aliquot of phage suspension was used for the second round of selection 
using streptavidin magnetic beads (Invitrogen). Beads labeled with target 
protein were washed and incubated with pre-panned phage for 1 hour then 
washed five times using a KingFisher robotic platform (ThermoFisher), then 
eluted and amplified as above. The final pan used neutravidin high binding 
capacity plates (Pierce), as previously described for panning round one, with 
phage eluted as described above. Eluted phage were recovered from wells 
containing target protein and control wells, then used to infect ER2738 cells 
for 1 hour at 37° C and 90 rpm. A range of volumes (0.1µL to 100µL) of 
culture from target wells were plated onto LB agar plates with 100 mg/ml 
carbenicillin and grown overnight. 10µL of culture from control wells was also 
plated to determine the level of amplification in target wells. 
 
2.2.4.2 Phage ELISA 
 
Individual ER2738 colonies were grown in 200 µl of 2TY with 100 m g/ml of 
carbenicillin in a 96-deep well plate at 37° C (900 rpm) for 6 hours. A 25 µl 
aliquot of the culture was added to 200 µl of 2TY containing carbenicillin and 
grown at 37° C (900 rpm) for 1 h. Helper phage (10 µl of 1011 /ml) was 
added for 30 minutes (450 rpm), followed by kanamycin to 25 mg/ml with 
overnight incubation at 25° C (450 rpm). Streptavidin-coated plates (Pierce) 
were blocked with 2 x  casein blocking buffer (Sigma) overnight at 37° C. 
The plates were incubated with biotinylated target protein or blocking buffer 
(control) for 1 hour, and 45 µl of growth medium containing the phage was 
added and incubated for 1 hour. Following washing, phage were detected by 
a 1:1000 dilution of HRP-conjugated anti-phage antibody (Seramun) for 1 
hour, visualised with 3,3’,5,5’ -tetramethylbenzidine (TMB) (Seramun) and 
measured at 610 nm. 
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2.2.4.3 Affimer synthesis and purification 
 
The DNA coding sequences of affimers were amplified by PCR, restriction 
digested with NheI and PstI and cloned into pET11a containing the affimer 
scaffold similarly digested. Plasmid DNA was purified (Qiagen) from 
transformant colonies and sequenced to confirm the correct insert. Following 
transformation into BL21 (DE3) Rosetta 2 cells, affimers were purified using 
the Nickel Affinity Chromatography protocol described above. 
	
2.2.4.4 Affimer binding ELISA 
	
100µL of target protein diluted to 2µg/mL in PBS was added to each well of a 
F96 Maxisorp Nunc-Immuno Plate (Thermo Scientific). After overnight 
incubation at 4°C, all wells were washed in PBST, then blocked by the 
addition of 100µL PBST with 2% BSA (Sigma) for 1 hour at 25°C. All wells 
were washed with PBST, then 200µL affimer diluted to 20µg/mL in PBS was 
added to the first column well of each row. 100µL PBS was added to all 
remaining wells, and serial dilutions made down each row. Plates were 
incubated a further 1 hour at 25°C, then washed with PBST. 100µL of poly-
Histidine−Peroxidase conjugated monoclonal antibody (Sigma) diluted 
1:4000 in PBS was added to each well, with incubation at 25°C for 1 hour. 
After a final wash with PBST, all wells were developed by adding 50µL 
3,3’,5,5’-Tetramethylbenzidine (TMB) (Thermo Fisher). Reactions were 
stopped by adding 50µL 2M H2SO4. Absorbances were read using a 
Powerwave XS2 plate reader (Biotek).  
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Chapter 3 - Expression, purification and characterisation of 
Bcl-2 family proteins 
 
3.1 Selecting BCL-2 family members for study 
 
The work described in this chapter was undertaken to produce and quality 
control the reagents (BCL-2 family proteins) required to pursue the thesis 
aims as described in the introduction.  
 
The mitochondrial apoptotic pathway is initiated through the transcriptional 
and/or post-transcriptional activation of BH3-only proteins in response to 
various upstream signaling events (e.g. hypoxia, withdrawal of growth 
signals). However, BH3 only family members, with the notable exception of 
BID, are intrinsically disordered proteins, which makes them unsuitable 
targets for recombinant expression.  
 
By contrast, all pro-survival members, and the pro-apoptotic effectors BAX 
and BAK have a high degree of structural homology, including the presence 
of a hydrophobic BC binding groove. BAX, BAK, BCL-2, BCL-XL and MCL1 
were therefore chosen for use in this study, providing a good representative 
selection of pro- and anti-apoptotic family members.  
3.2 Protein Purification 
 
All target proteins were over expressed in competent E.coli cells, but a 
variety of vectors, cell strains, and protein purification methods were used to 
purify individual family members (fully detailed in Materials and Methods).  
 
BCL-2 was previously sub-cloned into the pGEX-6P-1 plasmid by the 
Edwards group, creating a GST fusion, which both enhances solubility and 
allows for single step purification on glutathione conjugated sepharose resin. 
The fusion vector was transformed into BL21 (DE3) Rosetta 2 E. coli cells. 
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found to produce the greatest yield of fusion protein with minimal bacterial 
protein contamination, better facilitating further purification.  
 
BCL-XL and MCL1 were both previously sub-cloned into the pET-28a-SUMO 
plasmid by the Edwards group, creating a hexa-His-SUMO fusion. The hexa 
His tag allows for purification by metal affinity chromatography, while the 
SUMO tag enhances solubility of the fusion product. These fusion vectors 
were also transformed into BL21 (DE3) Rosetta 2 E. coli cells, after 
expression trials showed that this strain gave the best and cleanest yield of 
fusion protein for both MCL-XL and MCL1. 
 
BAX and BAK were both previously sub-cloned into the pTXB1 plasmid by 
the group of Jane Clarke (Dept. of Chemistry, Cambridge), creating an 
intein-chitin binding domain (CBD) fusion, allowing for single step 
purification. The fusion vector was transformed into C41 (DE3) E. coli cells. 
C41 cells were used in this instance as they are particularly suitable for use 
with difficult to express and / or toxic proteins. 
 
The methods used for subsequent protein expression and purification are 
summarised in Figure 3-1. 
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Figure 3-1– Summary of expression and purification protocols used for target 
BCL-2 family proteins. 
 
3.3 Protein Characterisation 
 
A variety of biophysical methods were used to characterise and quality 
control purified proteins, ensuring protein purity, determining whether 
proteins expressed as monomers or higher order oligomers, and checking 
for correct secondary and tertiary folded structures. 
 
3.3.1 Size Exclusion Chromatography 
 
Size Exclusion Chromatography (SEC) is used primarily as a final ‘polishing’ 
step in protein purification, to provide as clean and homogenous a protein 
sample as possible (Figure 3-2). It is also useful in determining the 
oligomerisation state of proteins in solution, and can be used to detect 
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protein aggregation. SEC works by filtering a homogenous molecular mix 
through a sepharose resin of spherical beads that contain pores with a 
defined size distribution. Molecules of different sizes are either able to enter, 
or are excluded from the pores: small molecules diffuse into the pores, 
hence their flow through the column is retarded; larger molecules do not 
enter the pores and flow through the column more freely. Consequently, 
molecules are separated based on their size as they pass through the 
column and are eluted in order of decreasing molecular weight, with large 
aggregates eluting in the void volume. 
 
 
Figure 3-2 - Size Exclusion Chromatography (SEC). a) Filtering through a 
sepharose resin enables a homogenous molecular mix to be sorted by 
size. Beads in the resin have pores with a defined size distribution. 
Smaller molecules are able to enter the pores and their progress 
through the column is thereby retarded, so that homogenous species 
will be eluted from the column in order of decreasing size. b) A standard 
SEC chromatograph, showing individual protein peaks, is useful for 
enhancing protein purity, and can also be used to determine the 
oligomerisation state of an eluted protein by comparing its peak elution 
volume against the elution volumes of a panel of protein standards. 
 
3.3.1.1 Use of Protein Standards for Column Calibration in SEC 
 
All SEC experiments described in this chapter were carried out using a 
HiLoad 26/60 Superdex 75 pg column (GE healthcare). Prior to assaying 
target proteins, the column was calibrated by running the protein standards 
detailed in Table 3-1. Blue Dextran was loaded to the column to determine 
the void volume. 
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Table 3-1 – SEC column calibration. Details of protein standards used to 
calibrate the HiLoad 26/60 Superdex S75 pg column, including molecular 
weight and observed elution volume. 
 
Protein standard Molecular weight 
(kDa) 
Source Observed elution 
volume (mL) 
Aprotinin 6.5 Bovine lung 246 
Ribonuclease A 13.7 Bovine pancreas 213 
Carbonic 
anhydrase 
29.0  Bovine 
erythrocytes 
183 
Ovalbumin 43.0 Chicken egg white 159 
Conalbumin 75.0 Chicken egg white 141 
Blue dextran 2,000 N/A 111 (void volume) 
 
The chromatogram showing all protein standard elution peaks is shown in 
Figure 3-3. 
 
 
 
 
Figure 3-3 – Chromatogram of elution peaks for protein standards used in 
HiLoad 26/60 Superdex S75 pg column calibration. 
 
The determination of molecular weight (Mw) by SEC is achieved by 
comparing the partition coefficient (Kav) of the target protein with the Kav 
values obtained for the calibration standards. The Mw (and oligomerisation 
state) of the target protein can then be determined by plotting Kav against 
log10 Mw. Kav is calculated using the following equation: - 
 
0 50 100 150 200 250 300
-40
-20
0
20
40
60
UV
 tr
ac
e 
(m
Au
)
Volume (ml)
S75 calibration curves
conalbumin - 75kDa
ovalbumin - 43kDa
carbonic anhydrase - 29.5kDa
ribonuclease A - 13.7kDa
aprotinin - 6.5kDa
S75	standards	
- 62 - 
Kav = (Ve – Vo) / (Vt – Vo) 
 
where Ve is the target protein elution volume, Vt is the total volume of the 
column used, and Vo is the column void volume. The HiLoad 26/60 
Superdex S75 pg column has a Vt  of 320mL, and a void volume, 
established using blue dextran, of 111mL. Using the known molecular 
weights and observed elution volumes for protein standards from Table 3-1, 
log10 Mw and Kav values were calculated (Table 3-2), and the calibration curve 
in Figure 3-4 was produced. 
Table 3-2 – Calculated Log10 Mw and Kav values for protein standards. 
 
Protein 
standard 
Mw (kDa) Log10 Mw Ve (mL) Kav 
Conalbumin 75 1.9 141 0.144 
Ovalbumin 43 1.6 159 0.230 
Carbonic 
Anhydrase 
29 1.5 183 0.344 
Ribonuclease 
A 
13.7 1.1 213 0.488 
Aprotinin 6.5 0.8 246 0.646 
 
A line plotting the best fit of all data points on the calibration curve was 
calculated to have gradient - 0.48018 and intercept 1.03568 intercept, giving 
the equation 
y = -0.48018x + 1.03568 
 
which was used to calculate expected elution volumes for the target 
proteins, and subsequently to determine oligomeric states based on the 
actual elution volumes seen. 
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Figure 3-4 – HiLoad 26/60 Superdex S75 pg column calibration curve for 
protein standards 
 
3.3.2 Fluorescence Anisotropy 
 
Fluorescence anisotropy (FA) assays measure the tumbling rate (rotational 
diffusion) of fluorescently tagged molecules. Rotational diffusion is a function 
of molecular size: the larger the molecule, the slower the tumbling rate, 
which is measured in FA as a ratio of plane polarized light within the total 
light intensity. Plane polarized light is applied to a group of randomly 
oriented fluorophores. Only those fluorophores oriented within a narrow 
range of angles to the applied polarisation will become excited and emit 
light. If these fluorophores have low rotational diffusion (i.e. are larger 
molecules), their orientation will change slowly, emitted light will remain in 
the same plane of polarisation, and there will be high anisotropy. If the 
fluorophores are small and have a high rate of rotational diffusion, they will 
rapidly change orientation and much more of the emitted light will be in a 
different plane from the excitation light, resulting in low anisotropy. FA can 
therefore be used to measure the potency of binding events between 
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molecules as follows: one molecule (the smaller of the two) is fluorescently 
labelled; upon binding to its larger binding partner, the rotational diffusion is 
reduced, and the level of observed anisotropy increases. Plotting the 
fluorescence anisotropy against protein concentration of the larger, 
unlabelled protein partner allows a Kd to be calculated. This direct binding 
assay can be adapted into a competition binding assay to measure the 
potency of molecular inhibitors. Starting with a pre-bound complex of 
fluorophore and binding partner, the rotational diffusion of the fluorophore 
will be low and anisotropy will be high. When an inhibitor disrupts this 
complex, the fluorophore will be released from the complex, and its 
rotational diffusion will increase, resulting in a decrease in anisotropy (Figure 
3-5). 
 
 
 
Figure 3-5 - Fluorescence Anisotropy (FA). FA uses the rotational diffusion 
(tumbling rate) of fluorescently tagged molecules to investigate binding 
events between molecules. Binding interactions decrease the tumbling 
rate and increase the anisotropy of polarised light emitted by the 
fluorophore. This assay can be used to measure direct binding, and also 
to measure the ability of molecular inhibitors to disrupt complexes, in 
competition binding mode. 
 
3.3.3 Circular Dichroism 
	
Secondary structure can be determined by Circular Dichroism (CD) 
spectroscopy in the ‘far-UV’ spectral region (190-250 nm). CD functions 
through the interaction of circularly polarized light with chiral molecules, such 
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as proteins. Circular polarised light has a “handedness”; it is either rotating 
left or right. Bonds around a chiral centre act as chromophores, absorbing 
left and right polarised light differently and this difference is measured by a 
spectrapolarimeter (CD spectrometer). The spectrapolarimeter lamp 
switches between left and right polarized light and compares the relative 
absorbance of each by the sample; the difference between the two signals is 
known as the ellipticity (θ). This measurement is combined with the mean 
residue molar concentration of the sample to calculate a mean residue 
ellipticity (MRE).  
 
At ‘far UV’ wavelengths, the chromophore in a protein sample is the peptide 
bond. Distinct CD signals arise when these bonds are arranged in regular, 
folded patterns, so that different distinct secondary structures have 
characteristic CD signatures (Figure 3-6).  
 
 
 
 
 
Figure 3-6 - Circular Dichroism secondary structure profiles. Of interest to 
this study is the standard alpha-helical profile (shown in green) with 
local absorption minima at 208 and 222nm.  
 
The spectrum relating to α-helix secondary structure, pertinent to all BCL-2 
family protein proteins used in this study, has MRE absorption minima at 208 
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nm and 222nm [295], while proteins with well defined anti-parallel β-sheets 
have absorption minima around 218nm [296]. 
3.4 Expression, Purification and Characterisation of Pro-
survival family members 
 
The following sections describe the purification and characterization of the 
pro-survival targets selected for this study (BCL-2, BCL-XL and MCL1). All 
proteins were expressed with a C terminal truncation, corresponding to the 
removal of the transmembrane domain, which is used in vivo to tether BCL-2 
family members to the mitochondrial membrane, where the majority of intra-
family interactions take place. Removal of the transmembrane domain 
greatly reduces the risk of protein aggregation during purification but does 
not affect residual protein structure or function [30, 52]. 
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3.4.1 BCL-2 
	
The BCL-21-205 protein, incorporating a 34 residue C terminal deletion was 
over-expressed as a GST tagged fusion protein in BL21 (DE3) Rosetta 2 
competent E.coli cells and purified by glutathione affinity chromatography. 
The GST tag was cleaved by overnight incubation with Prescission protease, 
allowing for single step purification of tag free recombinant protein (Figure 
3-7).  
 
 
Figure 3-7 - BCL-2 expression and purification. a) schematic of the BCL-2 1-205  
protein used in this study. A 34 residue truncation at the C terminal 
equates to removal of the transmembrane (TM domain). b) Cartoon 
representation of the crystal structure of BCL-2, showing alpha-helical 
secondary structure (PDB 1G5M). c) SDS-PAGE analysis of BCL-2 1-205  
expression. The 49.8kDa GST tagged fusion protein band can be seen 
between 37kDa and 50kDa markers. The large band just above the 25kDa 
marker in A and B is free GST. Cleaved protein at 23.4kDa can be seen in 
columns E and F. Key A: clarified lysate, B: column flow through, C: 
high salt wash, D: low salt wash, E: elute, F: post elute low salt wash. 
 
The cleaved and eluted protein was concentrated and further purified by 
SEC, producing a main A280 peak at 162mL, with a further small peak at 
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136mL (Figure 3-8). With reference to Figure 3-4, these correspond to dimer 
and tetramer peaks respectively. This result is not unexpected, as BCL-2 is 
known to homo-dimerise through different and extensive binding interfaces 
[297]. 
 
Good initial protein yields per litre of media were seen for BCL-2, and 
recovery of protein at each stage of purification was also favourable, as 
detailed in Table 3-3.  
Table 3-3 – BCL-2 yield and recovery for each stage of protein purification. All 
protein concentrations were measured using the Biorad assay. 
 
Purification stage mg / L media Yield (%) 
Column elute of BCL-2 18.15 100 
Concentrated and loaded 
to SEC column 
17 93 
Recovered from SEC 12 66 
 
 
 
 
 
 
Figure 3-8 – Size exclusion chromatography of eluted BCL-2 1-205 . The main 
peak at 162mL corresponds to a dimer.  
 
Fractions from the dimer peak were pooled, transferred to 50mM sodium 
phosphate buffer pH7, and analysed by CD to check for correct secondary 
structure. Figure 3-9a shows the expected α-helical spectrum. Local MRE 
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minima of -26923 and -24810 are seen at 208nm and 222nm respectively. 
Further analysis for correct, active tertiary structure was carried out by 
means of a FA direct binding assay against a FITC labelled BAX BH3 
peptide, which gave a binding curve with predicted Kd of 33.2 ± 4.4nM 
(Figure 3-9b). 
 
 
 
 
Figure 3-9 - BCL-2 characterisation. a) far UV circular dichroism (CD) shows 
the expected alpha-helical profile (trace shown is representative of 
multiple experiments). b) Direct binding fluorescence anisotropy assay 
of BCL-2 against FITC-BAX-BH3 produces a binding curve with Kd of 
33.2 ± 4.4nM, indicative of correctly folded, active tertiary structure. 
 
3.4.2 BCL-XL 
 
The BCL-XL ML (1-26, 83-209 ‘Missing-Loop’) protein, incorporating a C 
terminal 23 residue TM domain truncation, was over-expressed in BL21 
(DE3) Rosetta 2 competent E.coli cells and purified by nickel affinity 
chromatography (Figure 3-10). Initial expression was of a hexa-His-SUMO 
tagged fusion protein; the tag was cleaved by overnight dialysis in the 
presence of Sumo protease, and tag free protein purified with a second 
round of nickel affinity chromatography. 
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Figure 3-10 - BCL-XL expression and purification. a) schematic of the BCL-XL 
ML (1-26, 83-209 ‘Missing-Loop’) protein used in this study. An 
unstructured loop, corresponding to residues 27 – 82 inclusive, has 
been removed from the main body of the protein, and a further 23 
residue truncation, corresponding to removal of the TM domain, made at 
the C terminal. b) cartoon representation of the crystal structure of  
BCL-XL ML, showing alpha-helical secondary structure (PDB 5B1Z). c) 
SDS-PAGE analysis of BCL-XL ML expression. The 30.9kDa His-SUMO- 
BclXL ML fusion protein can be seen in columns F and G. Overnight 
dialysis in the presence of Ulp1 SUMO protease removes the fusion tag, 
allowing for purification of the 17.5kDa cleaved protein, shown as the 
lower band in columns I and J. Confusingly, the cleaved His-SUMO tag 
(13.4kDa) runs on the SDS-PAGE gel at approximately 17kDa, while the 
17.5kDa BCL-XL ML protein runs at approximately 14kDa, effectively 
reversing their expected positions on the gel. Key A: clarified lysate, B: 
insoluble pellet fraction, C: flow through, D-F: column buffer washes 
with increasing imidazole concentration, 15mM, 50mM, 100mM, G: elute, 
containing fusion protein, H: marker, I: cleaved elute, J: His trap column 
flow through of cleaved elute.  
 
Eluted protein was concentrated and further purified by SEC, producing a 
main A280 peak on the chromatogram at an elution volume of 179mL, which, 
with reference to Figure 3-4, corresponds to a dimer (Figure 3-11). As with 
BCL-2, this result is not unexpected, as BCL-XL is known to homo-dimerise 
by a variety of mechanisms [298-300]. 
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Good initial yields per litre of media were seen for the His-SUMO-BCL-XL 
fusion protein. Overnight dialysis with SUMO protease resulted in small 
amounts of precipitation, causing a small loss in yield prior to a second 
round of nickel affinity chromatography.  Good recovery of protein at each 
subsequent stage of purification was seen, as detailed in Table 3-4 below.  
Table 3-4 – BCL-XL yield and recovery for each stage of protein purification. 
All protein concentrations were measured using the Biorad assay. 
 
Purification stage mg / L media Yield (%) 
Fusion protein elute of 
His-SUMO-BCL-XL 
36 100 (fusion protein) 
Cleaved His-SUMO-BCL-
XL post dialysis 
32 89 (fusion protein) 
Tag free BCL-XL 19.25 100 
Concentrated and loaded 
to SEC column 
18.75 97 
Recovered from SEC 12.75 66 
 
	
	
 
	
 
Figure 3-11 - Size exclusion chromatography of BCL-XL ML. The main peak at 
179mL corresponds to a protein dimer. 
 
Protein was buffer exchanged to 50mM sodium phosphate buffer, pH 7. 
Biophysical analysis using far UV CD revealed the expected alpha helical 
profile with local MRE absorption minima of -25207 and -22721 seen at 222 
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and 208nm respectively. Direct binding FA of BCL-XLML  titrated against a 
FITC labeled BAX-BH3 peptide gave a binding curve with predicted Kd of 
40.8 ± 6.2nM, indicative of correctly folded, active tertiary structure (Figure 
3-12).  
	
 
 
 
 
Figure 3-12 - BCL-XL characterisation. a) Far UV CD shows expected alpha-
helical secondary structure (trace shown is representative of multiple 
experiments). b) Direct binding FA produces a binding curve with 
predicted Kd of 40.8 ± 6.2nM, indicative of correctly folded, active tertiary 
structure.  
	
 
3.4.3 MCL1 
 
The MCL1172-327 protein, incorporating an N terminal 171 residue deletion, 
and a C terminal 23 residue (TM domain) deletion, was over-expressed as a 
hexa-His-SUMO tagged fusion protein in BL21 (DE3) Rosetta 2 competent 
E.coli cells and purified by nickel affinity chromatography (Figure 3-13). The 
His-SUMO tag was removed by overnight dialysis in the presence of Sumo 
protease, and untagged MCL1 purified with a second round of nickel affinity 
chromatography. 
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Figure 3-13 - MCL1 expression and purification.  a) schematic of the MCL1172-
327 protein used. Truncations have been made at both N and C termini. b) 
cartoon representation of the crystal structure of MCL1172-327 
demonstrating a  predominantly alpha helical secondary structure (PDB 
5C3F). c) SDS-PAGE analysis of MCL1172-327 expression. The 31.1kDa His-
SUMO fusion protein can be seen midway between the 25kDa and 37kDa 
markers in columns A-H inclusive. Overnight dialysis in the presence of 
Ulp1 SUMO protease removes the fusion tag, allowing for purification of 
the 17.7kDa cleaved protein, shown as the lower band in columns I and 
J. Due to the previously mentioned anomaly with the His-SUMO tag 
running at above 17kDa, cleaved MCL1172-327 appears in the lower band 
below the 25kDa marker in columns I and J. Key A: clarified lysate, B: 
insoluble pellet fraction, C: flow through, D-E: column buffer wash with 
15mM and 50mM imidazole respectively, F-G: elutes with 400mM 
imidazole, H: sample to dialysis (from column E), I: cleaved elute, J: His 
trap column flow through. 
 
Eluted protein was concentrated and further purified by SEC. On the 
chromatogram, an A280 monomer peak was observed at an elution volume of 
208mL (Figure 3-14). 
 
Good initial yields per litre of media were seen for the His-SUMO-MCL1 
fusion protein. Overnight dialysis with SUMO protease resulted in small 
amounts of precipitation, causing a small loss in yield prior to a second 
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round of nickel affinity chromatography.  Good recovery of protein at each 
subsequent stage of purification was seen, as detailed in Table 3-5.  
Table 3-5 – MCL1 yield and recovery for each stage of protein purification. All 
protein concentrations were measured using the Biorad assay. 
 
Purification stage mg / L media Yield (%) 
Fusion protein elute of 
His-SUMO-MCL1 
40.75 100 (fusion protein) 
Cleaved MCL1 post 
dialysis 
37.25 91 (fusion protein) 
Tag free MCL1 21.5 100 
Concentrated and loaded 
to SEC column 
19.75 92 
Recovered from SEC 17 79 
 
 
 
 
 
 
Figure 3-14 - Size exclusion chromatography of MCL1172-327. The main peak at 
208mL corresponds to a monomer.  
 
The monomer peak was taken and buffer transferred into 50mM sodium 
phosphate pH7. Biophysical analysis using far UV CD revealed the expected 
alpha helical profile with local MRE minima of -21374 and -22510 seen at 
222 and 208nm respectively. Direct binding FA of MCL1172-327  titrated 
against a FITC labeled BAX-BH3 peptide gave a binding curve, indicative of 
correctly folded, active tertiary structure with predicted Kd of 7.5 ± 3.2nM.  
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Figure 3-15 - MCL1 protein characterisation. a) Far UV CD shows expected 
alpha-helical secondary structure (trace shown is representative of 
multiple experiments). b) Direct binding FA for MCL1 titrated against 
FITC labelled BAX BH3 produces a binding curve with predicted Kd of 
7.5nM, indicative of correctly folded, active tertiary structure. 
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3.5 Expression, Purification and Characterisation of Pro-
apoptotic family members 
 
3.5.1 BAX 
 
BAX in solution should present as a monomer [52], but is notoriously 
unstable and prone to aggregation [301]. This tendency was encountered 
during this study, with BAX proving far more difficult to purify and 
characterize than other BCL-2 family members. Initial work involved the sub-
cloning into pET-28a-SUMO of BAX 1-171 C-S, containing a 21 residue C 
terminal truncation corresponding to the TM domain, and BAX 10-171 C-S, 
containing a further 9 residue N terminal truncation (to aid in future planned 
future crystallography trials), using a synthetic gene optimised for 
recombinant expression in E.coli. In both proteins, cysteine residues at 
position 62 and 126 were mutated to serine to further reduce the risk of 
aggregation [52].  
 
Sub-cloning was carried out using Gibson Assembly™ protocols. PCR 
amplified inserts for each BAX protein were combined with pET-28a-SUMO, 
cut with BamH1HF and Xho1 restriction enzymes (Figure 3-16). The resulting 
product was used to transform DH5α cells. Plasmids were extracted from 
individual colonies and correctly subcloned inserts were confirmed by 
Sanger sequencing. 
 
 
 
 
Figure 3-16 - BAX subcloning. BAX 1-171 C-S and BAX 10-171 C-S subcloned into 
pET-28a-SUMO vector using Gibson Assembly™ protocols. Bands are 
shown for both PCR amplified inserts (left) and BamH1HF / Xho1 cut 
vector (right). 
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Recombinant plasmids containing BAX 1-171 C-S and BAX 10-171 C-S proteins 
respectively were used to transform E.coli BL21 (DE3) Star competent cells 
for protein expression trials. Recombinant fusion protein, incorporating a 
hexa-His SUMO tag, was extracted and purified using Nickel affinity 
chromatography using a 5ml His Trap column (GE), as detailed in Materials 
and Methods.  
 
From 2L each of bacterial culture in Star, 12mg and 15mg total fusion 
protein was purified for BAX 1-171 C-S and BAX 10-171 C-S respectively, as 
measured using a Biorad colorimetric protein assay. Bands corresponding to 
SUMO fused BAX proteins were detected by SDS-PAGE followed by 
Coomassie Blue staining (Figure 3-17a), with confirmation by Western Blot, 
using the ab7977 anti-Bax antibody (Figure 3-17b). 
 
 
 
Figure 3-17 - BAX initial expression trials - SDS-PAGE and Western Blot 
analysis. a) BAX 1-171 C-S and BAX 10-171 C-S . His-SUMO fusion proteins at 
32.4kDa and 31.5kDa respectively can be seen for both proteins in 
column G, and confirmed in b) by Western Blot using an anti-Bax 
polyclonal antibody (ab7977). c) Overnight dialysis in the presence of 
Ulp1 SUMO protease removes the fusion tag, allowing for purification of 
the cleaved protein, shown as the upper bands in columns I to O. Key: 
A: Insoluble pellet, B: clarified lysate, C: filtered lysate, D: flow through, 
E: column buffer wash with 25mM imidazole, F: column buffer wash with 
100mM imidazole, G: elute with 300mM imidazole, H: elute with 500mM 
imidazole, I: Cleaved sample, J: His trap column flow through, K-O: 
subsequent column washes with increasing imidazole concentration – 
25mM, 50mM, 75mM, 100mM, 500mM. 
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BAX fusion proteins were dialysed overnight with SUMO protease, then 
subjected to a second round of metal affinity chromatography, with flow 
through and elutes collected and analysed by SDS-PAGE and Coomassie 
Blue staining (Figure 3-17c). 3.1mg of BAX 10-171 C-S and 4.7mg of BAX 1-171 C-S 
was collected from the flow through. Washes with increasing concentrations 
of imidazole contained decreasing, but significant, concentrations of the 
same BAX proteins, indicating issues with non-specific binding of protein to 
the Nickel His Trap column.  
 
SUMO cleaved BAX proteins were buffer transferred to PBS and diluted to a 
concentration of 10μM. Analysis by far UV circular dichroism showed both 
proteins adopting an alpha helical secondary structure, with local 
absorbance minima at 208nm and 222nm as expected (Figure 3-18). 
 
 
 
 
Figure 3-18 - CD analysis of BAX trial proteins. Both BAX 1-171 C-S and BAX 10-171 
C-S show expected alpha-helical secondary structure, with local MRE 
absorption minima at 222nm and 208nm respectively.  
 
Attempts to ascertain correct, active tertiary structure for both proteins, using 
direct binding fluorescence anisotropy failed to produce binding curves (data 
not shown). Further purification of proteins by SEC provided a potential 
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explanation for this result, as both proteins eluted in the void volume, 
indicating either high level oligomerisation, or likely aggregation of the 
protein (Figure 3-19a). To see if removal of the SUMO tag had an adverse 
effect on protein aggregation, a further round of SEC was carried out, this 
time without cleavage of the hexa-His-SUMO tag. Once again, both fusion 
proteins eluted in the void volume (Figure 3-19b). 
 
 
 
 
Figure 3-19 – SEC of BAX trial proteins. All proteins, both (a) tag cleaved and 
(b) His-SUMO fusion proteins elute in the column void volume, 
indicative of protein aggregation.  
 
There are many variables that may affect protein solubility and oligomeric 
state during the purification process. To ascertain whether protein 
expression from the pET-28a-SUMO vector was incompatible with the 
synthesis of monomeric BAX, the BAX 1-171 C-S protein was subcloned into 
pGEX-6P-2, an expression vector used previously by the group to good 
effect in the expression of recombinant protein, including BCL-2. A PCR 
amplified insert was combined with pGEX-6P-2, cut with BamH1HF and Xho1 
restriction enzymes, using Gibson Assembly™ protocols (Figure 3-20a). The 
resulting product was used to transform DH5α cells with subcloned inserts 
confirmed by Sanger sequencing. Small scale expression trials using 
multiple strains of BL21 (DE3) competent cells identified the Codon Plus 
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(CD+) strain giving the best results for expression of the 43kDa GST-BAX 1-
171 C-S  fusion protein, as assayed using SDS-PAGE and Coomassie Blue 
staining (Figure 3-20b). 
 
 
 
 
Figure 3-20 - BAX in pGEX-6P-2 subcloning and trial expression. BAX 1-171 C-S 
subcloned into pGEX-6P-2 vector using Gibson Assembly™ protocols. 
a) Bands are shown both PCR amplified inserts and BamH1HF / Xho1 cut 
vector. b) Trial expression in BL21 (DE3) Codon Plus (CD+) competent 
cells shows a clear band at approximately 46kDa, corresponding to the 
GST- BAX 1-171 C-S fusion protein. 
 
Large scale expression of GST-BAX 1-171 C-S in CD+ followed. The fusion 
protein expressed well, and was incubated overnight with glutathione 
conjugated beads in the presence of Prescission protease. Eluted volumes 
of cleaved protein were low, at 1.85mg / L media, as measured with a Biorad 
colorimetric protein assay.  A Western Blot using an anti-Bax polyclonal 
antibody (Ab7977) detected bands for fusion and cleaved proteins (Figure 
3-21a). Eluted fractions were combined, concentrated and analysed by SEC, 
but once again, protein eluted in the void volume, indicating aggregation of 
BAX during the purification process (Figure 3-21b). 
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Figure 3-21 - BAX in pGEX-6P-2 large scale expression and characterisation. 
a) Both fusion protein at approximately 46kDa, and cleaved BAX at 
19.3kDa detected by Western blot (ab7977). Key – A: clarified lysate, B: 
flow-through, C: high salt wash, D: low salt wash, E-G: sequential 5mL 
elutes following overnight incubation with Prescission protease, H: 
fraction from SEC peak in: b) Analysis by SEC showed cleaved protein 
eluting in the void volume, indicating protein aggregation during the 
purification process. 
 
BAX was eventually expressed as a monomer using a protocol developed in 
the group of Jane Clarke at the University of Cambridge. BAX 1-171 C-S was 
cloned into the pTXB1 expression vector, and used to transform DH5α cells. 
The vector codes for a fusion protein with an intein CBD (chitin binding 
domain) tag, allowing for single step purification of BAX. The fusion protein 
was over-expressed in C41 (DE3) competent E.coli cells, and purified by 
means of chitin affinity chromatography (Figure 3-22). The intein-CBD tag 
was cleaved by overnight incubation at room temperature in the presence of 
50mM DTT, and tag free protein eluted. 
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Figure 3-22 - Bax expression and purification. a) schematic of the BAX 1-171 C-S 
protein used in this study. A 21 residue truncation, corresponding to 
removal of the TM domain is made at the C terminal. b) cartoon 
representation of the crystal structure of BAX 1-171 C-S, showing alpha-
helical secondary structure (adapted from PDB 1F16). c) SDS-PAGE 
analysis of BAX 1-171 C-S expression. The protein initially expresses as a 
46.8kDa intein-CBD (chitin binding domain) fusion. Overnight incubation 
in the presence of 50mM DTT causes the intein tag to self cleave, 
allowing for purification of the 18.9kDa cleaved protein, visible in 
columns G, J and K. Key – A: clarified lysate, B: filtered lysate (0.45µm), 
C: filtered lysate (0.22µm), D: flow-through, E: buffer wash, F: buffer + 
50mM DTT ‘flush’, G: column elute, H-I: buffer elute / wash, J: 
concentrated sample, K: filtered conc. sample (0.22µm) for SEC. 
 
Further purification by SEC yielded a monomer peak on the chromatogram 
at 187mL (Figure 3-23). A ‘shoulder’ on this peak corresponded to a band for 
the cleaved intein-CBD tag. Evidence of tag contamination in some 
monomer fractions was also seen. Only clean fractions were used for further 
analysis.  
 
Compared to expression of anti-apoptotic family members, and in line with 
results from other groups [32, 52], protein yield for BAX was low, at 
approximately 1.8mg from 6L bacterial culture. The sudden drop off in yield 
following SEC purification caused in part by the removal of impurities seen in 
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the sample loaded to the column (Figure 3-22c, row K), but may also 
explained by the fact that the first two protein concentration measurements 
were made using the Biorad assay, but the sample recovered from SEC was 
measured using absorbance at UV280, a more accurate method. 
Table 3-6 - BAX yield and recovery for each stage of protein purification. Yield 
compared to pro-survival proteins is very low, but this is in line with the 
experience of other groups. The first two protein concentrations were 
measured using the Biorad assay, the measurement for BAX recovered 
from SEC was made using absorbance at UV280. 
 
Purification stage mg / L media Yield (%) 
Column elute of BAX 1.6 100 
Concentrated and 
loaded to SEC column 
1.15 72 
Recovered from SEC 0.3 19 
 
 
 
 
 
Figure 3-23 - Size exclusion chromatography of BAX 1-171 C-S. The main peak at 
187mL corresponds to a monomer. The adjacent shoulder corresponds 
to a band for cleaved intein-CBD. 
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3.5.2 BAK 
 
BAK 16-185 C-S was over-expressed in C41 (DE3) cells and purified by chitin 
affinity chromatography, using an amended version of the protocol used to 
purify BAX 1-171 C-S, which is fully detailed in the Materials and Methods 
section. The protein was first expressed as an intein-CBD tagged fusion, 
with the tag removed by intein self cleavage after overnight incubation in the 
presence of 50mM DTT (Figure 3-24).  
 
 
 
Figure 3-24 - BAK expression and purification. a) schematic of the BAK 16-185 C-
S protein used in this study. A 21 residue truncation, corresponding to 
the TM domain is made at the C terminal, and a further 15 residue 
truncation made at the N terminus. b) cartoon representation of the 
crystal structure of  BAK 16-185 C-S, showing alpha-helical secondary 
structure (adapted from PDB 2YV6). c) SDS-PAGE analysis of BAK 16-185 
C-S expression. The protein initially expresses as a 47kDa intein-CBD 
fusion. Overnight incubation in the presence of 50mM DTT causes the 
intein tag to self cleave, allowing for purification of the 19.2kDa cleaved 
protein, visible in columns E-H. Key – A: clarified lysate, B: filtered 
lysate (0.45µm), C: filtered lysate (0.22µm), D: flow-through, E: buffer 
wash, F: buffer + 50mM DTT ‘flush’, G: column elute, H-I: buffer elute / 
wash, J: concentrated sample, K: filtered conc. sample (0.22µm) for 
SEC. 
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Further purification by SEC yielded a monomer peak on the chromatogram 
at 187mL, with an adjacent dimer peak at 170mL (Figure 3-25). 
 
Yield of cleaved protein was once again relatively low compared to anti-
apoptotic family members, but good compared to BAX, with approximately 
14mg BAK 16-185 C-S purified from 6L of bacterial culture.  
 
Table 3-7 - BAK yield and recovery for each stage of protein purification. Yield 
compared to pro-survival proteins is low, but good in comparison to 
BAX. The first two protein concentrations were measured using the 
Biorad assay, the measurement for BAK recovered from SEC was made 
using absorbance at UV280. 
 
Purification stage mg / L media Yield (%) 
Column elute of BAK 8 100 
Concentrated and 
loaded to SEC column 
6.5 81 
Recovered from SEC 2.3 29 
 
 
 
 
 
 
Figure 3-25 - Size exclusion chromatography of Bak 16-185 C-S. The main peak at 
187mL corresponds to a monomer. The adjacent shoulder at 170mL 
corresponds to a dimer.  
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Biophysical analysis on both BAX and BAK proteins using far UV CD 
revealed the expected alpha helical profile (Figure 3-26). For BAX, local MRE 
minima at 222 and 208nm  were -16443 and -18451 respectively. For BAK, 
the minima were recorded as -21367 and -22563.  
 
 
Figure 3-26 – BAX and BAK characterisation. Far UV CD shows the expected 
alpha helical profile for both proteins. BAX shows local absorption 
minima at 208nm and 222nm of -18451 and -16443 respectively. The 
corresponding figures for BAK are -22563 and -21367. Traces shown are 
representative of multiple experiments. 
 
Both proteins were assayed for correct teriary structure using FA direct 
binding assays, with titration against FITC labelled BH3 peptides from the 
BH3 only activators BID and BIM. Unfortunately, I was unable to obtain 
binding curves for either BAX or BAK (Figure 3-27): the hypothesised ‘hit and 
run’ nature of interactions in the BC binding groove of BAX and BAK would 
explain why this result was likely, as does the absence of such data 
published in the literature. 
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Figure 3-27 – Direct binding FA assays for BAX and BAK. a) BAX titrated 
against FITC-BID-BH3. b) BAX titrated against FITC-BIM-BH3. c) BAK 
titrated against FITC-BID-BH3. d) BAK titrated against FITC-BIM-BH3. 
Average anisotropy was measured for all reactions after 1 hour, and 
following overnight incubation at RT (17 hours). No binding curves were 
obtained. 
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3.6 Chapter Summary and Discussion 
 
This chapter describes the work undertaken to select, synthesise, purify and 
characterise target proteins from the BCL-2 family for use in this study. As 
the interacting surfaces on proteins have historically proved difficult to target 
[302, 303], only multi-domain family members were selected, as these all 
present a well defined, globular tertiary structure, unlike the BH3 only family 
members, which are intrinsically disordered. Proteins selected covered both 
pro-survival and pro-apoptotic members. 
 
All pro-survival family members, BCL-2, BCL-XL and MCL1, expressed well 
as either dimers or monomers, and were easily characterised. BAX and BAK 
expressed as monomers, but at much lower yield than their pro-survival 
counterparts, and were not amenable to analysis by direct binding FA. This 
has been an issue for other groups working with BAX and BAK, and is most 
likely due to the transient ‘hit and run’ nature of binding events in their 
respective BC grooves. By contrast, the nanomolar binding affinities 
obtained in FA direct binding assays for pro-survival proteins titrated against 
FITC-BAX-BH3 were in line with previously published results [304]. α-helical 
secondary structure was confirmed for all target proteins, with expected 
levels of CD spectrum absorption minima seen at 208nm and 222nm in 
every case1. BCL-2, BCL-XL, MCL1, BAX and BAK were taken forward as 
targets for Affimer panning in the next stage of this study.  
                                            
1 Using far UV CD, a hypothetical protein with 100% α-helical secondary structure would have MRE at 
222nm of around -30,000 deg cm2 dmol-1 305. Kelly, S.M., T.J. Jess, and N.C. Price, How to 
study proteins by circular dichroism. Biochim Biophys Acta, 2005. 1751(2): p. 119-39., providing a 
theoretical maximum for MRE. However, other studies have measured spectra for recombinant BCL-2 
family proteins with MRE readings between -15000 and -20,000 306. Wallgren, M., et al., 
Reconstitution of the anti-apoptotic Bcl-2 protein into lipid membranes and biophysical evidence for its 
detergent-driven association with the pro-apoptotic Bax protein. PLoS One, 2013. 8(4): p. e61452, 
307. Ivashyna, O., et al., Detergent-activated BAX protein is a monomer. J Biol Chem, 2009. 
284(36): p. 23935-46. 
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Chapter 4 – Identification and Characterisation of Affimers 
binding BCL-2 family proteins 
 
The previous chapter detailed the work carried out to express, purify and 
characterise a selection of pro- and anti-apoptotic proteins from the BCL-2 
family. This chapter describes the actions taken to raise Affimers, a class of 
engineered non-antibody binding protein, against these BCL-2 family 
members. It details the use of phage display experiments to isolate target 
binding clones from the Affimer phage display library, the subcloning and 
protein expression work carried out to purify these clones as Affimers, and 
the biophysical assays used to characterise individual Affimers and their 
interactions with target proteins. 
 
4.1 Preliminary Work 
 
Earlier work carried out in the Edwards group by Dr Jennifer Miles identified 
Affimers that selectively bound to MCL1 and BCL-XL  (Figure 4-1). Using 
fluorescence anisotropy competition binding assays, Affimers ADB10 and 
ADB132 were shown to bind BCL-XL with sub-micromolar IC50 values (0.74 ± 
0.08μM and 0.39 ± 0.05μM respectively) when titrated against a complex of 
BCL-XL and BODIPY labelled BAK BH3 peptide. Similarly, Affimers ADM1 
and ADM22 were shown to bind MCL1 with IC50 values of 3μM and 2μM 
respectively, when titrated against a complex of MCL1 and FITC labelled 
NOXA-B BH3 peptide (Figure 4-2 and Table 4-1). The ability of these Affimers 
to compete with peptides analogous to the BH3 domains of endogenous 
binding partners indicated that they were all interacting with the BC binding 
groove of their target protein. 
 
 
                                            
2 Affimers were previously known as adhirons, as reflected in the ‘ADB’ and ‘ADM’ prefixed 
nomenclature of binders raised against BCL-XL and MCL1 in this preliminary work. 
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Figure 4-1 – Affimers targeting BCL-XL and MCL1. Previous work in the group 
identified ADB10 and ADB13 as selective binders for BCL-XL, and ADM1 
and ADM22 as selective binders for MCL1. Details of residues in the two 
randomised Affimer loops are shown. Residues are coloured according 
to their side chain properties: Blue – polar, positive charge; red – polar, 
negative charge; green – polar, neutral; grey – non-polar, aliphatic; 
purple – non-polar, aromatic; orange – glycine and proline. 
 
	 	
	
	
	
	
 
Figure 4-2 – Affimers selectively bind target proteins. Fluorescence 
anisotropy competition binding assays were used to demonstrate the 
ability of Affimers to selectively compete with endogenous binding 
partners of their target proteins. Left panel: ADB10 and ADB13 show 
competitive binding when titrated against a complex of BCL-XL and 
BODIPY labelled BAK BH3 peptide, but no activity against a complex of 
MCL1 and FITC labelled NOXA-B BH3. Right panel:  ADM1 and ADM22 
show competitive binding when titrated against a complex of MCL1 and 
FITC labelled NOXA-B BH3 peptide, but no activity against a complex of 
BCL-XL and BODIPY labelled BAK. The ability of these Affimers to 
compete off BH3 peptides mimicking binding domains of BH3 only 
family members indicates binding interactions in the BC groove. Data 
courtesy of Dr Jennifer Miles. 
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Table 4-1 – IC50 values for Affimers in competition binding assays. ADB10 and 
ADB13 bind BCL-XL with IC50 values of 0.74 ± 0.08µM and 0.39 ± 0.05µM 
respectively when titrated against a complex of BCL-XL and BODIPY 
labelled BAK BH3 peptide. ADM1 and ADM22 bind MCL1 with IC50 values 
of 3µM and 2µM respectively, when titrated against a complex of MCL1 
and FITC labelled NOXA-B BH3 peptide. No competitive binding is seen 
against control protein in either case. Data courtesy of Dr Jennifer Miles. 
 
 IC50 (µM) 
Affimer vs BCL-XL : BODIPY-
BAK BH3 
vs MCL1 : FITC NOXA B 
ADB10 0.74 ± 0.08 - 
ADB13 0.39 ± 0.05 - 
ADM1 - 3 
ADM22 - 2 
 
Crystallisation trials undertaken by Dr Miles produced a low resolution (~ 3Å) 
structure for MCL1 bound to ADM22. These trials involved mixing protein 
and Affimer with overnight incubation and no further purification.  To 
advance this study, SEC was used to see if ADM1 and ADM22 would co-
purify with MCL1, and if so, whether the purified complexes would yield 
structural data for the MCL1:ADM1 complex, and higher resolution structural 
data for the MCL1:ADM22 complex. Affimers were mixed with MCL1 in a 
molar ratio of 1.2:1, incubated overnight at 4°C, then run on a HiLoad 26/60 
Superdex S75 pg column. Results showed both ADM1 and ADM22 co-
eluting in complex with MCL1 (Figure 4-3). The eluted complexes were used 
in crystallisation trials, with initial screening carried out against 384 unique 
buffer conditions. Unfortunately, the MCL1:ADM1 complex did not produce 
crystals in preliminary trials, and crystals produced and optimised for the 
MCL1:ADM22 complex failed to produce higher resolution data than that 
already obtained by Dr Miles. 
 
Despite drawbacks in obtaining structural data, our group had established 
that Affimers can be raised to selectively target individual BCL-2 family 
proteins, namely the pro-survival members BCL-XL and MCL1. The 
remainder of this chapter describes experiments designed to progress this 
work by raising selectively binding Affimers against BCL-2, and against the 
pro-apoptotic proteins BAX and BAK, as well as work to identify Affimers 
able to cross react with multiple pro-survival family members. 
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Figure 4-3 – Affimers co-purify with target proteins. ADM1 (a) and ADM22 (b) 
were mixed with MCL1 in a molar ratio of 1.2:1 and incubated overnight 
at 4°C. Left panels: Protein : Affimer complexes were purified by SEC 
using  a HiLoad 26/60 Superdex S75 pg column. Asterisks denote 
elution peaks used for analysis by SDS-PAGE. Right panels: Coomassie 
staining of SDS-PAGE gels clearly shows band for both protein and 
Affimer in the SEC fractions collected.  
 
4.2 Affimer Targeting of Pro-Survival BCL-2 Proteins 
 
Work with the pro-survival BCL-2 family members comprised two major 
strands. Firstly, Affimers were raised against BCL-2, to augment the work 
already done with BCL-XL and MCL1 and complete a library of selective 
binders against the pro-survival BCL-2 family members used in this study. 
Secondly, a comprehensive phage display ‘cross-panning’ exercise was 
carried out, with the aim of identifying cross-reacting Affimers able to bind 
combinations of BCL-2, BCL-XL and MCL1. 
 
To carry out phage display experiments, target proteins must first be 
immobilised. To this end, BCL-2, BCL-XL and MCL1 were heterogeneously 
labelled using EZ-link NHS-SS-Biotin to biotinylate primary amines, and 
were then immobilised on Nunc-Immuno™ MaxiSorp™ strips. Biotinylation 
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was confirmed by ELISA, using streptavidin HRP and 3,3',5,5'-
Tetramethylbenzidine (TMB) to develop the reaction. Absorbance was 
measured at 620nm, and successful biotinylation of all target proteins 
confirmed (Figure 4-4). 
	
	
	
Figure 4-4 – ELISA confirms biotinylation of pro-survival BCL-2 family 
proteins for use in phage display experiments. Target proteins were 
diluted 1:50 in PBS and bound to wells in Nunc-Immuno™ MaxiSorp™ 
strips. The control well contained PBS with no target protein. 
Streptavidin HRP was added to all wells. Biotinylation was confirmed for 
all pro-survival target proteins by the subsequent addition of TMB as a 
HRP substrate, with absorbance read at 620nm. 
 
4.2.1 BCL-2 
 
Well established protocols for Affimer panning, developed and optimised by 
the BioScreening Technology Group (BSTG) at the University of Leeds, 
were followed. Three Affimer panning rounds were carried out as described 
in Chapter 2, with BCL-2 binding phage clones eluted at each step for use in 
the next panning round. In the first panning round, biotinylated BCL-2 was 
immobilised in streptavidin coated wells prior to incubation with the Affimer 
phage library. For the second panning round, immobilisation was carried out 
using streptavidin coated magnetic beads, followed by incubation with phage 
eluted from round 1. After the final panning round, phage were eluted from 
neutravidin coated target wells in which BCL-2 had been immobilised, and 
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from control wells containing buffer but no target protein (to detect non-
specific binders). Target and control eluted phage were then used to infect 
ER2738 E. coli cells and grown in LB media. LB agar plates were 
subsequently inoculated with 10μL of culture from target wells, or 10μL of 
culture from control wells. Following overnight incubation at 37°C, the plate 
inoculated with target culture had >300 colonies; the plate inoculated with 
control culture had only seven colonies, confirming significant amplification 
of target binding phage in target wells, as opposed to non-specific binding 
phage in control wells.  
 
	
	
	
 
Figure 4-5 – Identification of Affimers targeting BCL-2. a) Results of phage 
ELISA following three Affimer panning rounds against BCL-2. 48 phage 
transduced colonies were picked; 20 of these demonstrated increased 
binding activity against controls (results show differences in 
absorbance after incubation with Anti-Fd-Bacteriophage-HRP, addition 
of TMB and allowing HRP:TMB reaction to develop for 2 minutes). b) 
Sanger sequencing of extracted phagemid DNA identified four unique 
binders, B-2 Aff D4, E5, E6 and F4.  Details of residues in the two 
randomised Affimer loops are shown. Residues are coloured according 
to their side chain properties (as described in Figure 4-1). 
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48 colonies were selected from the target plate and used in phage ELISA 
experiments (described in Chapter 2) to identify selectively binding clones 
for sequencing and further analysis (Figure 4-5a). Twenty clones were shown 
to demonstrate increased binding activity compared to blank controls. 
Phagemid DNA extracted from these clones was as sent for Sanger 
sequencing, and four unique binders, termed B-2 Aff D4, E5, E6 and F4, 
were identified (Figure 4-5b). Of these, D4 and E6 were each represented 
nine times in the pool of twenty, E5 and F4 each represented once only. 
 
DNA for each of the unique binding sequences was sub-cloned from 
phagemid into pET-11a vectors, then used to transform BL21 (DE3) Rosetta 
2 cells. Affimers were expressed as recombinant proteins with a hexa-His 
tag, and purified by Nickel affinity chromatography, providing good yields in 
all cases as detailed in Table 4-2. 
Table 4-2 - BCL-2 Affimer expression and initial purification yields. All 
Affimers were purified using Nickel affinity chromatography. Yield is 
expressed as the amount of protein detected in the 300mM imidazole 
Nickel column elute, measured using a Biorad assay. 
 
Affimer	 Yield	(mg/L	media)	
B-2	Aff	D4	 41	
B-2	Aff	E5	 34	
B-2	Aff	E6	 35	
B-2	Aff	F4	 21	
 
BCL-2 Affimers were further purified by size exclusion chromatography, then 
characterised using biophysical assays, the results of which are presented in 
Figure 4-6 - Figure 4-9, and described in the following paragraphs.  
 
4.2.1.1 Size Exclusion Chromatography 
 
Results of SEC are shown in Figure 4-6b - Figure 4-9b. The SEC 
chromatograms produced demonstrate a tendency for Affimers to elute late 
from the SEC column, an effect thought to be caused by Affimers interacting 
with the column itself, which makes it difficult to state with certainty whether 
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SEC peaks represent monomers or higher order structures. This is 
particularly apparent with the late elution peaks seen for E5 and E6, as 
detailed in Table 4-3 below.  
Table 4-3 – Results of SEC purification of BCL-2 Affimers. Affimers were 
purified by SEC using a HiLoad 26/60 Superdex S75 pg column. Actual 
elution volumes are compared with expected elution volumes, 
determined by comparison against calibration standards. Late elution 
peaks for E5 and E6 demonstrate the tendency of Affimers to interact 
with the column during SEC purification. F4 elutes at 111mL, in the void 
volume, indicating aggregation during purification and precluding F4 
from further study. 
 
Affimer	 Mw	(Da)	 Expected	Elution	
Volume	(mL)	
Actual	Elution	
Volume	(mL)	
B-2	Aff	D4	 13626	 213	 204	
B-2	Aff	E5	 12247	 218	 256	
B-2	Aff	E6	 12460	 217	 230	
B-2	Aff	F4	 13539	 214	 111	
 
Affimers may also demonstrate a tendency to oligomerise during purification.  
This effect has been witnessed in previous work carried out by the Edwards 
group with binders raised against p300 (unpublished data), and does not 
prevent such Affimers being used in further assays. In Figure 4-6 - Figure 4-9 
higher order structures are seen for all Affimers, in addition to the void 
volume eluates at 111mL. Affimer F4 eluted almost exclusively in the void 
volume, having unfortunately aggregated on the SEC column (Figure 4-9), 
and was consequently excluded from further studies.  
 
4.2.1.2 Far UV Circular Dichroism 
 
The remaining Affimers, D4, E5 and E6,  were buffer exchanged into PBS, 
and far UV CD was used to check for correct secondary structure. The 
Affimer backbone comprises two pairs of β-strands connected by loops and 
one α-helix, and the predominance of β-strands would dictate absorbance 
spectra with minima at around 218nm. This profile is indeed seen in all three 
cases (Figure 4-6c - Figure 4-8c), with MRE minima of -10,145, -8,665 and – 
10,713 for D4, E5 and E6 respectively. 
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4.2.1.3 Affimer target binding ELISA 
 
Finally, as false positive results are frequently seen in phage display 
experiments, binding ELISAs were used to test that D4, E5 and E6 were all 
genuine and selective binders of BCL-2 (Figure 4-6d - Figure 4-8d), with BCL-
XL and BAK also assayed as controls. All proteins were diluted in PBS, and 
200ng per well aliquoted to 96 well Nunc-Immuno™ MaxiSorp™ plates, with 
overnight incubation at 4°C. After washing and blocking with BSA, Affimers 
were applied to bound protein and serially diluted down the ELISA plate. 
Optimisation trials established an initial Affimer concentration of 1μg mL-1 
and 1:3 dilutions as the conditions providing optimum results. As all Affimers 
are expressed from pET-11a with a hexa-His tag for purification, binding was 
assayed through the addition of a HRP conjugated anti poly-His antibody. 
TMB was added as HRP substrate, the reaction was allowed to develop, 
then was quenched by the addition of 2M sulphuric acid3, with absorption 
read at 450nm. D4, E5 and E6 all presented as genuine and selective 
binders of BCL-2, with negligible binding to controls observed.  
 
 
 
 
 
 
 
                                            
3 Reaction quenching disrupts formation of the TMB radical cation dimer, resulting in a yellow colour 
in solution, the absorbance of which can be read at 450nm. 
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Figure 4-6 – Purification and Characterisation of B-2 Aff D4. a) Coomassie 
staining of SDS PAGE gel used to analyse D4 purification by Nickel 
affinity chromatography. Key: A = clarified lysate; B = filtered lysate; C = 
column flow through; D = column buffer (CB) wash; E = CB + 50mM 
imidazole wash; F = CB + 100mM imidazole wash; G = CB + 300mM 
imidazole elute. The 300mM imidazole elute was taken for further 
purification by SEC. b) Chromatogram of 300mM imidazole elute purified 
by SEC using a HiLoad 26/60 Superdex S75 pg column. The early peak 
shows high order oligomerisation. The late peak, eluting at 204mL, was 
taken for further biophysical analysis. c) Fractions collected from the 
selected Affimer peak were buffer exchanged into PBS and analysed by 
Far UV CD to check for correct secondary structure. The expected 
profile for predominantly β-sheet structures is seen, with an MRE 
absorption minima of – 10,145 seen at 217nm. d) ELISA results confirm 
selective binding of D4 for BCL-2 compared to BCL-XL and BAK 
controls. Immobilised proteins were exposed to 1:3 serial dilutions of 
Affimer. Binding was assayed through the addition of a HRP conjugated 
anti poly-His antibody, which binds the hexa-His tag on purified 
Affimers. Reactions were developed with TMB and quenched by the 
addition of 2M sulphuric acid, with absorption measured at 450nm. 
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Figure 4-7 - Purification and Characterisation of B-2 Aff E5. a) Coomassie 
staining of SDS PAGE gel used to analyse E5 purification by Nickel 
affinity chromatography. Key as for Figure 4-6. The 300mM imidazole 
elute was taken for further purification by SEC. b) Chromatogram of 
300mM imidazole elute purified by SEC using a HiLoad 26/60 Superdex 
S75 pg column. The early peak elutes in the void volume, with a 
shoulder of high order oligomers. The late peak elutes at 256mL, at a 
later volume than expected, a common artefact in Affimer purification. c) 
Fractions collected from the selected Affimer peak were buffer 
exchanged into PBS and analysed by Far UV CD to check for correct 
secondary structure. The expected profile for predominantly β-sheet 
structures is seen, with an MRE absorption minima of – 8,665 seen at 
217nm. d) ELISA results confirm selective binding of E5 for BCL-2 
compared to BCL-XL and BAK controls. Assay as described in Figure 
4-6. 
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Figure 4-8 -- Purification and Characterisation of B-2 Aff E6. a) Coomassie 
staining of SDS PAGE gel used to analyse E6 purification by Nickel 
affinity chromatography. Key as for Figure 4-6. The 300mM imidazole 
elute was taken for further purification by SEC. b) Chromatogram of 
300mM imidazole elute purified by SEC using a HiLoad 26/60 Superdex 
S75 pg column. The early peak elutes in the void volume, with an 
attached peak of high order oligomers. The late peak elutes at a later 
volume than expected, at 230mL. c) Fractions collected from the 
selected Affimer peak were buffer exchanged into PBS and analysed by 
Far UV CD to check for correct secondary structure. The expected 
profile for predominantly β-sheet structures is seen, with an MRE 
absorption minima of – 10,713 seen at 217nm. d) ELISA results confirm 
selective binding of E6 for BCL-2 compared to BCL-XL and BAK 
controls. Assay as described in Figure 4-6. 
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Figure 4-9 - Purification of B-2 Aff F4. a) Coomassie staining of SDS PAGE gel 
used to analyse F4 purification by Nickel affinity chromatography. Key 
as for Figure 4-6. The 300mM imidazole elute was taken for further 
purification by SEC. b) Chromatogram of 300mM imidazole elute purified 
by SEC using a HiLoad 26/60 Superdex S75 pg column, showing 
evidence of aggregation, with Affimer eluting predominantly in the void 
volume at 111mL, and no monomer peak. 
 
4.2.2 Cross-reactive Affimers to bind multiple pro-survival 
members 
 
Affimers for each of the pro-survival BCL-2 proteins used in this study had 
now been identified. All such Affimers demonstrated selectivity in binding 
their target proteins, with no evidence of cross-reactivity to other pro-survival 
proteins seen (Figure 4-2, Figure 4-6 - Figure 4-8).  
 
The next set of experiments were carried out to determine if it was possible 
to raise cross-reacting Affimers with binding affinity for multiple pro-survival 
family members. If feasible, such Affimers could help guide the design of 
small molecules able to bind and neutralise combinations of pro-survival 
proteins, which would prove useful in cellular assays to investigate 
physiological activities of individual family members, or test clones of cancer 
cells for BCL-2 addiction4.  
                                            
4 The concept of BCL-2 ‘addiction’ of specific cancers with regard to pro-survival family 
members was introduced in Chapter 1. To reiterate, cancer cells with elevated levels of 
BCL-2, BCL-XL or MCL1 gain a competitive and selective advantage and are described as 
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The EMBL-ESI Pairwise Sequence Alignment tool was used to compare the 
sequence identify of our three pro-survival proteins (Table 4-4). The most 
promising two way combination for cross-reactivity was BCL-2 with BCL-XL, 
having 40.3% identity. The likelihood of MCL1 being included in any cross-
reactivity was much lower, MCL1 having only 20.4% and 24.7% sequence 
identity with BCL-2 and BCL-XL respectively. 
Table 4-4 - Comparison of sequence identity for pro-survival BCL-2 proteins. 
Comparative data was obtained using the EMBL-ESI Pairwise Sequence 
Alignment tool. 
 
%	identity	 BCL-2	 BCL-XL	 MCL1	
BCL-2	 100.0	 40.3	 20.4	
BCL-XL	 40.3	 100.0	 24.7	
MCL1	 20.4	 24.7	 100.0	
 
Dual inhibitors of BCL-2 and BCL-XL already exist, for example ABT-737 and 
ABT-263, developed using structure based design, and enhanced using 
medicinal chemistry techniques [245]. Using phage display to identify dual 
inhibitors, or even three-way ‘pan inhibitors’, would be a more speculative 
exercise, but the ability of such experiments to probe the entire surface of 
target proteins opened up the possibility of identifying novel binding sites 
common to pro-survival members that might not be apparent from 
comparing their primary structures. With this in mind, a comprehensive 
phage display ‘cross-panning’ exercise was designed, where cross-reacting 
phage clones would be isolated using three panning rounds as usual, but 
with phage eluted from each panning round incubated in the next round with 
a different immobilised pro-survival target protein.  
 
Six different cross panning sequences were designed; these are outlined in 
Table 4-5, with each given a unique cross-pan sequence identifier, from A to 
F. To illustrate the design, in cross-pan sequence A, the first panning round 
                                                                                                                           
being ‘addicted’ to the pro-survival member they over-express: without them, they would be 
unable to survive the harsh inter-cellular environment that persists during tumour 
progression.  
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is carried out against immobilised BCL-2, with eluted phage panned in the  
second and third rounds against immobilised MCL1. Any identified binding 
clones would potentially be BCL-2 : MCL1 cross-reactive binders. In 
sequence B, the first pan is carried out against BCL-2, the second against 
BCL-XL, and the final pan against MCL1; any identified binding clones in this 
case would potentially be three-way ‘pan inhibitors’, with the ability to bind all 
three of our pro-survival target proteins.  
Table 4-5 – Cross panning exercise for pro-survival proteins. Six different 
cross-pan sequences, labelled A-F, were carried out. Individual cells 
identify the pro-survival protein immobilised and incubated with phage 
at each panning round. Following the final panning round, eluates from 
the different sequences A-F will contain phage panned against a 
combination of either 2 or 3 different pro-survival proteins. 
 
	 Cross-pan	sequence	
Pan	#	 A	 B	 C	 D	 E	 F	
1	 BCL-2	 BCL-2	 MCL1	 MCL1	 BCL-XL	 BCL-XL	
2	 MCL1	 BCL-XL	 BCL-2	 BCL-XL	 MCL1	 BCL-2	
3	 MCL1	 MCL1	 BCL-XL	 BCL-XL	 BCL-2	 BCL-2	
 
Following completion of the final panning round for each of the six cross-pan 
sequences A-F, phage was eluted from neutravidin coated target wells in 
which final round target protein had been immobilised, and from control wells 
containing buffer but no target protein. Target and control eluted phage were 
then used to infect ER2738 E. coli cells and grown in LB media. LB agar 
plates were subsequently inoculated with 10μL of culture from target wells, 
or 10μL of culture from control wells. This was to check for phage clone 
amplification in target wells, compared to any non-specific binders in control 
wells, as described previously for the BCL-2 Affimer pan. A significant 
increase in the number of colonies seen on target plates compared to control 
plates would be evidence for the presence of cross-reactive binders. 
Following overnight incubation at 37°C, amplification was seen on all target 
plates, though to a much lower extent than would typically be seen when 
panning against a single target (Table 4-6). This is not surprising, given the 
levels of sequence identity between BCL-2, BCL-XL and MCL1 detailed in 
Table 4-4.  
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Table 4-6 – Phage amplification on target plates compared to blank controls. 
Comparison of colony numbers on target and control plates after three 
panning rounds. Low levels of amplification are seen in all cases. 
 
Cross-pan	
identifier	
Cross	pan	detail	 #	colonies	(target)	 #	colonies	(control)	
A	 BCL-2	:	MCL1	:	MCL1	 48	 4	
B	 BCL-2	:	BCL-XL	:	MCL1	 13	 7	
C	 MCL1	:	BCL-2	:	BCL-XL	 10	 2	
D	 MCL1	:	BCL-XL	:	BCL-XL	 17	 4	
E	 BCL-XL	:	MCL1	:	BCL-2	 48	 7	
F	 BCL-XL	:	BCL-2	:	BCL-2	 16	 7	
 
Target colonies were selected, and phage ELISA was used to determine if 
any colonies contained clones with expected cross-reacting binding 
characteristics, compared to blank controls. With reference to Table 4-6, 
cross-pan sequences B, C and D showed no measurable absorbance in 
ELISA plates, for either target or blank wells (data not shown). Figure 4-10 
shows the results for the remaining sequences: A, E and F. For A and F (top 
and bottom panels respectively), no difference in binding activity was seen 
between target clones and blank controls, indicating false positive results. 
For cross-pan identifier E (middle panel), some clones showed potential 
binding to BCL-2 and BCL-XL compared to controls. However, as identifier E 
was a 3 way cross pan, and there was no binding for MCL1, these were also 
deemed to be false positive results, and were not subjected to further study.  
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Figure 4-10 – Cross-panning to identify cross-reactive Affimers. Phage ELISA 
results from pro-survival protein cross-panning exercise. Results show 
differences in absorbance after incubation with Anti-Fd-Bacteriophage-
HRP, addition of TMB and allowing HRP:TMB reaction to develop for >5 
minutes. No genuine binding clones were identified. 
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4.3 Affimer Targeting of Pro-Apoptotic BCL-2 proteins 
 
The pro-apoptotic proteins BAX and BAK were prepared for use as target 
proteins for Affimer panning. Both proteins were biotinylated using EZ-link 
NHS-SS-Biotin to tag primary amines, with biotinylation confirmed by ELISA. 
Absorbance was measured at 620nm, and successful biotinylation of both 
BAX and BAK confirmed as shown in Figure 4-11. 
	
	
	
Figure 4-11 – ELISA confirms biotinylation of BAX and BAK for use in phage 
display experiments. Target proteins were diluted 1:50 in PBS and 
bound to wells in Nunc-Immuno™ MaxiSorp™ strips. The control well 
contained PBS with no target protein. Streptavidin HRP was added to all 
wells. Biotinylation was confirmed for BAX and BAK by the subsequent 
addition of TMB as a HRP substrate, with absorbance read at 620nm. 
 
4.3.1 BAK 
 
Three Affimer panning rounds were carried out, with amplification of BAK 
binding clones at each stage. Following completion of the final panning 
round, agar plates inoculated with media from target and control wells (as 
previously described for BCL-2) were compared for evidence of amplification 
in target wells. The target well plate had >200 colonies, with no colonies 
seen on the control plate. 
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24 colonies from the target plate were selected, and phage ELISA was used 
to detect binding clones for sequencing and further analysis (Figure 4-12a). 
All clones were shown to demonstrate increased binding activity compared 
to blank controls. Sanger sequencing carried out on phagemid DNA 
extracted from all 24 clones identified four unique binders, termed BAK Aff 1, 
3, 6 and 15 (Figure 4-12b). Aff 1, Aff 3 and Aff 6 were represented multiple 
times from the pool of 24 clones. 
 
	
	
	
 
Figure 4-12 - Identification of Affimers targeting BAK. a) Results of phage 
ELISA following three Affimer panning rounds against BAK. 24 phage 
transduced colonies were picked; all demonstrated increased binding 
activity against controls (results show differences in absorbance after 
incubation with Anti-Fd-Bacteriophage-HRP, addition of TMB and 
allowing HRP:TMB reaction to develop for 2 minutes). b) Sanger 
sequencing of extracted phagemid DNA identified four unique binders, 
BAK Aff 1, 3, 6 and 15.  Details of residues in the two randomised 
Affimer loops are shown. Residues are coloured according to their side 
chain properties (as described in Figure 4-1). 
 
DNA for each of the unique binding sequences was sub-cloned from 
phagemid into pET-11a vectors, then used to transform BL21 (DE3) Rosetta 
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2 cells. Affimers were expressed and purified by Nickel affinity 
chromatography, providing good yields for Aff 1, Aff 3 and Aff 15 (Table 4-7). 
Following growth in bacterial media and induction with IPTG, it had been 
noted that the culture for BAK Aff 6 produced a notably smaller bacterial 
pellet, and the comparatively low initial yield of BAK Aff 6 was attributed to 
this.  
Table 4-7 - BAK Affimer expression and initial purification yields. All Affimers 
were purified using Nickel affinity chromatography. Yield is expressed 
as the amount of protein detected in the 300mM imidazole Nickel column 
elute, measured using a Biorad assay. 
 
Affimer	 Yield	(mg/L	media)	
BAK	Aff	1	 48	
BAK	Aff	3	 54	
BAK	Aff	6	 11	
BAK	Aff15	 45	
 
Table 4-8 – SEC purification of BAK Affimers. Affimers were purified by SEC 
using a HiLoad 26/60 Superdex S75 pg column. Actual elution volumes 
are compared with expected monomer elution volumes (as determined 
by comparison against calibration standards described in Chapter 3). 
Aff 1 and Aff 15 elute as monomers. The late elution peak for Aff 3 
demonstrates the tendency of Affimers to interact with the column 
during SEC purification. The main peak for Aff 6 elutes earlier than 
expected for a monomer peak, indicative of higher order 
oligomerisation. 
 
Affimer	 Mw	(Da)	 Expected	Elution	
Volume	(mL)	
Actual	Elution	
Volume	(mL)	
BAK	Aff	1	 12359	 218	 222	
BAK	Aff	3	 13652	 214	 259	
BAK	Aff	6	 13558	 214	 185	
BAK	Aff15	 13554	 214	 212	
 
BAK Affimers were further purified by SEC (Figure 4-13b – Figure 4-16b). BAK 
Aff1 and BAK Aff 15 eluted as monomers. BAK Aff 3 eluted later than 
expected, likely due to Affimer interaction with the SEC column, making it 
difficult to state with certainty whether the peak at 259mL represents a 
monomer or higher order structure. The main peak for BAK Aff 6 elutes in 
the correct position for a dimer (Table 4-8).  
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A considerable loss of Affimer yield following SEC of Aff 1 and Aff 3 was 
noted: only 1.6mg of Aff 1 and 3.4mg of Aff 3 were recovered, 3.3% and 
6.3% respectively of the protein samples loaded to the column. Though 
there was sufficient protein remaining to to carry out further assays, this loss 
of protein Is still a concern. All BAK Affimers, purified by Nickel affinity 
chromatography as previously stated, had been eluted from the His trap 
column using Tris buffer containing 300mM imidazole, then concentrated 
down for SEC. However, SEC was carried out using 50mM sodium 
phosphate buffer, to better facilitate later assays between purified Affimers 
and their target protein BAK5. It was postulated that the change in buffer 
conditions was causing Affimers to precipitate on the SEC column. To test 
this theory, Aff 6 and Aff 15 were dialysed into 50mM sodium phosphate 
buffer overnight. In line with the hypothesis, BAK Aff 15 precipitated during 
dialysis, with approximately 40% of protein lost after precipitate had been 
filtered out; this still left 27mg for SEC. There was also a small amount of 
precipitation for Aff 6, with 10mg remaining to be loaded to the SEC column 
post filtration. Dialysis resulted in greatly improved Affimer yield following 
SEC: 4.3mg of Aff 6 and 12.3mg of Aff 15 were recovered, representing 
43.0% and 45.6% respectively of protein loaded to the column. The large 
late peaks seen for Aff 1 and Aff 3 (Figure 4-13b and Figure 4-14b) were also 
absent on the Aff6 and Aff15 chromatograms. These peaks appeared just 
after the conductance spike, and were likely caused by imidazole present in 
the undialysed samples. 
 
SEC fractions were collected and pooled, then BAK Affimers were assayed 
to check for correct secondary structure using far UV CD. In all cases, MRE 
absorbance minima were seen at around 218nm, as expected due to the 
predominance of β-sheet in the Affimer backbone (Figure 4-13c – Figure 
4-16c).  
 
Binding ELISAs were used to test that Aff 1, 3, 6 and 15 were all legitimate 
binders of BAK (Figure 4-13d - Figure 4-16d), with BAX also assayed as a 
                                            
5 SEC of BAK was carried out using 50mM sodium phosphate buffer, pH 7.0 (see Chapter 
3). 
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negative control. The method used was an adaptation of that described for 
BCL-2 Affimers, though in this case, optimisation trials established an initial 
Affimer concentration of 20µg mL-1 and 1:2 serial dilutions as the conditions 
providing the best data. Reactions were developed with TMB, quenched 
after 2 minutes with 2M sulphuric acid, and absorbance read at 450nm. All 
four Affimers showed selectivity for BAK, with negligible binding to controls 
observed. Aff 6 and Aff 15 produced the best results over the dilution series, 
with Aff 1, and Aff 3 in particular, showing drop offs in absorbance at 
relatively high levels of Affimer concentration.  
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Figure 4-13 - Purification and Characterisation of BAK Aff 1. a) Coomassie 
staining of SDS PAGE gel used to analyse BAK Aff 1 purification by 
Nickel affinity chromatography. Key: A = clarified lysate; B = filtered 
lysate; C = column flow through; D = column buffer (CB) wash; E = CB + 
50mM imidazole wash; F = CB + 100mM imidazole wash; G = CB + 
300mM imidazole elute. The 300mM imidazole elute was taken for further 
purification by SEC. b) Chromatogram of 300mM imidazole elute purified 
by SEC using a HiLoad 26/60 Superdex S75 pg column. The early peak 
shows high order oligomerisation. The late peak occurs just after the 
conductivity spike and is caused by imidazole in the loaded sample. The 
middle peak, eluting at 222mL, was taken for further biophysical 
analysis. c) Fractions collected from the selected Affimer peak were 
buffer exchanged into PBS and analysed by Far UV CD to check for 
correct secondary structure. The expected profile for predominantly β-
sheet structures is seen, with an MRE absorption minima of – 8,730 seen 
at 217nm. d) ELISA results confirm selective binding of BAK Aff 1 for 
BAK against BAX control. Immobilised proteins were exposed to 1:2 
serial dilutions of Affimer. Binding was assayed through the addition of 
a HRP conjugated anti poly-His antibody, which binds the hexa-His tag 
on purified Affimers. Reactions were developed with TMB and quenched 
by the addition of 2M sulphuric acid, with absorption measured at 
450nm. 
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Figure 4-14 - Purification and Characterisation of BAK Aff 3. a) Coomassie 
staining of SDS PAGE gel used to analyse BAK Aff 3 purification by 
Nickel affinity chromatography. Key as for Figure 4-13. The 300mM 
imidazole elute was taken for further purification by SEC. b) 
Chromatogram of 300mM imidazole elute purified by SEC using a 
HiLoad 26/60 Superdex S75 pg column. The early peak shows a small 
amount of high order oligomerisation. The late peak occurs just after the 
conductivity spike and is caused by imidazole in the loaded sample. The 
middle peak, eluting at 259mL, was taken for further biophysical 
analysis. c) Fractions collected from the selected Affimer peak were 
buffer exchanged into PBS and analysed by Far UV CD to check for 
correct secondary structure. The expected profile for predominantly β-
sheet structures is seen, with an MRE absorption minima of – 7,987 seen 
at 213nm. d) ELISA results show only low levels of selective binding of 
Aff3 for BAK against a BAX control. Assay as described in Figure 4-13. 
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Figure 4-15 - Purification and Characterisation of BAK Aff 6. a) Coomassie 
staining of SDS PAGE gel used to analyse BAK Aff 6 purification by 
Nickel affinity chromatography. Key as for Figure 4-13. The 300mM 
imidazole elute was taken and buffer exchanged into 50mM sodium 
phosphate buffer prior to concentration and further purification by SEC. 
b) Chromatogram of 300mM imidazole elute purified by SEC using a 
HiLoad 26/60 Superdex S75 pg column. The early peak shows high order 
oligomerisation. The main peak, eluting at 185mL, was taken for further 
biophysical analysis.  c) Fractions collected from the selected Affimer 
peak were buffer exchanged into PBS and analysed by Far UV CD to 
check for correct secondary structure. The expected profile for 
predominantly β-sheet structures is seen, with an MRE absorption 
minima of – 8,878 seen at 218nm. d) ELISA results confirm selective 
binding of BAK Aff 6 for BAK against BAX control. Assay as described 
in Figure 4-13. 
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Figure 4-16 - Purification and Characterisation of BAK Aff 15. a) Coomassie 
staining of SDS PAGE gel used to analyse BAK Aff 15 purification by 
Nickel affinity chromatography. Key as for Figure 4-13. The 300mM 
imidazole elute was taken and buffer exchanged into 50mM sodium 
phosphate buffer prior to concentration and further purification by SEC. 
b) Chromatogram of 300mM imidazole elute purified by SEC using a 
HiLoad 26/60 Superdex S75 pg column. The early peak shows high order 
oligomerisation. The main peak, eluting at 212mL, was taken for further 
biophysical analysis. c) Fractions collected from the selected Affimer 
peak were buffer exchanged into PBS and analysed by Far UV CD to 
check for correct secondary structure. The expected profile for 
predominantly β-sheet structures is seen, with an MRE absorption 
minima of – 8,189 seen at 216nm. d) ELISA results confirm selective 
binding of BAK Aff 15 for BAK against BAX control. Assay as described 
in Figure 4-13. 
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binding to the target protein (see Figure 4-2). To carry out such assays, the 
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determine binding affinity. As detailed in the previous chapter, attempts to 
assay a number of FITC labelled peptides for binding to BAK failed to 
produce a binding curve. It was therefore decided to use Surface Plasmon 
Resonance (SPR) as an alternative means of establishing a Kd for the 
strongest BAK binding Affimers, Aff 6 and Aff 15. 
 
SPR was carried out using the BIACORE 3000 system. BAK Aff 6 and Aff 15 
were diluted to 5µg / mL in coupling buffer (10mM sodium acetate, pH5.0), 
and immobilised on a CM5 sensor chip (GE Healthcare). BAK was then 
flowed over the ligand surface and changes in refractive index were 
measured and plotted on the sensorgrams seen in Figure 4-17. Sensorgram 
curves were fitted using the Langmuir model [308], assuming a simple 1:1 
binding relationship between protein and Affimer. Biacore software was used 
to determine association and dissociation constants (kon and koff), from which 
Kds for BAK Aff 6 and BAK Aff 15 were calculated at 1.9µM and 8.7µM 
respectively (Table 4-9).  
 
	
	
	
Figure 4-17 - BAK Affimer SPR.  BAK Aff6 and BAK Aff15 were immobilised 
on a CM5 sensor chip (GE Healthcare). BAK at two different dilutions 
was then flowed over the chip surface, and changes in refractive index 
were measured over time and plotted in the sensorgrams shown. 
Biacore software was used to determine association and dissociation 
binding constants (kon and koff), from which Kds for BAK binding to Aff 6 
and Aff 15 were calculated to be 1.9µM and 8.7µM respectively. 
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Table 4-9 – Kinetics of Affimer binding to BAK 
 
Interaction	 Fitting	Model	 kon	(M-1	s-1)	 koff	(s-1	)	 Kd	(μM)	
BAK	:	Aff	6	 Langmuir	 9.98	 1.9	x	10-5	 1.9μM	
BAK	:	Aff	15	 Langmuir	 66.3	 5.76	x	10-4	 8.7μM	
 
 
4.3.2 BAX 
 
Three Affimer panning rounds were carried out as described for BCL-2, with 
amplification of BAX binding clones at each stage. Following completion of 
the final panning round, agar plates inoculated with media from target and 
control wells were compared for evidence of amplification in target wells. 
The target well plate had >250 colonies, with only three colonies seen on the 
control plate. 
 
72 colonies from the target plate were selected, and phage ELISA was used 
to detect binding clones for sequencing and further analysis (Figure 4-18a). 
31 clones were shown to demonstrate increased binding activity. Sanger 
sequencing carried out on DNA extracted from these clones identified five 
unique binders, termed BAX Aff 1, 3, 6, 7 and 31 (Figure 4-18b). BAX Aff 1 
was represented 22 times in this pool, other unique binders were all 
represented once only. Five clones failed to sequence. 
 
DNA for each of the unique binding sequences was sub-cloned from 
phagemid into pET-11a vectors, then used to transform BL21 (DE3) Rosetta 
2 cells as described for BCL-2. Affimers were expressed and purified by 
Nickel affinity chromatography, providing good yields in all cases (Table 
4-10). 
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Figure 4-18 - Identification of Affimers targeting BAX. a) Results of phage 
ELISA following three Affimer panning rounds against BAX. 72 phage 
transduced colonies were picked; 31 of these demonstrated increased 
binding activity against controls (results show differences in 
absorbance after incubation with Anti-Fd-Bacteriophage-HRP, addition 
of TMB and allowing HRP:TMB reaction to develop for 2 minutes). b) 
Sanger sequencing of extracted phagemid DNA identified five unique 
binders, BAX Aff 1, 3, 6, 7 and 31.  Details of residues in the two 
randomised Affimer loops are shown. Residues are coloured according 
to their side chain properties (as described in Figure 4-1). 
 
BAX Affimers were dialysed into 50mM sodium phosphate buffer prior to 
further purification by SEC. Dialysis resulted in some protein precipitation in 
all cases, with a consequent loss of protein yield prior to column loading 
(Table 4-10). 
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Table 4-10 - BAX Affimer expression and initial purification yields. All 
Affimers were purified using Nickel affinity chromatography. Yield is 
expressed as the amount of protein detected in the 300mM imidazole 
elute, measured using a Biorad assay. The final column details the yield 
after dialysing samples into 50mM sodium phosphate buffer prior to 
further purification by SEC, with recovered yield in brackets. 
 
Affimer	 Yield	(mg/L	media)	-	raw	 Affimer	yield	loaded	to	SEC	
(mg)	
BAX	Aff	1	 25	 9.3	(37.2%)	
BAX	Aff	3	 41	 21.7	(52.9%)	
BAX	Aff	6	 33	 14.0	(43.8%)	
BAX	Aff	7	 26	 10.6	(40.8%)	
BAX	Aff	31	 30	 20.8	(69.3%)	
 
Chromatograms of all BAX Affimer SEC elutions are shown in Figure 4-19 
and Figure 4-20, with details of expected and actual elution volumes detailed 
below in Table 4-11. 
Table 4-11 – SEC purification of BAX Affimers. Affimers were purified by SEC 
using a HiLoad 26/60 Superdex S75 pg column. Actual elution volumes 
are compared with expected monomer peak elution volumes (as 
determined by comparison against calibration standards described in 
Chapter 3). Late elution peaks for Aff 1 and Aff 6 demonstrate the 
tendency of Affimers to interact with the column during SEC 
purification. The main peaks of other BAX Affimers elute earlier than 
expected for monomer peaks, indicative of higher order oligomerisation. 
 
Affimer	 Mw	(Da)	 Expected	Elution	
Volume	(mL)	
Actual	Elution	
Volume	(mL)	
BAX	Aff	1	 13388	 214	 245	
BAX	Aff	3	 12444	 218	 167	
BAX	Aff	6	 13694	 213	 245	
BAX	Aff	7	 13656	 213	 182	
BAX	Aff	31	 12478	 217	 199	
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Figure 4-19 - Purification of BAX Aff 1, Aff 3 and Aff 6. a) Coomassie staining 
of SDS PAGE gel used to analyse Aff 1, Aff 3 and Aff 6 expression. Key: 
A = clarified lysate; B = CB + 50mM imidazole wash; C = CB + 100mM 
imidazole wash; D = CB + 300mM imidazole elute. b) – d) SEC 
chromatograms of Aff 6, Aff 1 and Aff3, with elution peaks at 245mL, 
245mL and 167mL respectively.  
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Figure 4-20 - Purification  of BAX Aff 7 and Aff 31. a) Coomassie staining of 
SDS PAGE gel used to analyse Aff 7 and Aff 31 expression. Key as for 
Figure 4-19. b) – c) SEC chromatograms of Aff 7 and Aff 31, with elution 
peaks at 182mL and 199mL respectively.   
 
The elution peaks detailed in Table 4-11 were used in binding ELISAs to test 
for genuine and selective binding, with BAK and MCL1 used as negative 
controls. The method used was as described previously for BAK Affimers, 
with initial Affimer concentration of 20μg mL-1 and 1:2 serial dilutions across 
wells in the ELISA plate. Reactions were developed with TMB, quenched 
after 2 minutes with 2M sulphuric acid, and absorbance read at 450nm. 
Unfortunately, no absorbance was measured for sample or control plates 
(data not shown), and no further studies were carried out on BAX Affimers. 
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4.4 Chapter Summary and Discussion 
 
This chapter describes the results of Affimer panning undertaken against the 
recombinant BCL-2 family proteins purified and characterised in Chapter 3. 
The aim was to identify selective binders for the pro-apoptotic effectors BAX 
and BAK, to augment existing Affimers for MCL1 and BCL-XL with Affimers 
selectively targeting BCL-2, and, through the completion of a comprehensive 
cross-panning exercise, to produce cross-reactive Affimers able to 
simultaneously target multiple pro-survival BCL-2 family proteins. The ideal 
outcome would be a ‘toolkit’ of Affimers, whose interactions with their target 
proteins could be structurally investigated to uncover novel interactions with 
known binding sites, potentially uncover previously unknown binding 
surfaces, and provide structural data to aid in the design of small molecules 
able to modulate apoptotic activity in cells. 
 
Disappointingly, the cross-panning exercise for pro-survival BCL-2 family 
members failed to produce any usable binders, most likely due to limited 
levels of sequence homology between our recombinant target proteins. 
Cross-reactive small molecules able to inhibit multiple BCL-2 family 
members have already been developed: ABT-737 and ABT-263, as dual 
inhibitors of BCL-2 and BCL-XL were mentioned previously. Additionally, the 
natural product Gossypol and some of its rationally designed derivatives 
have proven to be true pan-inhibitors of the main pro-survival BCL-2 family 
members, binding to all of BCL-2, BCL-XL and MCL1 with sub micromolar 
affinities [214, 309]. Cross panning with Affimers to identify dual or triple 
inhibitors was always considered unlikely to yield better results than the 
rational, design based approaches undertaken to produce these small 
molecules. However, the chance that the phage display based approach 
might uncover novel cross-reactive binding sites on our target proteins 
meant that undertaking this work was still a worthwhile exercise. 
 
It was also disappointing that all of the Affimers identified from the pan 
against BAX appeared to be false positives, with no genuine binding activity 
demonstrated in later assays. The presence of false positives is a common 
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artefact of phage display experiments. Phage may bind to other components 
in the experimental system, such as biotin, streptavidin, or potential 
contaminants in the sample. False positives may also occur from clones that 
simply benefit from a faster propagation rate, with increased replication 
giving them an advantage in the overall phage pool [310]. For this reason 
and as a more general point, there is no correlation between the frequency 
of appearance of a specific clone at the end of the panning process and its 
potential potency as a binder / inhibitor of its target protein.  
 
Positive results were obtained from the Affimer pan against BCL-2: four 
unique Affimer sequences were identified that showed binding affinity for 
BCL-2, and were able to characterise three of these as legitimate and 
selective binders for the target protein. This means we now have a small 
library of Affimers shown to selectively bind our three pro-survival BCL-2 
family members.  Future work should include structural investigations into 
how these Affimers interact with their target proteins and whether novel 
binding sites are engaged, together with cell based assays to ascertain the 
ability or otherwise of these Affimers to modulate mitochondrial apoptosis in 
cellulo. 
 
In the last decade, a great deal of research has been carried out to identify 
molecules that interact with the BCL-2 family. BH3 mimetics have been 
developed that have potential to act against various forms of cancer, but 
they are all targeted against pro-survival members [245, 249, 257, 311]. By 
comparison, relatively little progress has been made in developing 
molecules to modulate the activities of BAX and BAK. The fact that four 
Affimers were identified as selective binders of BAK is therefore potentially 
of great interest, especially as no cross reactivity was seen against BAX.  
 
Notwithstanding the fact that BAK dysregulation is rarely employed as a 
survival mechanism by cancer cells, it remains true that molecules able to 
constitutively activate BAK could provide the basis for powerful new anti-
cancer therapies; the use of such molecules would also avoid the 
deleterious side effects seen in the clinic when administering inhibitors of 
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pro-survival BCL-2 family members. Conversely, the ability to dampen or 
inhibit the activities of BAK may also be useful in limiting the levels of 
ischaemic cell death in patients suffering heart attack or stroke.  
 
Until very recently, there were no reported specific inhibitors of BAK. 
Brouwer and co-workers have since described a BH3 derivative (BIM like 
peptide), incorporating a non-natural amino acid, which acted to inhibit BAK. 
Structural and biochemical data from this study provide evidence that 
ligands forming a stable complex with BAK at its activation site (BC groove) 
can block induction of apoptosis [312], thereby acting as inhibitors. There is 
also a body of evidence indicating that BAK activation involves low affinity 
binding of a BH3 only direct activator at the BAK BC groove, with 
subsequent conformational changes that expose the BAK BH3 domain [50], 
leading first to dimerisation, then higher order oligomerisation and apoptotic 
pore formation. On limited data obtained by SPR6, our Affimers appear to 
bind BAK with low affinity and are therefore less likely to carry out an 
inhibitory role, but may have BAK activating features. Future work should 
include further assays to characterise the binding affinities of identified 
Affimers for BAK, structural studies to determine where and how binding is 
taking place, and cellular assays to determine whether our BAK binding 
affimers are able to modulate BAK activity in cellulo, in either activating or 
inhibitory roles. 
 
  
                                            
6 To generate a full kinetic profile by SPR for interaction of Affimer and target protein (or more 
generally analyte and ligand), and obtain the binding constants (kon, koff, Kd), the interaction should be 
measured using a broad range of protein concentrations that span a range from 10x greater to 10x 
lower than the expected Kd. Experiments established legitimate binding of Affimers to BAK, but a 
broader range of protein concentrations should be used to obtain a more accurate figure for binding 
affinity. 
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Chapter 5 - Investigations into mechanisms underpinning the 
oligomerisation of BAX 
 
BAX acts as a pro-apoptotic effector, existing as a quiescent cytosolic 
monomer in healthy cells, but migrating to the mitochondrial outer 
membrane (MOM) under conditions of cytotoxic stress, where it oligomerises 
to cause mitochondrial outer membrane permeabilisation (MOMP). MOMP, 
which allows cytochrome c to escape to the cytosol, is considered the point 
of no return in mitochondrial apoptosis and effectively commits the cell to 
undergo apoptotic cell death. Despite intense levels of study, the molecular 
mechanisms underpinning oligomerisation and BAX induced MOMP remain 
unclear, though there is now a good body of evidence to suggest that BAX 
monomers initially form symmetric BH3 in groove homo-dimers (as 
described in the Introduction), and that these constitute the basic 
oligomerisation unit for BAX and its homologue BAK [52, 195-199]. 
However, due to an absence of high resolution structural data, the 
mechanism by which these dimers combine to form higher order oligomeric 
structures remains one of the key outstanding questions in the field of 
apoptosis research [52, 313, 314]. 
 
This chapter describes preliminary structural investigations undertaken with 
the aim of making progress towards answering this question. 
 
5.1 BAX treatment with Tween20 induces oligomerisation 
 
Early expression trials undertaken by the group of Professor Jane Clarke at 
the University of Cambridge failed to produce monomeric BAX. Instead, SEC 
results suggested BAX oligomerisation, with production of a single 
chromatogram peak thought to represent soluble hexameric species. These 
early trials purified BAX in the presence 0.2% Tween20, which is not 
unusual as moderate concentrations of nonionic detergents such as Tween 
are commonly used during protein purification for their ability to compromise 
the integrity of cell membranes, aid in the lysis of cells and help enable the 
- 126 - 
extraction of soluble protein. However, in the case of some BCL-2 family 
members, including BAX, it has also been shown that treatment with non-
ionic detergents can cause protein dimerisation [52, 201], and higher order 
structures may also be formed under these conditions.  
 
When a further series of purifications were carried out in the absence of 
Tween20, soluble protein was still produced, but in this case SEC showed 
no oligomer peak and BAX eluted from the column as a monomer. 
Interestingly though, subsequent incubation of purified BAX monomers with 
Tween20 (24 hours, room temperature) caused the formation of oligomers, 
with the same oligomeric peak reproduced on the SEC chromatogram. 
 
5.2 Structural studies of BAX oligomers 
 
The Tween20 induced BAX oligomers described above eluted from SEC in a 
single peak, representing an apparently homogenous species. It was 
questioned whether these oligomers might be forming regular structures, 
and whether these structures could provide data pertinent to understanding 
the mechanisms underpinning BAX oligomerisation at the MOM.  Existing 
evidence supporting potential mechanisms for BAX dimerisation and 
subsequent oligomerisation is predominantly from biochemical studies [39, 
52, 195-201] [202, 203]. To better investigate the nature of the oligomers 
formed, experiments were designed and carried out with the aim of  
augmenting this evidence using structural techniques. 
 
5.2.1 Crystallisation trials 
 
Preliminary crystallisation trials were carried out. Tween20 treated BAX, 
concentrated to 1mM7 was screened for crystal production against 384 
different buffer conditions. Unfortunately, the oligomerised protein failed to 
produce crystals under any of the tested conditions. This was possibly due 
                                            
7 Tween20 treated BAX for use in preliminary crystallisation trials was kindly provided by Basile 
Wicky, Jane Clarke group, University of Cambridge. 
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to the presence of residual Tween20 causing a fall in surface tension in the 
protein samples, which prevented drop formation on crystal plates. 
 
5.2.2 Electron Microscopy 
 
The apparent homogeneity of the BAX oligomer sample, which made it 
appropriate for use in crystal trials also signified its potential suitability for 
analysis by cryo-electron microscopy (cryo-EM). In recent years, cryo-EM 
has emerged as a powerful tool for solving structures at high resolution 
(<5Å) [315-318]. Many of these structures have been for proteins or 
complexes in the megadalton size range, which is the traditional domain of 
cryo-EM. Indeed, until very recently, there was thought to be a lower 
molecular size limit of around 300 kDa for use of this technique. In 2014, Lu 
and co-workers used cryo-EM to solve a 170kDa structure from the γ-
secretase complex at 4.5Å resolution [319], and since then, continued 
advances in detector technology and software have combined to push the 
lower size limit further still, meaning that it could be possible to analyse BAX 
oligomers using cryo-EM. However, as recombinant BAX monomers are 
19kDa, the reported hexameric oligomers would have a molecular weight of 
approximately 114kDa, still towards the extremes of the lower size limit, 
even at current capabilities. 
 
While excellent results can be achieved using cryo-EM, it is a relatively high 
cost technique, both in terms of time and resources. Therefore, to visually 
check for levels of structural homogeneity, BAX samples were first analysed 
using negative stain transmission EM, a technique which benefits from being 
far cheaper than cryo-EM, with relatively easy sample preparation and 
loading procedures. 
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5.2.2.1 Sample preparation and analysis 
 
A Superdex S200 5/15 GL column (GE Healthcare) was calibrated using a 
subset of the protein standards listed in Table 3.1. The peaks shown in 
Figure 5-1 then provided data points from which to plot a calibration curve for 
use in testing our samples of untreated and Tween20 treated BAX for 
evidence of oligomerisation (Figure 5-2). 
 
	
	
	
 
Figure 5-1 – Chromatogram of elution peaks for protein standards used in 
Superdex S200 5/150 GL column calibration. 
 
 
 
 
 
 
 
 
 
 
Ribonuclease	A	–	13.7	kDa	(2.82mL)	
Carbonic	Anhydrase	–	29	kDa	(2.64	mL)	
Cobalbumin	–	75kDa	(2.36	mL)	
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Monomeric BAX was purified as described in Chapter 3 and concentrated to 
50μM, then an aliquot was taken and incubated for 24 hours at room 
temperature with 0.2% Tween20. Untreated and Tween20 treated BAX 
samples were assayed for evidence of oligomerisation using analytical SEC. 
Untreated BAX eluted predominantly as a monomer, with a main elution 
peak at 2.79mL. A small shoulder of higher order species was also seen. By 
contrast, the Tween20 treated sample eluted at 2.35mL.The position of the 
elution peak is indicative of BAX tetramers, and not the putative hexameric 
species previously reported by the Clarke group in Cambridge, for which an 
elution peak at around 2.22mL would be expected according to our 
calibration calculations.  
 
	
	
	
 
Figure 5-2 – Analytical SEC of BAX samples. The untreated sample (blue) 
elutes with a main monomer peak at 2.79mL, with a small shoulder of 
higher order oligomers. The Tween20 treated sample (orange) elutes at 
2.35mL. This matches the elution peak for the 75kDa protein calibration 
standard Cobalbumin, and indicates a tetrameric species, conflicting 
with data previously reported by the Clarke group in Cambridge. 
 
For comparison, analysis was carried out on a sample of BAX oligomer 
provided by the Clarke group: surprisingly, this also produced a peak at 
2.35mL with an attached shoulder indicating some degradation, but no 
evidence of higher order oligomers larger than the tetramers indicated by our 
BAX	untreated	
BAX	+	0.2%	Tween20	
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column calibration (Figure 5-3). BAX oligomers had previously been shown to 
be stable at 4°C for over six weeks, so there was no question of wholesale 
degradation in the Cambridge sample, and the likelihood was that the same 
oligomeric species were being seen in both locations.  
	
	
	
 
Figure 5-3 – Analytical SEC to compare Tween20 treated BAX samples 
purified at Leeds and Cambridge. Both samples produce elution peaks 
at 2.35mL. The shoulder on the peak for the Cambridge sample indicates 
some oligomer dissociation, but there is no evidence of higher order 
BAX species larger than tetramers. 
 
SEC results indicated that incubating BAX with Tween20 for 24 hours 
allowed for full conversion of monomer to oligomer. Work carried out by 
Subburaj and co-workers to determine the kinetics of BAX oligomerisation at 
membranes reported monomers assembling into dimers and higher order 
structures very rapidly, in under one minute [314]. To test whether this was 
also true under our experimental conditions, we prepared a sample of BAX 
incubated with 0.2% Tween20 for five minutes, and tested it for presence of 
oligomerisation peaks using analytical SEC.  
 
The results shown in Figure 5-4 appear to support the analysis carried out by 
Subburaj, with rapid oligomer formation seen. Though the largest 
BAX	(Camb)	
BAX	(Leeds)	
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chromatogram peak is still monomeric, a significant secondary peak of 
oligomeric species is also seen. 
 
 
	
	
	
 
Figure 5-4 – Analytical SEC to compare effects of Tween20 treatment of BAX 
over time. BAX incubated at room temperature for 24 hours with 0.2% 
Tween20 results in full conversion of monomer to oligomer (orange 
peak). BAX incubated with Tween20 at room temperature for 5 minutes 
(green peak) shows evidence of rapid BAX oligomer formation on 
exposure to detergent. 
 
5.2.2.2 Negative Stain EM analysis 
 
To begin negative stain EM analysis, a sample dilution series of 
oligomerised species was tested to ascertain the optimum protein 
concentration for use, one at which high numbers of molecules were visible, 
but also sufficiently well dispersed to allow individual particle picking in later 
analysis.  BAX at a concentration of 10μM was treated with 0.2% Tween20 
and allowed to incubate for 24 hours at room temperature. The sample was 
subjected to a set of 10x serial dilutions, with each dilution loaded to a glow 
BAX	untreated	
BAX	+	0.2%	Tween20	(24	hours)	
BAX	+	0.2%	Tween20	(5	minutes)	
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discharged carbon coated copper grid8, which was then stained with 1% 
uranyl acetate and viewed to check for levels of particle dispersal. Repeats 
of this process established an optimum protein concentration of 10nM. 
 
Two 50µL samples of 10µM BAX were then prepared for analysis. One 
sample was treated with 0.2% Tween20, and 20µL aliquots were removed 
after 5 minutes and 24 hours. Both aliquots, together with a control sample 
of untreated BAX were quickly loaded to grids as described above; 
immediately prior to loading, all samples were diluted 1:1000 in 50mM 
sodium phosphate buffer to achieve the optimum 10nM protein 
concentration.  
 
5.2.2.2.1 Untreated BAX 
 
Samples were imaged at a calibrated magnification of 25,500x. Untreated 
BAX presented as extremely small, monomeric particles, with the presence 
of a small number of much larger heterogeneous aggregates (image not 
shown).  
5.2.2.2.2 BAX incubated with Tween20 (5 minutes) 
 
The sample treated with Tween20 for 5 minutes contained a large quantity of 
monomeric BAX, together with a heterogeneous mix of small oligomeric 
species and a very small number of larger protein aggregates (Figure 5-5).  
 
                                            
8 Prior to sample loading the grids were glow discharged; this process covers the carbon surface of 
the EM grid with negative ions, making it hydrophilic and more amenable to sample loading. 
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Figure 5-5 – Sample micrograph of BAX incubated with 0.2% Tween20 for 5 
minutes 
 
To better visualise the species present, a data set of images was taken and 
used to produce particle class averages. The data set used comprised 32 
micrographs, from which 500 protein particles were manually picked as a 
representative sample of species present. Utilising RELION software, these 
were used as templates for an auto-picking exercise, which returned a total 
pool of 4736 particles. Three rounds of 2D image alignment and 
classification refined this pool down to 2810 particles, comprising the nine 
most common class averages, which are shown in Figure 5-6. 
 
50	nm	
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Figure 5-6 – Calculated particle class averages for BAX incubated with 0.2% 
Tween20 for 5 minutes. 32 micrographs were taken and RELION 
software was used to pick 4736 particles, which were then subjected to 
three rounds of 2D image alignment and classification. This refined the 
pool down to 2810 particles represented in nine class averages. Species 
1-9 are shown in descending order of prevalence in the data set. 
 
Images 1-9 are shown in descending order of their prevalence in the data 
set, though there is little discrepancy between the most and least commonly 
occurring, as seen in Table 5-1; 1 appears 391 times (13.91% of total data 
set), 9 appears 263 times (9.36%). Class averages other than those shown 
were either of indistinct images, or appeared with very low frequency in the 
data set. Though some images appear to show distinct species, for example 
monomeric (1), dimeric (3) or tetrameric (5), the resolution obtained for these 
class averages is insufficient for definite statements to be made about the 
oligomerisation state of BAX seen in all cases. 
1	 2	 3	
4	 5	 6	
7	 8	 9	
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Table 5-1 – Numerical analysis of particle class averages for BAX incubated 
with 0.2% Tween20 for 5 minutes. Frequency of appearance, and 
percentage totals of the refined data set are shown. 
 
Class	#	 Frequency	 %	Total	 	 Class	#	 Frequency	 %	Total	
1	 391	 13.91	 	 6	 274	 9.75	
2	 346	 12.31	 	 7	 274	 9.75	
3	 336	 11.96	 	 8	 271	 9.64	
4	 333	 11.85	 	 9	 263	 9.36	
5	 322	 11.46	 	 	 	 	
	 	 	 	 TOTALS	 2810	 100.00	
 
A better idea of the oligomerisation states seen may be achieved by 
measuring the apparent dimensions of the species in each image, then 
comparing them to the estimated size of a BAX monomer. Figure 5-7 shows 
monomeric recombinant BAX, with approximate dimensions determined 
using the Pymol measurement tool. Depending on its orientation on the EM 
grid, such a monomer should appear as a particle with dimensions between 
3.3 and 4nm.  
 
 
 
Figure 5-7 – Approximate dimensions of a BAX monomer. Molecular 
dimensions were determined using the Pymol measurement tool (PDB 
1F16). 
 
Using this information, it can be speculated that in Figure 5-6, monomeric 
species are seen in images 1 and 2, dimeric species in images 3 and 4, 
32.6Å	
39.1Å	 39.5Å	
90°	
- 136 - 
trimers in image 7, tetramers in images 5 and 8, and hexamers in images 6 
and 9. This represents a more heterogeneous mix of oligomeric states than 
would be suggested by the chromatogram in Figure 5-4. The presence of 
apparently hexameric species within this mix also casts doubt on whether 
this peak is, in fact, representative of tetramers. 
5.2.2.2.3 BAX incubated with Tween20 (24 hours) 
 
The 24 hour Tween20 treated sample contained a much reduced quantity of 
monomeric BAX, together with a heterogeneous mix of small oligomeric 
species (Figure 5-8), in significant contradiction to the single homogenous 
peak seen on the SEC chromatogram in Figure 5-2.  
 
 
Figure 5-8 – Sample micrograph of BAX incubated with 0.2% Tween20 for 24 
hours. 
 
50	nm	
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A data set of images was taken and used to produce particle class 
averages, as described previously. 500 protein particles were manually 
picked from 36 micrographs to act as templates for an auto-picking exercise, 
which returned a total of 6998 particles. Three rounds of 2D image alignment 
and classification were carried out, refining this pool down to 5150 particles. 
These comprise the nine most common class averages, shown in Figure 5-9. 
 
As with the previous sample, images 1-9 are shown in descending order of 
their prevalence in the data set, and details of frequency of appearance 
together with the percentage of total pool comprised by each species are 
shown in Table 5-2. The images in this dataset are particularly difficult to 
interpret. Image 5 would appear to present a BAX monomer; 7 and 9 have 
similar features to the putative hexameric structures assigned to images 6 
and 9 in Figure 5-6; the remainder do not even warrant speculation as to their 
oligomeric state, though it is interesting to note that images 3, 6 and 8 all 
appear to show the same species in different orientations. 
 
The heterogeneity of species seen in this sample means that it is unsuitable 
for further analysis by cryo-EM at present. Optimisation of sample 
preparation protocols will be required to progress this work further. 
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Figure 5-9 - Calculated particle class averages for BAX incubated with 0.2% 
Tween20 for 24 hours. 36 micrographs were taken and RELION software 
was used to pick 6998 particles, which were then subjected to three 
rounds of 2D image alignment and classification. This refined the pool 
down to 5150 particles represented in nine class averages. Species 1-9 
are shown in descending order of prevalence in the data set. 
 
Table 5-2 - Numerical analysis of particle class averages for BAX treated with 
0.2% Tween20 for 24 hours. Frequency of appearance, and percentage 
totals of the refined data set are shown. 
 
Class	#	 Frequency	 %	Total	 	 Class	#	 Frequency	 %	Total	
1	 882	 17.13	 	 6	 504	 9.79	
2	 686	 13.32	 	 7	 441	 8.56	
3	 672	 13.05	 	 8	 420	 8.15	
4	 656	 12.74	 	 9	 350	 6.79	
5	 539	 10.47	 	 	 	 	
	 	 	 	 TOTALS	 5150	 100.00	
 
1	 2	 3	
4	 5	 6	
7	 8	 9	
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5.3 Chapter Summary and Discussion 
 
This chapter describes structural studies carried out with the aim of helping 
to elucidate the mechanisms underpinning BAX oligomerisation. 
 
It was shown that adding 0.2% Tween20 to recombinant BAX monomers 
induced oligomerisation, with full conversion from monomer to oligomer 
within 24 hours of incubation at room temperature. A 0.2% concentration is 
over 20 times the critical micelle concentration (CMC) for this detergent, so 
this was by no means mimicking physiological conditions. The aim was to 
collect structural data on the oligomers formed: BAX dimerisation is 
generally accepted as the initiating action and it was hoped that our 
structural studies would provide evidence for how dimers then combine to 
form higher order oligomers. 
 
Analytical SEC of Tween20 treated BAX produced a single chromatogram 
peak, eluting in the same place as cobalbumin, the 75kDa protein standard 
used in column calibration. This suggested a BAX tetramer, and not the 
hexameric species reported by the Clarke group at the University of 
Cambridge. A Tween20 treated sample provided by the Clarke group 
produced an identical peak when analysed on the same column. The 
stability of Tween20 induced BAX monomers precluded the chance of 
wholesale sample degradation, raising the possibility of an instrumental error 
relating to  calibration of our column.  
 
Structural studies were carried out using negative stain EM. Untreated BAX 
appeared monomeric, matching results from analytical SEC. Class averages 
calculated for BAX incubated with Tween20 for 5 minutes presented a 
heterogeneous mix of monomeric and oligomeric species. The SEC 
chromatogram suggested two major species (monomers and tetramers), but 
the particle class averages produced also appeared to include dimers, 
trimers and hexamers, with the presence of putative hexamers raising 
further doubt on the reliability of our SEC column calibration.  Finally, BAX 
incubated with 0.2% Tween20 for 24 hours also presented a heterogeneous 
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mix of monomers and oligomeric species. Although class average image 
resolution made it difficult to identify each species with certainty, a reduction 
in monomers and an increase in higher order oligomers was apparent, as 
would be expected from the longer Tween20 incubation period.  
 
As stated, image resolution of the class averages made it difficult to identify 
oligomeric species with certainty, but it is notable in both Tween20 treated 
samples that many of the oligomers appear to comprise monomers arranged 
in pore like structures (Figure 5-6, Figure 5-9). Mitochondrial apoptosis is 
initiated on induction of MOMP caused by BAX (or BAK) oligomerisation, 
allowing molecules including cytochrome c to escape to the cytosol from the 
mitochondrial. The molecular dimensions of cytochrome c are shown in 
Figure 5-10a below. Simple observational analysis of putative tetramers 
(Figure 5-10b) and hexamers (Figure 5-10c) indicates pore sizes of 
approximately 3nm and 5nm respectively, both of sufficient size to allow the 
passage of cytochrome c (it is worth iterating here, though, that the 
experimental conditions in no way mimic the physiological cellular 
environment in which BAX oligomerisation takes place). 
 
 
Figure 5-10 – Analysis of putative pore like structures in BAX oligomers. a) 
Approximate molecular dimensions of a cytochrome c monomer 
Molecular dimensions were determined using the Pymol measurement 
tool (PDB 3NWV). b) Putative BAX tetramers from Figure 5-6 (8) (top) and 
Figure 5-9 (7) (bottom) indicate a pore with approximate diameter of 
3nm. c) Putative BAX hexamers from Figure 5-6 (9) (top) and 5-9 (9) 
(bottom) indicate a pore with approximate diameter of 5nm. 
2.5	nm	
2.8	nm	
8	nm	
a	 b	 c	
12	nm	
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Notwithstanding the comments above, it was questioned why a 
heterogeneous mix of particles was being seen at all, when the single 
oligomeric peak seen on SEC suggested the presence of a single 
homogenous species. The discrepancy between the single species peak in 
the analytical SEC chromatogram and the mix of particles seen in EM may 
be explained in a number of ways. It may simply be due to artefacts caused 
during EM sample preparation, as production of a pure biological sample 
does not necessarily result in a homogenous sample when viewed by EM 
[315]. Another plausible explanation is that the heterogeneity seen was 
caused by the 1:1000 sample dilution carried out immediately prior to 
loading sample to EM grids, which reduces the Tween20 concentration in 
the sample to below its CMC. Incubating BAX with Tween20 had shown to 
induce a rapid rate of oligomer formation; it could also be the case that 
dilution of Tween20 to sub-CMC concentrations causes an equally rapid 
disintegration of BAX oligomers. Indeed, some of the class average images 
seen in Figure 5-9 could be interpreted as showing oligomeric species that 
have started to dissociate. 
 
Regardless of the reason, the heterogeneity currently seen in our oligomer 
sample makes it unsuitable for study by cryo-EM. To progress this work, 
methods for isolating and stabilising BAX oligomers need to be developed 
and optimised, together with protocols for removing detergent without 
causing oligomer dissociation. A credible approach would be to use 
chemical cross-linking of Tween20 induced oligomers, followed by sample 
dialysis into detergent free buffer. If successful, this approach would also 
enable a fresh round of crystallisation trials to be carried out, using samples 
of detergent free BAX oligomers. Our recombinant BAX protein contains 7 
lysine residues, 13 aspartates and 10 glutamates, which would facilitate 
cross linking via primary amines or carboxyl groups.  
 
It will be interesting to obtain confirmation of whether the dominant 
oligomeric species is tetrameric, as indicated in our analytical SEC assays, 
or hexameric, as reported by the Clarke group and supported at least in part 
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by the presence of putative hexamers in our EM images. BAX tetramers 
would be 75kDa and hexamers 114kDa, neither at a size that would make 
them obvious candidates for structure determination by cryo-EM alone. It is 
worth noting, however, that the 66kDa structure of haemoglobin has recently 
been solved by this means [320].  
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Chapter 6 – Thesis Summary and Future Work 
 
Apoptosis is an essential process during embryonic development, acts as a 
balance to mitosis in maintaining a steady level of healthy cells in adults, and 
provides a clean and efficient mechanism for the removal of old, diseased or 
infected cells before they become a risk to the health of surrounding tissues. 
 
The BCL-2 family of proteins are important regulators of apoptosis; 
dysregulation of BCL-2 family activity in the cell is implicated in the 
progression of many forms of cancer, and is also a common feature in 
chemo-resistance [17]. The development of molecules able to bind and 
modulate BCL-2 family interactions as the basis for novel therapies is thus 
highly desirable, and has been the subject of a great deal of research effort. 
Techniques including structure based design and peptidomimetic 
approaches have been used to  notable success in this area, but few of the 
synthesised molecules have successfully transitioned from laboratory to 
clinic, often due to their lacking potency as single agents, or the rapid 
appearance of resistant clones[262].  
 
The first part of this project was designed to expand the existing library of 
BCL-2 family binding molecules. It employed a novel approach, combining 
the use of phage display to identify selective binding sequences by probing 
the surface of target proteins, with the subsequent expression of those 
binding sequences in purified non-antibody scaffold proteins called Affimers 
[280]. It aimed to develop a ‘toolkit’ of Affimers, whose interactions with their 
target proteins could be structurally investigated to uncover novel 
interactions with known binding sites, potentially uncover previously 
unknown binding surfaces, and provide structural data to aid in the design of 
small molecules able to modulate apoptotic activity in cells. Five BCL-2 
family proteins, BCL-2, BCL-XL, MCL1, BAX and BAK, were selected as 
targets for study, comprising a good cross section of pro- and anti-apoptotic 
members. Recombinant versions of each of these proteins were expressed 
in bacteria, purified, and characterised using biophysical assays.  
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Affimers that selectively bound to MCL1 and BCL-XL had been produced in 
earlier work carried out by the Edwards group. The project was able to 
augment these with selective binders for BCL-2, thereby completing a set of 
Affimers able to selectively bind to the three chosen pro-survival targets.  
 
Successful experiments were also carried out to identify, purify and 
characterise four Affimers that bound selectively to the pro-apoptotic effector 
BAK. As the majority of molecules developed to modulate the BCL-2 family 
have been targeted against pro-survival members, this result could 
potentially be of great interest [245, 249, 257, 311]. Though BAK 
dysregulation is rarely seen in cancer, molecules able to constitutively 
activate BAK could nonetheless provide the basis for powerful new anti-
cancer therapies.  
 
Though novel binders were identified for BCL-2 and BAK, further work is 
required to fully characterise the nature of their binding interactions with their 
target proteins. Time constraints also precluded any assays to test these 
Affimers for the induction of pro- or anti-apoptotic activity in cellular systems. 
To progress this part of the project, future work will include structural 
investigations into how BCL-2 and BAK binding Affimers interact with their 
target proteins and whether novel binding sites are engaged, together with 
cell based assays to ascertain the ability or otherwise of these Affimers to 
modulate mitochondrial apoptosis in cellulo. 
 
In order to carry out its pro-apoptotic activities in the cell, BAX must first 
oligomerise at the mitochondrial outer membrane (MOM). A good body of 
evidence exists that suggests BAX monomers first form symmetric BH3 in 
groove homo-dimers, but the structural details for how these dimers combine 
to form higher order oligomeric structures remains unresolved [52, 313, 314]. 
The second part of this project was designed to shed some light on this 
mechanism, which remains one of the key outstanding questions in the field 
of apoptosis research. During BAX expression trials, it was shown that 
incubation of BAX monomers with Tween20 induced oligomerisation. As the 
Tween20 induced BAX oligomers eluted from SEC in a single peak, it was 
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postulated that these oligomers might be forming regular structures, and 
whether these structures could provide data pertinent to providing answers 
to this question.  
 
The apparent homogeneity of the BAX oligomer sample meant that it might 
be suitable for analysis by cryo-electron microscopy (cryo-EM). Due to the 
high cost involved with this technique, samples were first analysed using 
negative stain EM. Disappointingly, the homogeneity seen in the SEC peak 
for oligomerised BAX was not recreated in the negative stain EM images; 
instead, a heterogeneous mix of species was seen, including a proportion of 
monomeric BAX. An optimum concentration of grid loading for BAX of 10nM 
was established (this to provide a good level of visible particles, sufficiently 
dispersed to allow particle picking for further analysis). This required a high 
level of dilution of our oligomerised samples before grid loading, taking the 
Tween20 concentration below CMC, which may result in the rapid 
breakdown of BAX oligomers.  
 
The heterogeneity currently seen in the BAX oligomer sample makes it 
unsuitable for study by cryo-EM. To progress this part of the project, 
methods for isolating and stabilising BAX oligomers will be developed and 
optimised, together with protocols for removing detergent without causing 
oligomer dissociation. The recombinant BAX protein contains multiple lysine, 
aspartate and glutamate residues, which would facilitate chemical cross 
linking via primary amines or carboxyl groups. This approach, followed by 
sample dialysis into detergent free buffer, could be a credible approach to 
obtaining more homogenous, detergent free oligomers, which would be 
suitable for use in cryo-EM and in x-ray crystallography.  
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Appendix A Vectors used for Recombinant Protein 
Expression 
A.1 pET-28a-SUMO 
 
Used for the expression of MCL1172-327 and BCL-XLML. Both constructs were 
cloned into the MCS of vector cut with BamH1 and Xho1. 
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A.2 pGEX-6P-2 
 
Used for the expression of BCL-21-205. This construct was cloned into the 
MCS of vector cut with BamH1 and Xho1. 
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A.3 pTXB1 
 
Used for the expression of BAX 1-171 C-S and BAK 16-185 C-S. Constructs 
were cloned into vector cut with Sap1 and Nde1. 
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Appendix B Protein Sequences and Mass Spec 
Analysis 
B.1 BAX 
 
BAX1-171 C-S – INTEIN-CBD fusion  
Intein self cleaves at Sap1 site, leaving no linker residue 
Molecular Weights: Fusion protein - 46773.97 Da, tag cleaved - 18933.56 
Da 
 
Sequence 
MDGSGEQPRG GGPTSSEQIM KTGALLLQGF IQDRAGRMGG EAPELALDPV 
PQDASTKKLS ESLKRIGDEL DSNMELQRMI AAVDTDSPRE VFFRVAADMF 
SDGNFNWGRV VALFYFASKL VLKALSTKVP ELIRTIMGWT LDFLRERLLG 
WIQDQGGWDG LLSYFGTPTW QCITGDALVA LPEGESVRIA DIVPGARPNS 
DNAIDLKVLD RHGNPVLADR LFHSGEHPVY TVRTVEGLRV TGTANHPLLC 
LVDVAGVPTL LWKLIDEIKP GDYAVIQRSA FSVDCAGFAR GKPEFAPTTY 
TVGVPGLVRF LEAHHRDPDA QAIADELTDG RFYYAKVASV TDAGVQPVYS 
LRVDTADHAF ITNGFVSHAT GLTGLNSGLT TNPGVSAWQV NTAYTAGQLV 
TYNGKTYKCL QPHTSLAGWE PSNVPALWQL Q 
 
Mass Spectrum 
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B.2 BAK 
 
BAK 16-185 C-S – INTEIN-CBD fusion 
Intein self cleaves at Sap1 site, leaving no linker residue 
Molecular Weights: Fusion protein – 47058.05 Da, tag cleaved – 19217.64 
Da 
 
Sequence 
MEPALPSASE EQVAQDTEEV FRSYVFYRHQ QEQEAEGVAA PADPEMVTLP 
LQPSSTMGQV GRQLAIIGDD INRRYDSEFQ TMLQHLQPTA ENAYEYFTKI 
ATSLFESGIN WGRVVALLGF GYRLALHVYQ HGLTGFLGQV TRFVVDFMLH 
HSIARWIAQR GGWVAALNLG NCITGDALVA LPEGESVRIA DIVPGARPNS 
DNAIDLKVLD RHGNPVLADR LFHSGEHPVY TVRTVEGLRV TGTANHPLLC 
LVDVAGVPTL LWKLIDEIKP GDYAVIQRSA FSVDCAGFAR GKPEFAPTTY 
TVGVPGLVRF LEAHHRDPDA QAIADELTDG RFYYAKVASV TDAGVQPVYS 
LRVDTADHAF ITNGFVSHAT GLTGLNSGLT TNPGVSAWQV NTAYTAGQLV 
TYNGKTYKCL QPHTSLAGWE PSNVPALWQL Q 
 
Mass Spectrum 
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B.3 BCL-2 
 
GST – BCL-2 1-205  
GST tag + linker with Prescission protease cleavage site leaves GPLGSPEF 
residues N terminal to protein sequence 
Molecular Weights: Fusion protein - 49818.04 Da, tag cleaved - 23405.34 
Da 
 
Sequence 
MSPILGYWKI KGLVQPTRLL LEYLEEKYEE HLYERDEGDK WRNKKFELGL 
EFPNLPYYID GDVKLTQSMA IIRYIADKHN MLGGCPKERA EISMLEGAVL 
DIRYGVSRIA YSKDFETLKV DFLSKLPEML KMFEDRLCHK TYLNGDHVTH 
PDFMLYDALD VVLYMDPMCL DAFPKLVCFK KRIEAIPQID KYLKSSKYIA 
WPLQGWQATF GGGDHPPKSD LEVLFQ/GPLG SPEFMAHAGR TGYDNREIVM 
KYIHYKLSQR GYEWDAGDVG AAPPGAAPAP GIFSSQPGHT PHTAASRDPV 
ARTSPLQTPA APGAAAGPAL SPVPPVVHLT LRQAGDDFSR RYRRDFAEMS 
RQLHLTPFTA RGRFATVVEE LFRDGVNWGR IVAFFEFGGV MCVESVNREM 
SPLVDNIALW MTEYLNRHLH TWIQDNGGWD AFVELYGPS 
 
Mass Spectrum 
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B.4 BCL-XL 
 
HIS-SUMO-BCL-XL  
SUMO protease recognizes tertiary structure of SUMO, rather than specific 
sequence of residues. No linker residue attached. 
Molecular Weights: Fusion protein – 30896.56 Da, tag cleaved – 17489.57 
Da 
 
Sequence 
MGSSHHHHHH SSGLVPRGSH MSDSEVNQEA KPEVKPEVKP ETHINLKVSD 
GSSEIFFKIK KTTPLRRLME AFAKRQGKEM DSLRFLYDGI RIQADQTPED 
LDMEDNDIIE AHREQIGGMS QSNRELVVDF LSYKLSQKGY SWSQMAAVKQ 
ALREAGDEFE LRYRRAFSDL TSQLHITPGT AYQSFEQVVN ELFRDGVNWG 
RIVAFFSFGG ALCVESVDKE MQVLVSRIAA WMATYLNDHL EPWIQENGGW 
DTFVELYGNN AAAESRKGQE R 
 
Mass Spectrum 
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B.5 MCL-1 
 
HIS-SUMO – MCL1 
SUMO protease recognizes tertiary structure of SUMO, rather than specific 
sequence of residues. No linker residue attached. 
Molecular Weights: Fusion protein – 31144.19 Da, tag cleaved – 17737.20 
Da 
 
Sequence 
 
MGSSHHHHHH SSGLVPRGSH MSDSEVNQEA KPEVKPEVKP ETHINLKVSD 
GSSEIFFKIK KTTPLRRLME AFAKRQGKEM DSLRFLYDGI RIQADQTPED 
LDMEDNDIIE AHREQIGGSE LYRQSLEIIS RYLREQATGA KDTKPMGRSG 
ATSRKALETL RRVGDGVQRN HETAFQGMLR KLDIKNEDDV KSLSRVMIHV 
FSDGVTNWGR IVTLISFGAF VAKHLKTINQ ESCIEPLAES ITDVLVRTKR 
DWLVKQRGWD GFVEFFHVED LEGG 
 
Mass Spectrum 
 
 
 
 
